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This dissertation investigated the effects of iron depletion without anemia 
(IDNA) on physical performance and training in female collegiate rowers.  In a cross-
sectional study, 165 rowers were screened for iron status at the beginning of a 
competitive season (10% anemic, 30% IDNA, Hgb>12.0, Hgb>12.0 g/dL and ferritin 
<20 µg/L).  IDNA rowers reported 2K times that were 21 seconds slower compared to 
rowers with normal iron status (p=0.004).  During the first week of training, 48 rowers 
(n=24 IDNA) had their physical performance assessed (VO2peak, 4K time, gross 
energetic efficiency) and recorded their training regimen.   Compared to rowers with 
normal iron status, IDNA rowers trained ~10 minutes/d less (p=0.02), and had a 0.3 
L/min lower VO2peak (p=0.03). Less highly-trained rowers with poor iron status had a 
lower VO2peak (-0.32 L/min, p=0.02), and were less energetically-efficient (-1.7%, 
p=0.09) compared to more highly-trained rowers with poor iron status. 
 In a randomized controlled trial, 43 rowers received 100 mg/d FeSO4 (n=22) or 
placebo (n=21) for 6 weeks, and completed daily training logs. Iron status, 
performance, and training quality were assessed at baseline and 6 weeks.  Thirty-one 
rowers (n=15 iron, 16 placebo) completed the trial.  Rowers supplemented with iron 
improved their body iron stores (log ferritin, total body iron, p=0.07), and those with 
most depleted stores at baseline improved the most.  Blood lactate concentration 
during the first 2000m of a 4K TT and 5 min post-recovery was significantly lower in 
 the iron group (p<0.01), and rowers in the iron group had a greater improvement in 
work efficiency (p=0.15) compared to placebo.  Additionally, the energetic efficiency 
of those rowers with poorer baseline stores (ferritin <20 µg/L) benefitted more from 
supplementation.  Finally, rowers in the iron group had an improved training quality 
score (p=0.03) compared to those in the placebo group. 
We conclude that iron status should be screened at the beginning of a training 
season, and that iron supplementation (~15 mg iron/d) improves iron stores in female 
rowers during training, especially in the most deplete.  The iron status of those with 
marginal/low stores should be monitored to prevent detrimental effects on training and 
performance.   
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CHAPTER 1 
 
INTRODUCTION 
Iron deficiency (ID) is the most common nutrient
 
deficiency in the United 
States, affecting 13% of pre-menopausal women, and approximately 30% of 
physically-active women (1, 2).  Iron deficiency anemia (IDA) is clinically defined as 
hemoglobin (Hgb) less than 12.0 g/dl.  Iron depletion without anemia (IDNA), or low 
iron stores, is defined as Hgb greater than 12.0 g/dl and serum ferritin (sFer) less than 
20.0 µg/L.  Female athletes are at higher risk of IDNA due to their menstrual status, 
poor dietary intake, and high training volume and intensity (3).  Consequences of 
IDNA that may be relevant to athletes include reduced work capacity, endurance, and 
energetic efficiency (4-6); and increased local muscle fatigue (7). The mechanism by 
which IDNA affects endurance and physical performance remains unclear, and the 
functional consequences
 
of IDNA are not fully understood in trained individuals, as 
studies to examine these relationships have been underpowered (8, 9).  
Our lab has previously reported the effects of iron deficiency on physical 
performance in untrained, IDNA women adapting to an aerobic training program.  
Hinton et al (5) showed that the effect of iron supplementation on physical 
performance was mediated by changes in iron status (sFer), and concluded that IDNA 
reduces the potential benefits of aerobic training on endurance.  In that study, subjects 
who were supplemented with iron for 6 weeks during aerobic training improved their 
time to complete a 15-km cycling time trial by 3.4 min compared to 1.6 min in the 
placebo group (p<0.05).  Given these convincing results, the study of highly-trained 
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competitive female athletes training at a high volume and intensity was warranted.  
We expected these significant effects to persist in competitive collegiate athletes. 
However, we expected the magnitude of these effects to be somewhat less due to 
collegiate athletes’ advanced training status, and thus a smaller margin of 
improvement in performance due to response of increased body iron stores.  The goal 
of the proposed study was to determine whether marginal
 
iron deficiency (IDNA) 
impairs the ability of moderately- to highly-trained female collegiate rowers to 
increase their training quality, as well as their performance in response
 
to 6 weeks of 
iron supplementation, in addition to their usual endurance training.  
 
The specific aims of the current study were: 
1. To determine the prevalence of IDNA in a sample of female rowers at the 
beginning of a training season. 
2.  To determine how IDNA affects endurance training and performance at the 
beginning of a training season. 
3. To determine how iron supplementation affects iron status, training and 
performance in IDNA female collegiate rowers. 
 
It was hypothesized that: 
1) IDNA is highly prevalent among female collegiate rowers. 
2) IDNA affects endurance performance in female collegiate rowers both in and 
outside of the laboratory. 
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3) Iron supplementation of IDNA rowers will improve iron status, and 
consequently, training quality via increased energetic efficiency. 
4) Iron supplementation of rowers with and without IDNA will prevent the 
deterioration in iron status resulting from endurance training, and thus 
significantly improve endurance capacity above the effect of training alone.   
5) IDNA rowers with the most-compromised iron status will benefit the most 
from iron supplementation. 
6) As training quality improves (with improved iron status), endurance 
performance will also improve; those with the most improvement in iron status 
will show the greatest improvement in performance. 
 
Our long-term goal is to inform standard iron status screening and intervention 
practices among female collegiate endurance athletes in order to improve health status 
and benefit endurance athletic performance. 
 
This study was conducted in three phases.  Phase 1 was a cross-sectional study 
designed to describe the iron status of a diverse sample of female collegiate rowers 
around central New York state.  Iron status was screened with a venous blood sample, 
and demographic and other health and self-reported performance data were also 
collected.  One-hundred and sixty-five female collegiate endurance athletes were 
screened to identify IDNA subjects (sFer <20 µg/l, Hgb >12 g/dL) for an iron 
supplementation trial.   
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Phase 2 was a cross-sectional study designed to measure and compare  the 
metabolic and functional consequences of ID in a sample of highly-trained female 
rowers across a broad range of both fitness levels (novice to varsity)and iron status 
(normal, ID, and IDNA).  This cross-sectional study was an analysis of the baseline 
data for potential RCT participants (IDNA) at the beginning of a training season.  In 
addition to those IDNA subjects participating in the supplementation trial, we included 
a sample of non-anemic, non-iron deficient rowers.  These subjects completed all 
baseline protocols in the lab, and recorded one week of training activities, in addition 
to all other baseline data collected.  This cross-sectional study enabled us to 
investigate potential relationships between iron status and early training season 
performance.   
This plausibility analysis was useful, in light of the putative mechanisms 
(correlations between iron status and physical performance), to explain how iron status 
may affect physical performance.  These analyses suggested relationships between 
iron status and performance, but did not provide strong causal evidence, as temporal 
relationships between iron status and performance cannot be determined in a cross-
sectional study.  We did, however, need to identify and control confounding factors 
related to both iron status and performance to control bias.  
Phase 3 was a randomized, placebo-controlled supplementation trial designed 
to explore how IDNA and iron supplementation affect iron status, performance, and 
training over 6-weeks of rowing training.  Rowers with normal iron status were 
included in this study to examine training effects (if any) on iron status and 
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performance.  This study was designed to elucidate the cause-effect relationship(s) 
between iron status (and iron supplementation), training and performance.    
This dissertation is structured in the following manner: after the literature 
review (Chapter 2), the general methods of the three studies are presented (Chapter 3).  
Research papers are then presented in Chapters 4-8 in chronological order (Chapters 
4-5, Cross-sectional studies; Chapters 6-8, results of RCT), followed by a general 
discussion (Chapter 9).   
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CHAPTER 1 
 
LITERATURE REVIEW 
 
Overview:  This chapter will review aspects of iron metabolism (absorption, storage, 
assessment of iron status).  Dietary and supplemental iron is then discussed, followed 
by a discussion of how IDNA affects physical performance and endurance training.    
 
Iron Absorption and Balance  
Iron’s low solubility rules out urinary or intestinal excretion as a means of 
maintaining iron balance, thus iron balance is regulated by three mechanisms:  1) 
continuous re-utilization of iron from catabolized erythrocytes (RBCs); 2) 
mobilization of iron stores; and 3) regulation of iron absorption from the intestines.  
Iron turnover is mediated by the destruction and recycling of RBCs by the 
reticuloendothelial system (1).  Erythrocytes contain 80% of the body’s functional iron 
and have a 120-day lifespan.  Eighty-five percent of (non-storage) iron derived from 
hemoglobin (Hgb) degradation is re-released to the body as iron bound to transferrin 
or ferritin in the plasma, returning the iron to RBC synthesis in bone marrow and to 
other tissues; 0.66% of the body’s total iron content is recycled this way each day (1).  
Uptake and distribution of body iron is regulated by the synthesis of transferrin 
receptors (sTfR) on the cell surface, also influenced by cellular iron status.  sTfR is 
ultimately regulated by iron-response proteins (IRP-1, IRP-2) binding to mRNA iron-
response elements (IREs) (1) .  As the cellular pool of iron decreases, there is up-
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regulation of iron intake into cells and a down-regulation of the synthesis of iron-
storage proteins.   In the absence of iron, IRP-1 binds to the IREs of various iron 
proteins to regulate translation of mRNA transcripts (1).   
Access to ferritin, the body’s iron storage protein found mostly in the liver and 
spleen, is another mechanism by which iron balance is achieved.  Ferritin binds iron in 
periods of relatively low need and releases it to meet excessive iron demands.  Storage 
iron concentration varies from 0-15 mg/kg body weight, depending on age, sex, and 
individual iron status (1). 
The negative feedback control on iron transport and absorption also regulates 
intestinal iron absorption: iron transport is optimized when an individual is iron 
depleted, and is limited when iron stores are replete.  Hepcidin is a hormone (signaling 
protein) from liver cells that links with its receptor ferroportin to regulate iron release 
from macrophages and enterocytes (1).  Prolonged negative iron balance due to either 
chronic basal losses or an acute rapid blood loss depletes iron stores, which can 
contain 2000-3000 mg of iron.  Storage iron bound in ferritin is used to meet daily iron 
requirements not provided by dietary iron, and will become depleted with negative 
iron balance.  Iron mobilized from tissue (stores of <5 mg) is transported by 
transferrin, which is 25-50% saturated with iron in iron-replete individuals (1).  
 
Iron losses from body in female athletes  
About half of the basal iron losses are from blood loss and occur primarily in 
the gastrointestinal tract. Both gastrointestinal losses and the menstrual iron losses are 
influenced by individual iron status; with a depletion of stores, menstrual and basal 
9 
 
iron losses will decrease. In a state of more severe iron deficiency, skin iron losses, 
which are generally minimal, may also decrease. Iron balance (state in which 
absorption equals losses) may be present not only in normal subjects, but also during 
iron deficiency and iron overload (2). As mentioned, iron balance is maintained by the 
regulation of iron absorption as it is related to iron loss.  Iron is mainly lost with cells 
exfoliated from the skin and from the interior surfaces of the body (intestines, urinary 
tract, airways). The total amount lost is estimated at 1.4 mg per day (3), and is affected 
by iron status.   
Menstruating women carry an increased risk for iron deficiency
 
due to monthly 
menstrual blood loss (~34 ml/month), regardless of training status (4).  Menstruation 
is the primary source of iron loss and this loss increases menstruating women’s iron 
requirement by 0.55 mg/d (5); oral contraceptives can reduce this loss.  Blood loss via 
donation contains 210-240 mg of iron per unit (pint) of blood donated.   
Runners and other long-duration weight-bearing athletes may experience 
greater gastrointestinal iron losses through feces and hematuria than non-athletes (3, 
6).  Telford et al (7)  found that in male triathletes, plasma free Hgb and sHaptoglobin 
were increased after exercise, and that this increase was four times greater after a run 
phase than a cycle phase, suggesting foot-strike is a major contributor to hemolysis 
during running activities.    
Earlier studies have suggested that sweat iron losses could be considerable, 
especially in a hot, humid climate (3). However, Brune et al (8), conducted a study 
taking precautions to avoid the contamination of iron from the skin during body sweat 
collection and showed that sweat iron losses, though directly related to the volume of 
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sweat loss, were negligible (22.5 µg iron/L sweat), and unlikely to impact iron 
requirements (8).  Waller and Haymes (9) found that the sweat rate of female athletes 
actually decreases over time and that the greatest concentration of iron in sweat 
occurred during the first 30 min of exercise.  This loss was lower in a hot versus a 
neutral environment.  Sweat iron concentration in this study was related to sFer, 
suggesting a possible conservation of iron with reduced stores.  The researchers 
estimated that 5.7% of daily iron absorbed (1.2 mg/d) would be lost by female athletes 
during that first hour of exercise, contributing to a depletion of iron stores over time 
(9).   
Strong evidence showing that prolonged training impacts iron stores is lacking.  
In a study using radioactively-labeled iron, Ehn et al (10)  showed that the half-life of 
body iron in eight runners was ~1000 d, which was not statistically-significant, but 
shorter than 2100 and 1300 d in non-athletic males and females. No controls were 
used in this study, limiting the strength of the evidence. In another study, using a 
factorial analysis approach Brune et al estimated that athletes were excreting 3L/d of 
sweat containing 0.21 mg/L iron (which equals 0.6 mg iron/d lost in sweat) (8), which 
may also be a possible contributor to athletes’ increased daily iron losses with 
prolonged training.   
From a dietary intake perspective, many female athletes, attempt to lose weight 
or body fat in hopes of improving performance or meeting weight expectations of their 
specific sport. 
 
In their attempts to lose weight and fat, or
 
gain muscle mass, some 
athletes resort to dietary energy restriction either seasonally or year-round, which can 
potentially be
 
harmful to their performance and their health (11-13).  As energy intake 
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decreases, dietary iron consumption is likely to be compromised.  Dietary energy 
restriction is especially prevalent in female athletes involved in weight-sensitive sports
 
such as figure skating, gymnastics, diving, sprinting and long-distance running,
 
rowing, and swimming, though dietary intake is rarely evaluated with precision in 
these populations (14-17).  Studies examining dietary intake (via 7d records, not 
including supplements) of endurance athletes have reported average iron intakes 
ranging from 9 – 42 mg of iron per day (18, 19).  Steen et al (20)  found that although 
a sample female rowers met the RDA for kcal and many vitamins, they had 
suboptimal intakes of many minerals, including iron.  The rowers in this study 
reported low intakes of sources of bio-available iron, such as beef and poultry. 
 
Iron requirements 
The recommended daily allowance (RDA, meets the needs of almost all 
individuals in a group) of iron for pre-menopausal women is 18 mg of iron/day.  A 
tolerable upper level (TUL, maximum level likely to pose no risk of adverse effects) 
has been set at 45 mg/day (21).  The estimated average requirement (EAR, used to 
calculate RDA) is 8.1 mg/d.  Proposed mechanisms for increased iron requirements in 
female athletes include the losses discussed above, however, it is hard to conclude 
how exercise affects iron requirements in female athletes based on available research.   
The U.S. military, however, has set iron’s RDA for female soldiers who are 
training at 22 mg/day (22) .  Estimates of basal losses (1.7 mg/d) by Weaver and 
Rajaram (23)  were used to base these recommendations on iron requirements for 
training military personnel, accounting for sweat losses and training duration/ work 
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load.  This results in an EAR of 13 mg/d.  The EAR, along with the SD for 
requirements (4.66 mg/d) was then used to calculate an RDA for training female 
soldiers (RDA = EAR + 2 SD) of 22 mg/d (22).  
If female athletes (including military personnel and other active females) do 
require more iron, it may most likely be for those women engaged in weight-bearing 
activities which result in gastrointestinal losses and foot-strike hemolysis.  Few study 
protocols control for dietary intake or menstrual status, or have standardized testing 
and treatment protocols or measures and classification of iron status (markers and 
cutoff points).  Screening for ID and monitoring iron status in athletes (and soldiers) 
upon recruitment, during training, and throughout the competitive season (and military 
deployment) may help to substantiate the argument over increased iron requirements 
for female athletes (and soldiers). 
 
Bioavailability of Dietary Iron 
Dietary iron is absorbed in the small intestine where it is taken in by and 
transferred across mucosal cells into the blood.  There are specific receptors on the 
brush border for various forms of iron and its transport protein within the mucosal 
cells for moving iron into plasma (1).  Dietary iron is classified as heme or non-heme 
iron, and the bioavailability of these two forms is different.  Heme iron is soluble in an 
alkaline environment and is absorbed into the intestinal mucosal cells as intact 
metalloporphorin molecules, so its absorption is not affected by dietary factors other 
than calcium.  Primary sources of heme iron are animal tissue, which contains 
hemoglobin and myoglobin (see Table 2.1).  The average absorption of heme iron 
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from meat-containing meals is about 25% (24) , which can vary depending on iron 
status (from ~ 10% during iron repletion to ~ 40% during iron deficiency to (25) , and 
on dietary calcium, which negatively influences the absorption of heme iron (26).   
Non-heme iron is the main form of dietary iron and is obtained from cereals, 
legumes, fruits, and vegetables (see Table 2.1). Non-heme iron has variable solubility 
depending on the amounts of ferric and ferrous iron, as well as the amount of dietary 
inhibitors (phytates, phenols, calcium) and enhancers (vitamin C, animal tissue) of 
absorption.  These compounds form large polymers or precipitate with the non-heme 
iron making it inaccessible to the mucosal cells, thus reducing iron absorption. 
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Table 2. 1.  Iron content of selected iron-rich foods – USDA National Nutrient Data 
Base 
Food Serving Size Mg Iron/Serving 
Ground beef 4 oz, cooked 3 
Roast beef 4 oz, cooked 35 
Chicken, dark meat 4 oz, cooked 3 
Tuna, fish 3 oz, cooked 1 
Ham 4 oz, cooked 2 
Lentils 1c, cooked 7 
Chick peas 1 c, cooked 5 
Eggs 2, cooked 2 
Nuts/seeds ¼ c 1 
Bagel 1-3.5 inch 4 
Cereal, fortified 1 c 5 (varies) 
Raisins, dates ½ c 1 
Spinach 1c, boiled, drained 6 
 
Iron supplementation 
Ferric iron’s absorption rate is about one-fourth of ferrous iron, and ferric iron 
supplementation was not effective in improving iron status in IDA patients (27).  The 
more bio-available ferrous iron is available as different salts: sulfate, lactate, fumarate, 
glutamate, and gluconate, all of which have comparable rates of absorption and 
incidence of gastrointestinal side-effects (e.g. constipation, nausea, vomiting, diarrhea, 
darkened stools) (3).  Twelve to 13% of an iron supplement is elemental iron, 
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available for absorption in the body.  Average absorption from ferrous salts is 20% 
from sulfate, 33% fumarate, and 12% gluconate (28).   
Supplementation of more than 45 mg/d elemental iron (e.g. as 225 mg ferrous 
sulfate) increases chances for gastrointestinal side-effects, which are still possible with 
lower-dose iron supplementation, but these effects may not be experienced in all 
subjects (3).  Side effects can be minimized by using a slow-release preparation (slow-
Fe), which reduces the concentration of iron on the mucosal surface, though these 
slow-Fe preparations are more slowly absorbed than quick-dissolving formulations.  
Iron supplements containing heme iron have a higher bioavailability and lower 
incidence of side effects than those containing only non-heme iron (29, 30).  
Administering ferrous salts immediately after a meal decreases absorption (3).  Since 
iron from non-heme iron supplements enters the same non-heme iron pool in the 
intestinal lumen as does the iron in food, the dietary factors affecting bioavailability of 
dietary non-heme iron will also affect the absorption of supplemental iron.   
Data from a recent analysis of NHANES 2003-2006 show that 53% of US 
females were consuming dietary supplements.  Fifteen percent of supplement-
consuming females aged 19-30 y reported taking one containing iron (31).  Data from 
NHANES III showed that 23% of pre-menopausal women were consuming iron-
containing supplements (32), and 40.7% of supplement-users were consuming more 
than the RDA for iron (<18 mg/d) from supplements alone (33).  Additionally, no 
difference in iron status between supplement-users and non-users was shown in this 
study (33).  Survey data report that 7-30% of female athletes consume an iron 
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supplement (34-36), although a larger number of female athletes (72.7%) report 
consuming a multiple vitamin-mineral supplement that contains iron (36) .  
 
Prevalence of Iron Deficiency 
Iron deficiency (ID) is the most common micronutrient deficiency in the 
United States.  There is a wide distribution of Hgb concentration in healthy, non-ID 
subjects (in women, 120–160 g/l; in men, 140–180 g/l) (37).  While 4% of US women 
20-49 years of age are iron deficient anemic (IDA), the prevalence of anemia 
underestimates that of ID in the population by more than 50% (38), as more than 12% 
are iron deficient without anemia (IDNA) based on sFer<12.0 (or 20.0) µg/L (39, 40). 
Pre-menopausal women are at increased risk of ID due to the additional iron losses via 
menstruation.  IDNA is particularly prevalent among college-aged women, female 
athletes and soldiers and the physically-active (41, 42).  These women are at a higher 
risk of IDNA due to their particularly prevalent low energy intakes (and consequently 
low iron intakes), as well as their training status, which may increase basal losses.  
Our research group has found the prevalence of IDNA to be about 30-35% in a sample 
of female collegiate endurance athletes (43).  As of 2005, nearly 165,000 female 
athletes were competing in NCAA sports, thus many active college women are 
affected by IDNA and would benefit by ameliorating the problem (44). 
 
Assessment of Iron Status 
The most common consequence of iron deficiency is anemia, or blood 
hemoglobin (Hgb) concentration below a specified level (12 g/dL for women of child-
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bearing age). The main use of the cut-off value in defining anemia is to compare 
prevalence between population groups.  During the development of a negative iron 
balance in subjects with depleted iron stores (serum ferritin concentration <12 µg/L), 
there will be a decrease in Hgb, mean corpuscular hemoglobin (MCH), mean 
corpuscular volume (MCV). This will lead to an overlap in the distributions of Hgb in 
iron-deficient and iron-replete women. The extent of overlap depends on the 
prevalence and severity of iron deficiency (37). 
Anemic young adult females are commonly identified using Hgb<12 g/dL as 
the clinical definition of anemia.  Hgb concentration decreases with a decline in 
hematopoiesis, although this does not only occur as a result of depletion of iron stores.   
In the early stages of endurance training, hematological adaption can be observed in 
athletes.  For example, although absolute Hgb mass is increased with training due to 
erythrocytosis, there is often a dilution of Hgb, Hct, and RBC (termed psuedo- or 
sports anemia) with increased plasma volume associated with endurance training due 
to exercise-induced release of aldosterone, renin, and vasopressin, as well as increased 
synthesis and retention of plasma albumin (45).  This is a transient condition common 
in endurance-type athletes (runners, swimmers, rowers).  This rapid increase in plasma 
volume is proportional to the amount and intensity of training (from 5-20%), and 
disappears within a few days of adaptation to a training load (or as one becomes de-
trained).   
Hemolysis induced by exercise and resulting in low blood Hgb, hematuria, and 
hemoglobinuria has also been proposed as a mechanism of increased iron loss in 
athletes, particularly in runners (7).  The increases in RBC mass and decreases in 
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haptoglobin with hemolysis, have been attributed to increased turnover and destruction 
of red blood cells via inevitable mechanical trauma during various types of endurance 
training (e.g. “foot-strike hemolysis”; muscle contraction in capillaries; increased renal 
blood flow and blood pressure) (46, 47).    
Iron deficiency anemia (IDA) occurs when iron stores become depleted 
(sFer<12 µg/L) and Hgb falls below 12 g/dL.  Consequently, insufficient amounts of 
iron will be delivered to transferrin (Tf, iron transport protein), and the binding sites 
for iron on transferrin will contain less iron, resulting in a reduction in transferrin 
saturation (TS), and an increase in total iron binding capacity (TIBC),  and ultimately 
reduction in iron delivery to cells and tissues in need, as well as serum iron. When TS 
drops to a certain critical level, RBC precursors will not have enough iron to form 
Hgb.  As liver cells receive less iron, more Tf will be synthesized, and the 
concentration of Tf in plasma will increase. The uptake of iron is related both to TS 
and the number of transferrin receptors (TfR) on the cell surface (1). There is a 
marked diurnal variation in the saturation of Tf because of the high turnover rate of 
iron in plasma, making it difficult to evaluate iron status from a single measurement of 
TS.  
To identify individuals who are iron deficient without anemia (IDNA), iron 
status can be examined using a number of indicators (or combinations of indicators) to 
elucidate various body iron storage pools that are useful for understanding the 
functional consequences of ID.  With excessive iron loss or inadequate iron intake, 
body iron stores decline and ID occurs.  When iron stores have become completely 
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depleted but Hgb has not yet declined to a level indicative of anemia, this is a state of 
IDNA.   
The best single indicator of iron stores is serum ferritin (sFer), which is stored 
predominantly in the liver, spleen, and bone marrow.  Each µg/L ferritin in the plasma 
represents about 8 mg of storage iron (1).  There is also an inverse relationship 
between ferritin and iron absorption, indicating that sFer is a sensitive indicator of 
body iron stores.  sFer identifies iron depletion at concentrations as high as 20.0 µg/L, 
though the clinical cut-off for iron deficiency is 12.0 µg/L (1, 3) . A sFer <12.0 µg/L 
indicates complete depletion of Fe stores in the bone marrow; 12-20 µg/L indicates 
minimal stores; and >20.0 µg/L indicates adequate Fe stores.  Based on NHANES III, 
median sFer was 36-40 µg/L for healthy, non-pregnant menstruating women of child-
bearing age (21).  Normal or high ferritin levels, however, do not
 
guarantee adequate 
iron stores. Ferritin is an acute phase protein (explained below)
 
and may therefore vary 
in certain conditions without changes
 
in iron storage, such as infection, inflammation, 
and increased training intensity which may mask potential iron depletion (48, 49).  
Serum transferrin receptor (sTfR) is an index of functional iron deficiency, and 
is independent of sex, inflammation, and training status.  Transferrin (Tf) distributes 
iron to cells that have transferrin receptors (TfR) on their cellular surface.  Almost all 
cells have TfR on the cell membrane, with the largest number of TfRs found in 
rapidly-dividing cells, Hgb-synthesizing tissues, and the placenta (50).  As mentioned 
previously, a negative feedback loop controls TfR synthesis:  low iron stores results in 
stimulation and excess iron suppresses TfR synthesis. sTfR  provides a continuous 
measure of iron status in an individual, rather than using categorical classification.  
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sTfR, independent of Hgb, is directly correlated with total mass of erythroid 
precursors  and increases in proportion to severity of ID, and is therefore indicative of 
IDNA.  In ID, as there is increased demand for iron at the level of skeletal muscle 
tissue, increased sTfR (>8.0 or 8.5 mg/L, depending on the assay kit used) indicates 
that this demand is not being met by circulating iron.  sTfR identifies IDNA 
individuals who will potentially benefit from iron supplementation (51).  As sTfR 
reflects overall erythropoiesis, endurance athletes should have higher sTfR 
concentration levels than untrained or in moderately-trained individuals (52, 53).  
Banfi et al (54) found that the sTfR of female rugby players increased over 10 months 
of training and during competition.   
Mean corpuscular volume (MCV) is one of the last parameters to change with 
onset of iron deficient erythropoiesis.  Ferritin and MCV models use multiple criteria 
to determine IDA vs. IDNA vs. anemic, non-ID vs. non-ID, non-anemic.  If an 
individual has more than two abnormal values (sFer, FEP, MCV, TS), they are 
considered ID.  
In 1986, Cook et al developed an algorithm to estimate body iron (55) that 
relies on multiple criteria of iron status (Hgb, sFer, FEP, TS) and several equations to 
estimate body iron stores and distinguish ID from non-ID.  In anemic individuals, Hgb 
drives the model, and in IDNA, sFer drives the model.  Mild (though functional) ID 
may go undetected when using only Hgb and sFer, as individuals with Hgb in the 
upper-normal range must lose 20-30% of body iron before ID can be detected by 
anemia (48).  Recently, Cook et al (56) have developed another algorithm to estimate 
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total body iron (TBI) from the log of sTfR/sFer, which permits detection of mild tissue 
ID in non-anemic individuals:   
Iron stores (mg/kg) = -[log(sTfR*1000/sFer) – 2.8229]/0.1207 
 
Inflammation and the assessment of iron stores 
Inflammatory processes present a challenge when evaluating measures of iron 
status.  Although sFer is the most common index of iron stores, and reflects iron 
stored in the liver, it is an acute-phase protein (APP) and can be elevated in an 
inflammatory state (e.g. infection, post-exercise), potentially masking ID (53, 57, 58). 
The acute phase response (APR) is a protective inflammatory response.  Following an 
injury (e.g. muscle tear) or acute or chronic inflammation (e.g. allergic response or 
upper respiratory infection), both iron transport and absorption are suppressed.  During 
this APR, ferritin levels become inflated by 20-38% for several days, making 
accurate assessment
 
of iron stores difficult, and possibly masking iron deficiency (59, 
60).  Iron is sequestered into ferritin, compromising iron availability for incorporation 
into Hgb.  Therefore, it is important to estimate how much influence the inflammatory 
response may be having on iron status and its assessment.  
An inflammatory marker such as C-reactive protein (CRP) or alpha-1-acid 
glycoprotein (AGP) can partially rule-out falsely-elevated sFer (60-62).  These APPs  
have different temporal responses to inflammation.  The peak response of AGP (5-6 d) 
matches that of ferritin (up to 10 d) more closely than does CRP (1-2 d).  Rocker et al 
(52)  examined the iron status of 12 female triathletes before and after a single 
competition (1.5 K swim, 20 K cycle, 10 K run) and found that sFer remained elevated 
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after correcting for hemoconcentration; no inflammatory markers were measured in 
this study.  Beard et al (61)  measured CRP and AGP along with sFer and sTfR in 
several studies  to determine which APP performed better in predicting sFer levels 
responding to current inflammation.  They found that only sFer was related to APP 
concentrations, though it had a poor positive predictive value (<72%) due to a low 
prevalence of inflammation in their sample.  AGP, however seemed to be a better 
predictor of sFer.  Most recently, Thurnham et al reported that correcting ferritin 
values for inflammation (using AGP and/or CRP) improved the assessment of iron 
status using ferritin, enabling correct classification of subjects as iron deficient 
(decreased number of false negatives) (60), however, an appropriate correction factor 
in training athletes has not been published.   
Aside from the effects of the APR on sFer as an indicator of iron status, recent 
research has suggested that the iron regulatory protein hepcidin is the mediator 
between the inflammatory response and poor iron status via iron absorption (63).  
Endurance exercise has been shown to evoke an APR in post-exercise cytokines, and a 
2-3-fold increase in pro-inflammatory and in inflammation-responsive (IL6) cytokines 
have been reported (64).  These exercise-induced elevations may up-regulate hepcidin, 
which then enters the circulation to negatively control the export of iron from the 
intestinal enterocyte.  Iron uptake by macrophages in response to hemolysis would not 
be retainable due to the internalization of the macrophage surface ferroportin channels 
(64).  Thus, acute increases in hepcidin may lead to a decrease in the absorption of 
dietary iron (65).  This absorption of iron from post-exercise meals may then be 
limited for a prolonged time period as a result of the effect on duodenal enterocytes 
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within the gut.  Roecker et al (66) found that urinary levels of hepcidin 24-h post-
marathon were 2.5 times greater than pre-marathon levels.  The researchers suggest a 
possible exercise-induced increase in inflammatory up-regulation of hepcidin, which 
may lead to ID over time.   
Several studies have shown associations between or increases in urinary 
hepcidin and inflammation post-exercise, suggesting that high levels of training may 
negatively affect iron status (46, 59, 64, 66-68).  Most recently, researchers found that 
although serum hepcidin was not affected by basic combat training in female military 
soldiers, hepcidin was lower in IDA soldiers and was positively associated with sFer 
and CRP levels before and after training (69). This mechanism may explain the 
increased prevalence of iron deficiency in female athletes and/or changes in iron status 
with training, as well as the reduced potential for improved sFer with iron 
supplementation in athletes.   
 
Relationship between iron status, physical performance, and physical activity  
It is commonly known that anemia, the most severe form of ID, has severe 
consequences on physical performance due to the inadequacy of Hgb to transport O2 
to the peripheral tissues (70, 71).  In an extensive review of the literature, Haas and 
Brownlie cited strong evidence to support the finding that IDA impairs aerobic 
capacity due to inability of Hgb to transport O2 (72).  However, iron plays an 
important role in muscle metabolism beyond O2 transport (Figure 2.1).   
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Figure 2.1.  Effect of Iron deficiency on physical activity.  Adapted from Haas and 
Brownlie (73).  
 
There are many iron-containing enzymes involved in transforming chemical 
energy to mechanical energy (work) that are affected by iron depletion (energy 
produced by mitochondrial cytochromes, Table 2.2).  About 5% of body iron is found 
in iron-containing enzymes, and 10% is found in myoglobin (muscle storage of O2).  
These iron-containing enzymes are employed in oxidative metabolism in the 
transformation of chemical to mechanical energy via the Krebs cycle (TCA cycle 
through iron-sulfur proteins) and electron transport chain (ETC, through heme-
dependent cytochromes).   
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Table 2.2. Iron-dependent enzymes 
Heme Compounds Non-heme Compounds Iron-Dependent 
Enzymes 
Myoglobin 
Cytochromes 
Catalase 
Peroxidases 
NADH dehydrogenase 
Succinate dehydrogenase 
Xanthine oxidase 
Aldehyde oxidase 
Alpha-glycero-phosphate 
oxidase 
Phenylalanine hydroxylase 
Lipid peroxidase 
Proline hydroxylase 
Lysine hydroxylase 
 
 
Evidence from human studies (70, 74, 75)  supports findings from animal 
studies (76-82)  that both mitochondrial content, as well as the activities of iron-
containing oxidative enzymes in skeletal muscle mitochondria essential to O2 
utilization within working muscles are decreased in ID (independent of anemia), 
leading to reduced work performed and endurance capacity.  Changes in these 
enzymes due to ID can occur in many tissue types, but it is the changes in skeletal 
muscle fibers that are most important relative to physical performance (77, 79).   
Another consequence of IDNA related to physical performance is energetic 
efficiency (EF), which is defined as the ratio of the amount of physical work produced 
from a process (W) to the amount of metabolic work/energy that went into the process 
(energy expended, VO2).   Studies of IDNA non-athletes have shown that repletion of 
iron stores improves EF (83-85).  This means that women with sufficient iron stores 
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completed the same exercise/workload at a lower energy cost than women with 
depleted iron stores.  Iron is presumed to play a role in EF via oxidative capacity, or 
controlled in part by levels of iron-containing enzymes (e.g. muscle pyruvate oxidase) 
at the tissue level, as mentioned previously (77).  A limitation of EF as an outcome is 
that the total amount of work done during exercise is the total sum of both internal and 
external work outputs, however, internal work (for example, the O2 cost of breathing) 
usually goes unmeasured.  Because EF is based on whole body VO2 and is not a 
specific measure of muscle EF, this outcome is often corrected to isolate the EF of 
working muscle by subtracting baseline energy expenditure form total energy 
expenditure (termed net efficiency).   
Lactate concentration is used as a proxy for anaerobic metabolism, and is 
highly correlated with endurance performance (86-90).  Results from animal studies 
suggest that increased blood lactate is due to a reduction in enzyme activity involved 
in glycolytic pathways (76).  Higher blood lactate concentrations during moderate 
exercise may increase one’s susceptibility to fatigue and result in poor endurance 
performance – this has been shown in both animals and humans with ID.  This means 
that those with ID are using more energetically- “costly” anaerobic energy pathways 
to produce the same amount of work compared to those with normal iron status.   
Other functional consequences of ID found in both male and female athletes 
and non-athletes are shown in Figure 2.2.  From a broader public health perspective, 
social and economic consequences of ID include low work/school productivity, 
increased food/energy needs, reduced time spent in leisure-time physical activities, 
and low-educability (55, 91), all of which apply to student athletes. 
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IDNA and Physical Performance in Non-Athletes 
Our lab has completed a series of studies reporting the effects of iron 
deficiency on physical performance in untrained, IDNA women with differing 
experience in aerobic training (83, 92, 93).  In the first study (n=30), Zhu and Haas 
(83)  reported that the effect of iron supplementation in non-exercising women was 
mediated by changes in iron status (sFer), and it was concluded that IDNA reduces the 
efficiency with which work is performed at moderate levels of exertion. In the second 
study (n=42), Hinton et al (93) found that those supplemented with iron for 6 weeks 
while participating in an aerobic training program improved their time to complete a 
15-km time trial by 3.4 min compared to 1.6 min in the placebo group (p<0.05, see 
Figure 2.3).  IDNA untrained women in our studies have also shown significant 
improvements in energetic efficiency (83, 84, 92, 94); resistance to local muscle 
fatigue (95); and maximal aerobic power post-training (94).  Given the magnitude of 
these effects, the study of highly-trained competitive female athletes training at a high 
volume and intensity seems warranted.  We expected to observe similar effects in 
trained athletes, although we predicted that the magnitude of the effect to be somewhat 
less, due to athletes’ advanced training status, and thus a smaller margin of 
improvement in performance with improved iron status.
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Figure 2.3.  Improvements in time (min) for moderately-trained women to complete a 
15-km time trial after 4 wk aerobic training while supplemented with either iron or 
placebo (*p<0.05 iron compared to placebo, controlling for Baseline) (93).   
 
IDNA and Physical Performance in Athletes  
Studies of how iron status affects non-anemic endurance athletes are limited, 
but research suggests that female endurance athletes and military soldiers with IDNA 
have impaired physical performance (47, 85, 96-98).  Friedmann et al (96) studied 40 
young male and female IDNA athletes and showed that those athletes who were 
supplemented with iron for 12 wk showed a 10% improvement in endurance 
(p<0.001),  which was also significantly different from the placebo group (p<0.05).   
Rowland et al (74) also reported improvement in endurance time in IDNA female 
runners after supplementation, although the placebo group in this study inexplicably 
decreased their endurance time.  Other studies have shown decreased blood lactate, as 
well as improvement of (mildly anemic) Hgb status in non-anemic athletes 
supplemented with iron (87, 99). Most recently, Hinton et al found that after 6 weeks 
of iron supplementation, recreational athletes’ (n=3M, 17 F) post-trial energetic 
efficiency was significantly increased (+1.1%) compared to placebo (+0.7%), although 
the post-trial EF measure was not significantly different between the treatment groups 
* 
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(85). A recent study of female military soldiers with repleted iron status showed 
improvements in 2-mile run time after basic combat training (100).  These studies did 
not investigate the role of training itself, and how IDNA may affect the intensity of 
training in order to affect post-training performance.  Studies examining the effect of 
IDNA on training in trained individuals have not been conducted. 
 
IDNA and Physical Activity in Non-Athletes 
While much of the focus has been on the relationship between IDNA and 
physical performance or work capacity, only a few studies have attempted to address 
the relationship between IDNA and training or other leisure-time physical activities 
(LTPA).  After inducing ID in animals, voluntary physical activity decreased in a 
dose-response manner (increased severity of ID, further decreases in physical activity) 
(101-103).   
Human studies conducted in field settings have shown that women with iron 
deficiency with and without anemia working on tea plantations (104) and in cotton 
mills (105) significantly increased their voluntary physical activity when provided 
with iron supplementation.  Ameliorating IDNA also contributes to improved worker 
productivity (72, 106-108) and quality of life (72, 109, 110) at both the macro 
(economy) and micro (individual, family) levels.  To the best of our knowledge, there 
have been no published studies examining IDNA’s effects on LTPA in athletes who 
are in-training.  We do not know how athletes who are IDNA compensate for the 
effects of IDNA outside of their sport training by, for example, reducing their time 
spent in activities at home, school, and work.   
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Training intensity and load 
Endurance athletes at the collegiate level spend many hours per week 
participating in specific training for their sports in order to improve their competitive 
performance.   Training can be quantified in terms of frequency, intensity, time 
(duration), and type (of activity), commonly referred to as “FITT” (111).  The 
intensity of athletes’ training is the major variable influencing the overall effects of 
training on endurance performance (112).  Intensity is a function primarily of speed 
(miles per hour, mph; strokes per minute, spm, etc) for endurance athletes, because 
they are focused on completing a certain distance in as little time as possible.   
A basic concept of training is that of progressive overload, or of the adaptation 
to increased amounts of work over time.   Training load is a combination of intensity, 
duration and frequency.  To maximize athletes’ potential benefits of or adaptation to 
training, the level of the training load must be appropriate for both the individual and 
for the outcome (e.g. endurance performance in a given event) (112).  Specificity is 
also important, as adaptations to training should result in training of the muscles 
required to perform the activity, as opposed to general aerobic or strength conditioning 
(113).  Specificity also becomes important when deciding upon the mode of testing to 
measure the effects of training (or other variables) on sport-specific performance (114, 
115).   
The majority of pre-season endurance training programs consist of an initial 
conditioning phase lasting 4-6 weeks, encompassing a high volume of general aerobic 
conditioning (cross-training) and strength training.  During this period, much of 
training is done at or just below an oxygen consumption above which aerobic energy 
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production is supplemented by anaerobic mechanisms (around 75-85% VO2 max).  
This training level is known as the anaerobic threshold (AT), and causes a sustained 
increase in lactate and metabolic acidosis (116).  Training then becomes preparation 
for competition, incorporating technical skill of the sport (speed, coordination, etc).  
As the competition approaches, training focuses on sport-specific high-intensity, short 
duration activities with recovery time.  Maximal oxygen consumption (VO2 max) can 
be maintained up to 28d with a decrease in training of about 30% (maintenance of 70-
80% of maximal training load).  If a training load volume is not maintained, VO2max 
can decrease 4-14% within 4 weeks (111).   
There are many changes to the anaerobic and aerobic energetic systems with 
endurance training.  Anaerobic changes include increased levels of anaerobic 
substrates (ATP, PCr, free creatine, glycogen); increased number and activity of 
enzymes that control the anaerobic phase of glucose catabolism; and increased 
capacity to generate high levels of blood lactate during exercise (via increased levels 
of glycogen and glycolytic enzymes, improved pain/fatigue tolerance) (111, 117).  
Endurance training also induces several adaptations in a variety of functional 
capacities related to O2 use and transport within skeletal muscle, namely increases 
oxidative capacity, where iron plays an essential role.  Endurance-trained muscles 
contain larger and more numerous (2x more) mitochondria (site of O2 diffusion, 
oxidation of ACoA NADH, FADH2, and electron transfer of O2NADH, FADH2) 
than less active muscle fibers.  This increases mitochondrial capacity (via increased 
aerobic system enzymes, including those dependent on iron) to aerobically generate 
ATP (111, 118).   
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This increased enzymatic activity increases an endurance athlete’s ability to 
sustain longer duration, higher-intensity activity without significant blood lactate 
accumulation (118, 119).  High blood lactate levels are an indication that the 
glycolytic anaerobic pathway has been used during physical work, and serves as a 
reflection of the balance between lactate production and its removal.   As mentioned, 
high lactate concentrations during exercise may result in increased fatigue, poor 
endurance performance, and/or sub-optimal maximal exercise performance (VO2max). 
Endurance training increases an athlete’s capacity to mobilize, deliver, and 
oxidize fatty acids for fuel during sub-maximal exercise, which spares carbohydrate 
for maximal exercise.  Increased fat catabolism is due to increased blood flow within 
trained muscle; increased numbers of fat-mobilizing and –metabolizing enzymes; 
improved muscle mitochondrial respiratory capacity; and decreased catecholamine 
release at a given level of work (111, 117, 119).   
Trained muscle also has a greater capacity to oxidize carbohydrate during 
maximal exercise, as glycogen is spared with increased fat oxidation.  Additionally, 
endurance athletes have larger slow-twitch (ST) muscle fibers than fast-twitch (FT) 
fibers within the same muscle; ST fibers have a high capacity to aerobically produce 
ATP and contain large amounts of myoglobin (111).  Work efficiency plays a 
significant role in endurance exercise performance.  The O2 cost (ml/kg/min) of an 
activity at a given workload or power output (W) varies with individuals’ fitness 
levels, as well as technical/skill level (biomechanical factors).  The efficiency with 
which ATP is converted to work depends upon muscle fiber type and mitochondrial 
density (117).  
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There are also a number of specific cardiovascular adaptations to endurance 
training which augment O2 delivery to active muscle.  The heart’s mass and volume 
increase with long-term aerobic training, just as skeletal muscle mass increases with 
progressive overload.  Athlete’s plasma volume increases from 5-20%, without 
changes in RBC mass, as soon as within 24h of the first training session, and persists 
as long as adaptation to progressive overload continues (45, 120).  This increased 
plasma volume enhances circulatory reserve, increases stroke volume and O2 
transport.  Resting heart rate (HR) and sub-maximal HR are also decreased (by 12-15 
bpm) in the endurance-trained athletes, and is a main indicator of training 
improvement, reflecting increased stroke volume and cardiac output (111).  Blood 
flow to active muscle improves with training, which increased muscles’ ability to 
deliver, extract and use O2.  This is due to increased cardiac output and enlargement of 
capillary arteries and veins, as well as increased capillarization per gram of muscle 
(111). 
It is has been suggested that the iron status of experimental animals and 
humans is related to their physical training, but the direction of this relationship is 
unclear (49, 80, 81, 103, 121-123).   Many studies have examined changes in iron 
status that occur with training, but the effects of iron status on training itself (training 
intensity, time) have not been adequately evaluated.  Ashenden et al (49) examined the 
effect of seasonal variation in hematological parameters related to the onset of 
competitive sports training in female athletes, including rowers and court-sport 
athletes, and found a 25% decline (p<0.01) in mean serum ferritin concentrations for 
all athletes
 
during
 
the training season, although physical performance measures, 
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training intensity and volume, and sTfR were not evaluated. Schumacher et al (47) 
screened 747 male athletes and found that increased physical duration and work load 
(self-reported training) was associated with decreased sFer.  Similar results were 
found by Petersen (124) who found that after examining 18 swimmers over a 16-week 
training season, sFer had decreased by ~30%.   More recently, McClung et al studied 
female soldiers before and after basic combat training and found declines in iron status 
(decreased sFer, increased sTfR) after 9 weeks (125).  None of these studies assessed 
inflammation or controlled for changes in plasma volume.  Nor did these studies 
measure dietary intake, or use standardized measures of training or performance.  
Furthermore, none of the mentioned studies have separated conditioning phase 
training periods from pre-competition phase/steady state periods.  
 
Rowing 
Rowing is among the oldest modern organized sport (126).  Rowing, as a 
weight-supported sport, requires a high level of coordination and sophisticated motor 
control, as rowers need to coordinate their body movement with the oar’s movement, 
as well as maintain boat balance.  Biomechanically, rowers need to expend more 
power (W) to overcome higher drag resistance in order to increase boat speed.  Power 
from rowers’ legs contribute to about 50% of rowing power; trunk muscles contribute 
about 30%, and arms 20-25% (126).  Mechanical efficiency of rowing at <25 spm is 
18% and increases to 20-23% at 35 spm in experienced rowers; Novice rowers are 
10% less efficient.  The metabolic cost of a race assumes constant mechanical 
35 
 
efficiency of 22%, which is equivalent to about 5.3 L O2/min for elite female rowers 
(126, 127).   
Specific traits associated with competitive success in rowing include tall 
stature and high muscle mass, which yield a greater potential leverage and high power 
output (126, 128).  On average, successful or elite female rowers are about 182 cm tall 
and weigh 80 kg, and 15-25% body fat (126).  Anthropometrics and body composition 
are two important predictors of rowing performance.  A tall height contributes to a 
higher body mass and strength endurance, and increased muscle mass contributes to 
both strength and VO2 (r=0.73); aerobic power has been shown to increase as a cubic 
function of stature (126, 129).  Rowers have a high proportion of active muscle mass 
to propel the dead weight of the boat, oars, and coxswain (if rowing in a crew).  About 
75% of rowers’ total muscle mass is used during rowing, which is relatively high 
compared to weight-bearing sports due to the fact that rowers’ mass is supported in the 
boat (126).   
Rowing ergometers (aka “erg”) have been used as rowing training and valid 
testing devices since the 1960s. A standard rowing ergometer (Model C, Concept 2, 
Morrisville, VT, USA, Figure 2.3) is used by rowers of all levels of skill and 
competition, especially during the winter/indoor training season.  Rowing ergometer 
“scores” are used regularly by coaches to assess performance and assign boat 
placement/racing line-up throughout both Fall and Spring rowing seasons.  Collegiate 
coaches routinely use the 2K erg score, as well as the maximal aerobic power (MAP) 
test to assess rowers’ training progress.  A standard ergometer is fixed to the floor, and 
all of the rower’s power output goes into an air-braked flywheel, which simulates drag 
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through the water. Power generated by the air friction on this flywheel is measured 
and converted into a virtual boat speed by a small computer monitor, using the cubic 
relationship between power and velocity (PM2+, Concept 2, USA; W= 2.8/pace per 
500 m
3
).   
 
   
Figure 2.3.  Concept 2 Rowing ergometer and output monitor, 
http://www.concept2.com 
 
A caveat to the use of the ergometer is that it does not require the same amount 
of teamwork and coordination or technical and mechanical skill as does the boat and 
oars on the water, although studies have shown good correlation between ergometer 
and on-water performance.  Urhausen (130)  compared physiological responses during 
rowing on an ergometer and in a single scull on the water in 17 male rowers and found 
no significant difference between the 2 modes of rowing.  Mikulic (131)  found that a 
2K rowing ergometer test was significantly correlated (p<0.05) with self-reported 
competition boat performance a sample of 398 rowers, the strongest correlations being 
for ergometer performance times in single sculls (r = 0.92; p < 0.001) versus larger 
boats (quads, fours, and eights, r = 0.31-0.70; p < 0.039). Simulated races (5-6K, 2K) 
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are commonly used as testing protocols on the ergometer (129), and have been shown 
to represent final minute maximal VO2 values in the laboratory (132).   
Rowing training consists of about 75-85% aerobic work (128), which increases 
aerobic capacity at the cellular level (mitochondrial changes, capillary density, 
enzyme changes), where it is presumed iron plays an important role, as discussed 
previously.  Row-specific training is high-intensity (intervals of up to 95% VO2max), 
long duration (bouts of 30-60 min), and high frequency.  Rowers do the majority of 
their training at or above their anaerobic threshold (around 75-85% VO2max).  
Rowing-specific training (in boat or on ergometer) yields significant effects on rowing 
performance (technical skill, efficiency), as this specific training works the muscles 
and transport systems that support the action of rowing (128, 133).  During the 
transition from off- to in-season, elite rowers can increase their VO2max by about 10% 
(5-15 ml O2/kg/min) (126).  As high-intensity endurance athletes, rowers have many 
more and larger slow twitch (ST) muscle fibers than fast twitch (FT) fibers, lending to 
their high aerobic capacity and anaerobic thresholds (86, 128).  ST fibers have 50% 
higher oxidative capacity, and 50% lower glycolytic capcity than FT fibers; in short, 
ST rely more on fat as an energy substrate and are the first to be activated during 
endurance activities, such as rowing.  
Due to rowers’ variable seated body positioning in the boat or on the 
ergometer, they have increased ventilation (VE, increased breathing frequency and 
lower tidal volume) than other endurance athletes, and employ a cyclic breathing 
pattern to compensate for this (134).  During rowing, VE: VO2 equals or exceeds that 
of most endurance athletes.  Lungs of rowers reflect their larger body size/height (vs. 
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runners) (126, 134). Rowers’ exhalations and inhalations are performed in phase with 
rowing strokes (2 breaths: 1 stroke). Cardiac output and stroke volume are also 
affected by rowers’ body positioning.  Central blood volume is reduced following 
rowing due to increased perfusion pressure and muscle vasodilation.  There is also a 
short diastolic interval (filling of the heart with blood) during rowing, and venous 
return to the heart is enhanced (126). 
Rowers’ pacing pattern is also important to endurance performance.  At the 
beginning of a 2K race, there is a brief sprint (30-40 s, high spm), resulting in a high 
O2 deficit (anaerobic) early in the race.  For the next 4-4.5 min, the work is aerobic 
(reduced spm), followed by a final sprint (anaerobic) to the finish during the last 
minute of the race.  Thus, rowers are performing near maximal work capacity for the 
duration of an entire 2K race (128, 133).  VO2max is a very important determinant of 
rowing performance.  The aerobic contribution of metabolism to power output has 
been reported to be 67-86% during a race (128, 135, 136).   
Motivation is an important factor in rowing training and performance.  Mental 
preparedness, good coaching, positive thinking, and confidence in individual and in 
teammates’ abilities are keys to successful rowing performance.  Rowers’ ability to 
resist feelings of mental and physical fatigue is enhanced by training.  
 
Bottom line of literature review and conceptual framework of dissertation 
Given iron’s important role in aerobic metabolism, the high prevalence of iron 
depletion among active women, and its consequences relevant to endurance athletes 
(poor endurance performance), further study of female endurance athletes in-training 
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is warranted.   There is little available evidence to show the effects of IDNA on 
training itself.  There is even less evidence to show how the relationship between iron 
and performance is mediated by training.   
As previously discussed, available evidence suggests that female athletes are 
more susceptible to depleted iron stores (resulting in IDNA) due to factors that can be 
attributed to the athletic environment (increased basal iron losses, inadequate dietary 
intake).  The reviewed literature has also suggested that training itself may negatively 
affect iron stores.  We know from animal and human studies that depleted iron stores 
results in IDNA, which affects oxidative capacity, endurance capacity, energetic or 
work efficiency, and local muscle fatigue.  We also know from animal and human 
studies that training improves physical performance, as measured by energetic 
efficiency, VO2max, endurance, and time to complete a time trial.   
The conceptual framework used to conduct the studies in this dissertation is 
shown in Figure 2.4.  The shaded portions of the framework will be the focus of this 
dissertation.  Major indicators of iron status (sFer, sTfR, TBI), measures of physical 
performance (VO2max, time to complete 4K time trial, and energetic efficiency), and a 
measure of training quality (training quality score) will be discussed.  We 
hypothesized that IDNA and its consequences negatively affect training quality as 
measured by time spent training, intensity of sessions, and rest/recovery time, and that 
this negative effect of IDNA on training quality would inevitably negatively affect 
physical performance.  We also hypothesized that training may negatively impact iron 
stores, which would negatively affect training quality, and result in poor physical 
performance.   
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Figure 2.4.  Conceptual framework to examine the relationships between iron status, 
training and performance 
 
Using a randomized, placebo-controlled trial design, we used iron 
supplementation to remedy depleted iron stores in order to test the effects of IDNA on 
training and performance, as well as training on IDNA.  We designed the study to see 
if iron supplementation (to replete iron stores) would prevent or reduce the negative 
effect of training on iron status, as well as allow for better training, and thus improved 
physical performance.   
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CHAPTER 3 
 
GENERAL METHODS 
 
This study was designed to examine the relationship between iron status and 
adaptation to endurance training as related to rowing performance in a group of 
highly-trained female endurance athletes.  The objectives of this study were meant to 
provide novel insight into the mechanisms mediating the relationship between IDNA 
and endurance training and performance.  This chapter describes the design and 
analysis plan for the cross-sectional and RCT studies. 
 
This study was conducted in three phases.  During Phase 1, 165 female 
collegiate endurance athletes were screened to identify IDNA subjects (sFer <20 µg/l, 
Hgb >12 g/dL) for phases 2 and 3.   Phase 2 was a cross-sectional comparison of 
physical performance measures across a broad range of both skill levels (novice to 
Varsity) and iron status (normal and  IDNA).  A 6-week randomized, placebo-
controlled iron supplementation trial was conducted during Phase 3.  During Phases 
2 and 3, we were interested in examining how IDNA rowers compensate for the 
effects of IDNA (e.g.  local muscle fatigue, training intensity, reduced energetic 
efficiency, decreased endurance capacity).  Both IDA and IDNA have been linked to 
decreased efficiency and work capacity in animals and humans, and it has been 
demonstrated that consequences of poor iron status include impaired adaptation to a 
training regimen (in previously untrained women) (1, 2).   
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We hypothesized that highly-trained female endurance athletes who are IDNA 
would not only have diminished physical performance as a consequence of IDNA, but 
that this reduced performance would result in part from impaired adaptation to their 
already-high training loads.  We hypothesized that IDNA rowers would also train less 
hard as a consequence of, or in order to compensate for the effects of IDNA, compared 
to their non-IDNA (normal iron status) counterparts.   
Prior to conducting this study, insufficient data existed on which to base 
nutritional supplement intake recommendations for iron in order to ameliorate IDNA 
in female collegiate endurance athletes.  Currently, the National Collegiate Athletic 
Association (NCAA) does not include iron status screening as part of pre-season or 
follow-up medical screening (3).  Data from this study provide novel information 
about iron status and training and performance for a specific group of female 
endurance athletes, and should inform recommendations for optimal iron nutrition 
status in this population.   
 
Institutional Review Board (IRB) Approval 
This study was approved by the Institutional Review Boards at the following 
colleges and universities: Cornell University (CU), Binghamton University (BU), 
Syracuse University (SU), Hobart and William-Smith Colleges (WS), and Ithaca 
College (IC, see Figure 3.1).  The athletic directors and rowing coaches at all five 
schools were notified of the study prior to subject recruitment.  Additionally, all 
coaches were interviewed prior to considering their rowing team eligible to participate 
in the study.  Both phone calls to head coaches and in-person meetings with head and 
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assistant coaches were conducted to gather information about each school’s rowers 
and rowing seasons, as well as to brief the coach on the study’s objectives and 
procedures, and address any questions or concerns.  The cooperation of all coaches 
were essential to the recruiting, screening, and testing processes at baseline and after 
6-weeks, as well as weekly visits to the team to monitor compliance and collect 
training data. 
 
Figure 3. 1.  Rowing teams recruited from central New York, USA 
 
Recruitment of subjects: This study was conducted in four separate cohorts.  
Data from the first cohort was collected from 32 rowers as part of a larger study of the 
iron status of female endurance athletes (runners, swimmers, and rowers from CU, IC, 
and BU) during the spring rowing season of 2006.   Subsequent data was collected in 
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Fall 2008 (WS, CU, IC), Spring 2009 (CU, IC, BU), and Fall 2009 (SU).  All female 
rowers at CU and the surrounding colleges and universities mentioned (n=200) above 
were eligible to participate in the screening if over 18 years of age, non-smokers, and 
regularly-training with their rowing team.   We recruited 165 female collegiate novice 
and varsity rowers between the ages of 18-30 years.  Rowers were screened on the 
Cornell University campus, as well as on rowers’ respective campuses (WS, IC, BU, 
SU).  The number of subjects we chose to screen was based on the assumption that 
30% would meet the criteria for IDNA and wish to continue participation in our 
supplementation trial.  
Data collection: All data collection, including blood sampling and exercise 
testing of CU and IC rowers was conducted on the Cornell University campus in the 
Human Metabolic Research Unit (HMRU), a research facility operated by Cornell’s 
Division of Nutritional Sciences (DNS).  Blood was drawn in the HMRU by a trained 
phlebotomist (DMDV); laboratory samples were analyzed in the HMRU’s Clinical 
Laboratory by a research lab technician (VS); exercise testing was conducted in the 
HMRU’s Human Performance Laboratory by trained and experienced research 
personnel (DMDV); body composition assessments were completed in the HMRU’s 
Body Composition Laboratory by trained research personnel (DMDV).  Rowers 
outside of Ithaca, NY (WS, BU, SU) were screened and tested on their respective 
campuses (DMDV), times and locations determined by coaching staff (as agreed upon 
by each school’s Human Subjects Committee/IRB).   
Screening and testing off-campus worked out well, with the help of rowing 
coaching staff at SU, BU, IC and WS.  Ithaca College rowers were screened on the IC 
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campus in the Wellness Center in order to minimize subject burden; all subsequent 
exercise and body composition testing was done in Cornell’s HMRU.  Weekly visits 
conducted by the researcher (DMDV) to IC students took place on the IC campus to 
maximize participation and compliance (capsule, log, and accelerometer drop-off and 
pick-up).  Any IC student who did not have personal transportation to Cornell for 
testing was provided with or reimbursed for transportation.  Rowers at WS, BU, and 
SU were both screened and tested on their respective campuses.  To maximize 
participation, screening and testing in these locations took place in an area easily 
accessible to the rowers, and accommodating for our testing equipment (chair, table, 
metabolic cart, bioelectrical impedance analyzer, anthropometry, cleaning, etc).  
Testing took place in a gymnasium at WS and BU, and in an exercise physiology 
laboratory at SU (c/o T. Brutsaert’s Human Performance and Body Composition labs, 
SU Exercise Science Department).  Our metabolic testing equipment (metabolic cart, 
body composition equipment, etc) was brought to WS and BU to conduct all testing.  
Weekly visits were made to all rowers (usually before or after daily boathouse training 
session) to collect and distribute capsules, logs, and accelerometers (weekly visits to 
all schools: DMDV; occasional visits to CU rowers: KA, EC, KK ).  
A medical screening (NCAA-required) prior to our study pre-excluded all 
athletes not healthy enough to participate in their rowing team training (current, acute 
or chronic illness, severe asthma, musculoskeletal problems, etc).  After NCAA 
medical clearance, and from a potential subject pool of ~250 female collegiate rowers, 
165 subjects were recruited and iron status was screened during the first week of the 
conditioning phase of their competitive season (see Figure 3.2).  A signed consent 
57 
 
form, explaining the details of the study and its different phases was obtained from 
each subject before any data collection (Appendix 2).   
Each rower’s iron status was assessed, and information on current dietary 
intake including  iron intake, supplement use, menstrual status, usual physical activity, 
and eating habits and attitudes was obtained using questionnaires (described in 
subsequent chapters, and contained within Appendix 2-8).  This screening of iron 
status occurred at the beginning of their training season (within the first week of 
training).  Within one week of being screened, subjects were given the results of the 
iron status assessment (RBC, Hgb, Hct, sFer) as the benefit of participation (Appendix 
10.8).  Subjects participating in the laboratory testing  were immediately given the 
results of all body composition and exercise testing variables as the benefit of 
participation in the cross-sectional and supplementation trials (Appendix 10.9).  All 
anemics  (Hgb<12.0 g/dL) were notified of their status immediately after blood test 
results (within 1 week of analysis) and were referred to campus health services for 
further instruction/monitoring.   
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Figure 3.2.  Time line and flow of subjects through 6-week supplementation study 
Screening of Iron status  
(Chapter 4) 
n= 165 female collegiate rowers 
(10% Anemic, 30% IDNA) 
 
Baseline data collection 
(Chapter 5) 
n=56 
n=48 non-anemic 
 
Randomization to treatment groups 
(Chapter 6, 7, 8) 
n=40 non-anemics 
(n=23 w/sFer<20 µg/L) 
 
100 mg/d FeSO4 
n=21 
(n=12 sFer <20.0 µg/L) 
 
Placebo 
n=19 
(n=11 sFer<20.0 µg/L) 
 
Lost to follow-up: 
(n=6) 
Sick (n=2) 
Injured (n=2) 
Unknown reasons (n=2) 
 
4 of 6 drop outs w/sFer <20.0 
µg/L) 
Analyzed 
n=16 completed placebo group  
(n=8 sFer<20.0 µg/L) 
 
Lost to follow-up: 
(n=3) 
Quit team (n=1) 
Injured (n=1) 
Unknown reasons (n=1) 
 
2 of 3 drop-outs had sFer<20.0 
µg/L) 
Analyzed 
n=15 completed Iron group 
(n=8 sFer <20.0 µg/L) 
 
Week 0-1 of training: 
Beginning of  training 
season 
 
Week 1 of training: 
Baseline data collection 
(body composition, 
performance testing, 
training) 
 
n=31 completed entire 6-week protocol and all baseline and 
endpoint testing 
 
(n=16 sFer<20.0 µg/L, 15 sFer>20.0 µg/L) 
 
Excluded: 
 
Anemic subjects (n=8) 
 
Declined further participation 
(n=8) 
Excluded: 
 
Declined further participation 
(n=109) 
Weeks 1-6: 
Training 
 
 
Week 3: 
Iron status 
assessment 
 
 
Week 1, 6: 
Iron status 
assessment 
 
Performance, 
body composition 
testing 
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Athletes would have been excluded from participating in the cross-sectional 
and supplementation trials if they had been clinically diagnosed with an eating 
disorder; were pregnant or lactating; had been taking iron supplements within 4 weeks 
of screening; or had any physical problems or presently take medications that would 
affect their ability to safely participate in exercise testing.  Additional exclusions 
included: hemolytic anemia, exercise-induced asthma, excess alcohol consumption, 
drug use (casual and/or prescription medications), steroid use.  No rowers who 
volunteered to participate in the laboratory testing were excluded based on these 
criteria. 
Within one week of the screening, 48 non-anemic rowers volunteered to 
complete the baseline laboratory testing, after which forty rowers were randomly 
assigned to treatment groups.  This study was a randomized, double-blind, placebo-
controlled iron supplementation trial. Each subject was randomly assigned to a 
treatment group by a research assistant who was not involved in data collection or 
contact with subjects (DS, SK).  Randomization was done by assigning each subject a 
random number, with even and odd numbers being assigned to either treatment group.  
After initial randomization, any imbalance in the distribution of treatment or 
representation of school or baseline iron status (sFer) was corrected by re-
randomization.  
Volunteers assigned to the placebo group were provided with capsules 
containing lactose filler; those assigned to the iron group were provided with capsules 
containing 50 mg ferrous sulfate (FeSO4) for six weeks. Capsules used for both groups 
were identical. Both iron and placebo capsules were prepared by a Registered 
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Pharmacist (PharmD) at the Cornell University College of Veterinary Medicine 
Pharmacy (Ithaca, NY).  The iron supplement capsules contained 50 mg FeSO4 per 
capsule, and the placebo capsules contained lactose.  The iron content of both placebo 
and iron capsules was analyzed via ICP mass spectrometry digestion by the USDA’s 
Robert Holley Center for Agriculture and Health (Ithaca, NY).  Twenty capsules were 
randomly selected for analysis from each of 2 batches.  No differences in the average 
iron content were found between the two batches of capsules, however, the capsules 
contained  30% elemental iron (15.8 ± 0.5 mg elemental iron per capsule), which is 
greater than  the 20% elemental iron expected from a typical FeSO4 preparation. 
Subjects were provided with 18 capsules each week, and were instructed to 
consume 2 capsules per day (total of 100 mg FeSO4/day, ~30 mg elemental iron/day, 
based on the analysis of our capsules). Subjects were instructed to consume one 
capsule each with their morning and evening meals to minimize potential 
gastrointestinal side-effects, and with a glass of citrus juice to enhance iron absorption.  
This dose was selected based on previous findings both in and outside of our lab 
reporting the beneficial effects and minimal side effects of 100 mg FeSO4 on iron 
status and performance in young, active women(4, 5).  
Subjects’ compliance with the iron treatment, as well as current health, 
menstrual status, and physical activity was assessed by daily logs (Appendix 10.10). 
Subjects were instructed to record the number of capsules they consumed daily in their 
log, even if they had consumed less than the prescribed daily amount.  Additionally, 
weekly capsule counts were conducted by the researcher.  
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Thirty-one rowers completed the six-week trial, including endpoint laboratory 
assessments.  No adverse events were reported during the trial.  A total of nine 
subjects did not complete the trial due to injury, illness, separation from the rowing 
team, or personal/unknown reasons. Subjects were debriefed after completing the 6-
week final assessments.  They were informed of their treatment assignments and given 
laboratory, body composition, and physical fitness assessment reports, with 
recommendations for treating iron deficiency as necessary.  All subjects who were ID 
and/or anemic at the end of the trial were given 30d of iron supplementation and/or 
referred to campus health services for further evaluation and/or counseling.   
Analytical approach:  Although the three phases of the study (screening, cross-
sectional analysis of the baseline data, and the supplementation trial) share a common 
sampling frame, methodology, and are parts of a whole (RCT), the analyses were 
conducted separately and each tell a unique story. Measurements and assessment 
techniques used throughout all phases of this study will be described in the chapters 
that follow.  This section outlines the analytical approach to each phase of the study. 
Screening of iron status (Phase 1, Chapter 4):  For this cross-sectional 
analysis, our main objective was to describe the iron status of our sample of female 
collegiate rowers at the beginning of a training season.  Our main outcomes were 
indicators of iron status, as well as prevalence of anemia and iron deficiency with and 
without anemia. We also collected a self-reported measure of ergometer performance 
(reported 2K personal record (PR)) from the previous training/competitive season.  
For this performance outcome, the 149 non-anemic subjects were analyzed. We 
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hypothesized that iron depleted rowers would have slower 2K PRs compared to 
rowers with normal iron status.   
Student’s T-test and ANOVA were used to analyze differences between groups 
for iron status (sFer group, iron depleted versus normal, based on sFer cutoff of 20.0 
µg/L) with respect to all variables measured.  Pearson’s correlations were used to 
examine associations between variables. To investigate the effects of iron status on our 
performance measure, multiple regression analysis (MIXED procedure with School as 
a random effect) between reported 2K time and sFer group status with potential 
confounders included as covariates in the regression models (height, years of 
experience).  A significance level of p<0.05 was used to test the main effects of the 
primary hypotheses, and p<0.10 was the level of statistical significance used to test 
interaction effects.   
Baseline laboratory assessments (Phase 2, Chapter 5): For this cross-sectional 
analysis, our main outcomes were measures of physical performance that were 
assessed in the laboratory at the beginning of the training season.  These included 4K 
time trial (TT) time, peak oxygen consumption reached during the 4K TT (VO2 peak), 
and gross energetic efficiency (EF).  This analysis included the 48 non-anemic rowers 
that completed all laboratory testing, as well as a 7-day training log at baseline. We 
hypothesized that rowers with depleted iron status would have lower VO2 peak, be 
less energetically-efficient, and have a slower 4K TT time compared to rowers with 
normal iron status.  We also hypothesized that iron-depleted rowers would train less 
hard during that first week of training, meaning that they would spend less time 
training at a lower intensity compared to rowers with normal iron status.  
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Student’s T-test and ANOVA was used to analyze differences between groups 
of non-anemics (Normal: sFer>20.0 µg/L vs Depleted: sFer<20.0 µg/L) with respect 
to all variables measured.  Pearson’s correlations were used to examine associations 
between variables.  To investigate the plausible effects of iron status on endurance 
performance, multiple regression analyses (MIXED procedure with School as a 
random effect) of the relationship between measures of physical performance assessed 
in the laboratory (VO2 peak, gross EF, 4K TT time) and total body iron stores (sFer, 
sTfR, TBI) was conducted, controlling for potential confounders. Covariates used in 
the development of regression models included training group (based on session RPE 
cutoff of 3200, low vs high); height, fat-free mass, deviation from prescribed work 
rate, and average work rate during the 4K TT.  A statistical significance level of 
p<0.05 was accepted for testing main effects.  We also explored the cross-sectional 
relationship between iron status and training on performance outcomes at the 
beginning of the training season using sFer group-by-training group.  A p<0.10 was 
considered significant for testing these interaction effects.   
Randomized, placebo-controlled iron supplementation trial (RCT, Phase 3, 
Chapters 6, 7, 8): At the end of the RCT, change from baseline in iron status, training 
quality, and measures of physical performance mentioned above were our main 
outcomes.  Supplementation trial analyses were conducted on an “as-treated” basis, 
including all randomized subjects, regardless of adherence or dose consumed.  A 
p<0.05 was considered significant for testing main effects, and p<0.20 for exploring 
interaction effects. Iron status data was log-transformed where appropriate prior to 
analyses.  
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 Independent Student’s t-test was used to test group differences at baseline, 
since randomization was not a guarantee that both treatment groups were identical in 
all respects.  The confounding potential of any factor that was significantly different 
between groups was further tested using correlation analysis.  All potential 
confounders were included as covariate in subsequent analyses. 
Repeated measures ANOVA were used to test group and time effects as well as 
group-by-time interactions for measures of iron status and performance.  Regression 
analysis with baseline measurements as covariates were used to analyze group 
differences in change in iron status or physical performance (endpoint minus 
baseline), as well as other potential confounding or mediating factors.  All models 
were tested for β not equal to zero at p<0.05 on a one-tailed test. 
The effects of change in iron status on change in other outcome variables were 
analyzed by multiple linear regression analysis (GLM, MIXED procedure with School 
as random effect), controlling for baseline outcome values and iron status as well as 
other potential confounding or mediating factors.  
 
Change from baseline (outcome variables)= 
β0 (constant) + β1Baseline + β2 group (S vs P) + βCXC (potential confounders) 
 
To test for plausibility, a dose-response in sFer was tested for the iron 
supplemented group by examining the correlation between change in sFer and dose of 
iron capsules consumed, showing that the changes in outcome variables were due to 
the iron treatment (those in iron group who took more capsules should have exhibited 
greater change in iron status).   Analyses were also conducted to test potential to 
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benefit, or baseline iron status by change in iron status (those with lowest baseline iron 
status should have exhibited greater response to treatment).  Similar plausibility 
testing was conducted for performance and training outcomes (dose-response, baseline 
values). 
 
Change from baseline (outcome variables) =  
β0 (constant) + β1Baseline outcome (pre-Tx) + β2 change-Iron status (post-Tx 
iron status minus baseline iron status) + βCXC (confounders) 
 
 The relationship between iron status and performance was hypothesized to be 
mediated by training.  Change in performance outcome variables with change in iron 
status, as well as change in training status were conducted.   
 
Change from baseline (outcome variables)= 
β0 (constant) + β1Baseline outcome (pre-Tx) + β2 change-Iron status (post-Tx 
iron status minus baseline iron status) +β3 change in mediator (final value minus 
baseline value) + βC XC   
 
 
Sample size estimation: Using a significance level p<0.05, 80% power, the 
following is a summary of effect sizes (Table 3.1) that we had expected with iron 
supplementation (Treatment vs Placebo) based on previous research with non-athletic 
women with good compliance (n=20/group)  in our lab (2, 6).  Based on previous 
reports of 30% IDNA in active females, we needed to screen approximately 150 
rowers to reach a sample size of 20-25 rowers per treatment group.   
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Table 3.1 Effect sizes of important outcome variables used to calculate sample size 
Main Outcome 
Measures 
Expected effect size  
(SD units)  
Control group  
SD 
 
Sample size needed 
per group 
Post-tx  sFer (µg/L) 1.12 4.0 11 
    
Change in TT time 
(min) 
 
0.70 2.2 26 
Change VO2max 
(ml/kg/min) 
 
0.65 8.7 29 
 
Effect size and sample size calculator:  
http://www.danielsoper.com/statcalc/default.aspx 
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CHAPTER 4 
 
IMPACT OF IRON DEPLETION WITHOUT ANEMIA ON TRAINED 
ENDURANCE ATHLETES AT THE BEGINNING OF A TRAINING SEASON:  
A STUDY OF FEMALE COLLEGIATE ROWERS IN CENTRAL NY STATE 
 
Abstract 
The objective of this study was to determine the impact of iron depletion 
without anemia in a sample of female collegiate rowers at the beginning of a training 
season (August 2008, January 2009, & September 2009).  One-hundred and sixty-five 
female collegiate rowers from five colleges and universities in central NY state 
participated in a screening of iron status.  Blood hemoglobin (Hgb), serum ferritin 
(sFer), and soluble transferrin receptor (sTfR) were measured to determine prevalence 
of iron depletion and anemia. Rowers’ habitual moderate and vigorous physical 
activity, as well as their best time (PR) to complete a 2K simulated race during the 
previous three months were self-reported.  Sixteen rowers (10%) were identified as 
anemic (Hgb<12.0 g/dL), nine of whom (5% of total) were iron-depleted (sFer<20.0 
µg/L).  Thirty percent (N=44) of the non-anemic rowers were identified as iron 
depleted without anemia.  Multiple regression analyses revealed that sFer group status 
(based on sFer cutoff of 20.0 µg/L) was a significant (p<0.001) predictor of rowers’ 
reported 2K performance times (mean 7 min 49 seconds) after controlling for height 
and years of rowing experience. Iron depleted rowers reported 2K times ~21 seconds 
slower (p<0.004) compared to rowers with normal iron status.  Iron depletion without 
anemia is a prevalent problem among female endurance athletes.  A sFer cut-off of 
20.0 µg/L is clinically useful to identify and treat non-anemic iron depletion at the 
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beginning of a training season, and improving sFer status may improve rowing 
performance. 
Introduction 
Iron deficiency (ID) is the most prevalent nutrient deficiency in the world.  In 
the United States, iron deficiency with anemia (IDA) affects 3-5%, and iron deficiency 
without anemia (IDNA) affects ~16% of premenopausal women (1).  Changes in 
energy metabolism and physical work capacity have been described in humans and 
animals with iron depletion (2-4).  Compared to their sedentary counterparts, female 
athletes are more susceptible to iron depletion without anemia (IDNA, 25-35%), 
which is 5-7 times more prevalent than IDA (5-10). Though the exact mechanism is 
unknown, the increased prevalence of IDNA in active or training females may be due 
to one or a combination of the following factors: hemolysis (foot strike, impact); 
increased blood loss (gastrointestinal tract, hematuria, sweat); poor dietary iron intake; 
or altered intestinal iron absorption, including the effects of inflammation due to 
training (11-13).   
Collegiate rowers train for and compete in racing competitions that last <30 
min (short-duration and high-intensity exertion), during which oxidative metabolism is 
the main energy pathway.  It has been shown that the activity of iron-dependent 
enzymes and cytochromes needed for oxidative metabolism are decreased in animals 
(14) and humans (15) with IDNA, which leads to impaired endurance performance.  
Thus, consequences of IDNA particularly relevant to endurance athletes include 
reduced endurance capacity and energetic efficiency (16), and increased local muscle 
fatigue (17). 
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Serum ferritin (sFer) is the most common index of body iron stores, and 
reflects iron stored in the liver.  sFer can be elevated in an inflammatory state (e.g. 
infection, post-exercise), however, an inflammatory marker such as C-reactive protein 
(CRP) or α-1-acid glycoprotein (AGP) can help identify individuals with false-positive 
iron depletion due to inflated sFer (18-20).  Soluble transferrin receptor (sTfR), a 
trans-membrane protein regulated by cellular iron status, reflects ID at the tissue level 
and is a more sensitive index of functional ID.  Unlike sFer, sTfR is unaffected by 
inflammation, and has been shown to have lower within-subject variability in 
intensely training athletes (5).  Total body iron (TBI, mg/kg) can be calculated using 
both sFer and sTfR (21), though in a population with a low prevalence of anemia, 
calculated TBI is driven by sFer.    
The purpose of this study was to examine the prevalence of IDNA among 
female collegiate rowers at the beginning of a training season, and determine the 
association between iron status and reported rowing performance.  
Methods 
Recruitment of subjects: This study was approved by the Institutional Review 
Boards of the following colleges/universities: Cornell University, Binghamton 
University, Syracuse University, Hobart & William Smith Colleges, and Ithaca 
College.  Rowers were recruited over a period of three years (Spring 2006, Fall 2008, 
Spring 2009, and Fall 2009).  Varsity and second-semester novice female rowers who 
were >18 years of age and able to begin regular training for their sport were eligible to 
participate in the screening.  Subjects were recruited at the beginning of the 
conditioning phases of their competitive rowing seasons (upon arrival to campus post- 
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summer and post-winter break). Training activities during this time included general 
aerobic conditioning (cycling, running, rowing on ergometer), resistance training, and 
high-intensity rowing training. 
Team coaches were instrumental in recruitment and screening efforts.  A 
medical screening (NCAA-required) prior to our screening excluded all athletes not 
healthy enough to participate in their rowing team training (current, acute or chronic 
illness, severe asthma, musculoskeletal problems, etc).  All rowers provided written 
voluntary informed consent prior to participating in the study.  A total of 165 female 
rowers out of 199 eligible rowers completed the iron status screening.  Subjects 
received iron status results as a benefit of participation, along with 
referral/recommendations to improve iron status as necessary.   
Measurements: After NCAA medical clearance, iron status variables were 
measured for each subject and demographic, as well as information on current dietary 
supplement use, health and menstrual status, and habitual physical activity. Height and 
weight were self-reported, and were later validated with measured height and weight 
in a sub-sample of 48 subjects who participated in an intervention trial (height: 
r=+0.98, p<0.001; weight: r=+0.99, p<0.001, and no systematic bias).  Time spent in 
light/moderate and vigorous physical activity was quantified via self-report (habitual 
endurance training, and leisure-time physical activity (LTPA) frequency, intensity, 
type, and duration).  Performance was assessed via self-reported best times (PRs) to 
complete a 2K simulated race on the ergometer from the previous season (2-3 months 
prior to iron status screening).  Reported 2K times were also later validated with 
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measured performance in the aforementioned subsample of 48 rowers (VO2peak, 
L/min: r=-0.69, p<0.001; 4K time, min: r=+0.64, p<0.001). 
Iron status variables measured immediately after non-fasting venous blood 
sampling (antecubital venipuncture, into two evacuated tubes with EDTA and serum-
separator) included hemoglobin (Hgb), hematocrit (Hct), red blood cell count (RBC, 
Beckman Coulter, Fulerton, CA); sFer (Immulite 2000); soluble transferrin receptor 
(sTfR, ELISA, Ramco Laboratories, Stafford, TX); and α-1-acid glycoprotein (AGP, 
radial immunodiffusion plate, Kent Labs, OR).  Rowers were classified as either iron 
depleted (sFer<20 µg/L) or normal (sFer>20 µg/L).  All anemic subjects (N=16) were 
notified of their status immediately after blood test results (within 1 week of analysis) 
and referred to their respective campus health services for further 
instruction/monitoring or treatment.   
Data Analysis: All data analysis on 149 non-anemic subjects was completed 
using SPSS (version 18.0, SPSS Inc, Chicago, IL).  Descriptive statistics are presented 
as means ± standard deviations (SD). Student’s T-test and ANOVA were used to 
analyze differences between groups for iron status (iron depleted versus normal) with 
respect to all variables measured.  When a significant overall difference was detected, 
Bonferroni’s post-hoc analysis was used. Pearson’s correlations were used to examine 
associations between variables. To investigate the effects of iron status on physical 
performance, multiple regression analysis between physical performance (2K time) 
and sFer group status (based on sFer cutoff of 20.0 µg/L) with potential confounders 
included as covariates in the regression models (variables correlated with physical 
performance, or significantly different between iron status groups) were included as 
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covariates.  A significance level of p<0.05 was used to test the main effects of the 
primary hypotheses, and p<0.10 was the level of statistical significance used to test the 
interaction effects.   
Results 
Sixteen rowers (10%) were identified as anemic (Hgb<12.0 g/dL) and 
eliminated from subsequent analyses of IDNA subjects.  Results of the iron status 
screening of non-anemic rowers are presented in Table 4.1. Thirty percent (N=44) of 
the non-anemic rowers were found to be iron depleted (sFer <20.0 µg/L), and 12% 
(N=18) were clinically iron deficient (sFer <12.0 µg/L).  There were no significant 
differences between rowers with depleted or deficient iron status and those with 
normal iron status in any demographic variable.  Nineteen non-anemic rowers (13%) 
had high values of sTfR (>8.5 mg/L) and 10% (N=15) had TBI <0 mg/kg, indicating 
severe iron deficiency.  Nineteen percent of screened subjects had a previous history 
of anemia or physician- diagnosed iron deficiency.   
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Table 4.1.  Iron status (mean±SD) of non-anemic female collegiate rowers (between 
schools) at the beginning of training season  
 
Iron status indices School A 
(CU) 
N=60 
School B  
(IC) 
N=39 
School C  
(BU) 
N=18 
School D  
(WS) 
N=16 
School E 
(SU) 
N=16 
Total 
(All) 
N=149 
Serum ferritin  
(sFer, µg/L) 
31.9±22.0 26.4±14.1 31.3±23.4 42.0±21.1 51.2±28.0* 33.6±22.1 
Log sFer (µg/L) 1.4±0.3 1.4±0.3 1.4±0.3 1.6±0.2 1.6±0.3 1.4±0.3 
Hemoglobin  
(Hgb, g/dL) 
13.1±0.7 13.3±0.7 13.2±0.6 13.1±0.7 13.6±0.7 13.2±0.7 
Red Cell 
Distribution Width  
(RDW, %) 
13.1±1.0 13.3±1.2 13.0±2.1 12.5±0.7 12.6±0.4 13.0±1.2 
Hematocrit  
(Hct, %) 
40.2±2.3 41.3±2.3 39.8±1.5 41.3±1.9 41.7±2.2 40.7±2.2 
Mean Cell Volume  
(MCV, fL) 
88.3±3.2 89.1±3.4 88.5±4.4 89.2±4.2 90.5±1.7 88.8±3.5 
Soluble transferrin 
receptor  
(sTfR, mg/L) 
6.4±1.6 6.9±2.1 6.1±2.0 5.8±1.4 7.1±2.7 6.5±1.9 
Total Body Iron  
(TBI, mg/kg) 
3.5±3.3 3.1±2.7 3.6±3.4 5.4±1.5 5.3±2.4 3.8±3.0 
 
Number  and prevalence (%) of iron depletion and normal iron status between schools  
Normal  
(sFer>20.0 µg/L) 
40 (67) 25 (64) 12 (67) 15 (94) 13 (81) 105 (70) 
Iron depleted 
(sFer<20.0 µg/L) 
20 (33) 14 (36) 6 (33) 1(6) 3 (19) 44 (30) 
Iron deficient 
(sFer<12.0 µg/L) 
9 (15) 5 (13) 4 (22) 0 (0) 0 (0) 18 (12) 
sTfR >8.5 mg/L 4 (7) 9 (23) 3 (2) 1 (6) 2 (13) 19 (13) 
TBI <0.0 mg/kg 7 (12) 5 (13) 2 (11) 0 (0) 1 (6) 15 (10) 
AGP>140.0 mg/dL 1 (2) 2 (5) 0 (0) 0 (0) 0 (0) 3 (2) 
*Significantly different from Schools A and B (p=0.014 and 0.04, respectively). 
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On average, rowers were 19.7±1.2 years of age, 170.7±7.3 cm tall, and 
weighed 69.5±8.1kg (BMI 23.7±3.3 kg/m
2
).  Across the sample, rowers had 3.0±2.3 
years rowing experience; a previous season 2K time of 7 minutes and 48 seconds 
(469±25 sec); and spent 6.4±2.2 hours per week in combined moderate and vigorous 
physical activity.  On average, School E rowers reported spending more time 
participating in vigorous physical activities (5.6±3.3 hr/week) compared to rowers at 
Schools A and C (2.7±2.3 and 2.7±2.0 hr/week, respectively).  Compared to the rest of 
the sample, rowers at School C reported slower 2K times (8 min and 12 sec, or 
493.4±25.2 sec).  Rowers at schools A and E were taller (175 cm), faster (7 min and 
42 sec, or 460 sec 2K time), and more experienced (3.8 y) than the other schools in the 
sample.   
Simple correlations revealed that reported time spent in light-to-moderate 
physical activity per week was positively associated with BMI (r=0.23, p=0.020) and 
years of rowing experience (r=0.29, p=0.03).  As expected, height and weight were 
negatively correlated with 2K performance time (r=-0.51 and -0.39, respectively, 
p<0.001).  Rowers with less experience were more likely to have lower sFer (r=0.30, 
p=0.01).  Total body iron was not correlated with 2K PR (r=-0.06, p=0.55) or weekly 
time spent in vigorous (r=0.05, p=0.65) or light-to-moderate (r=0.12, p=0.28) physical 
activity.  There was no significant correlation between supplement use and TBI (r=-
0.26, p=0.77).  Rowers reportedly taking a vitamin/mineral supplement (33% of 
sample) were more likely to have a higher BMI (r=0.18, p=0.03) compared to those 
who did not report taking a dietary supplement.   
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Multiple regression analyses revealed that sFer group, height, and years of 
rowing experience were each a significant predictor of 2K performance time (p<0.05).  
For these non-anemic subjects, Hgb was not a significant predictor of 2K time and was 
not included in the multiple regression models, and there were no significant 
interactions between iron status and the amount of time spent in physical activity.  On 
average, 2K times were 21 seconds slower for those rowers with iron depletion 
(sFer<20.0 µg/L) compared to rowers with normal iron status (p=0.004, see Figure 
4.1).   
 
Figure 4.1.  The impact of IDNA on rowers’ reported 2K performance (means 
adjusted for years of rowing experience and height, p=0.004).  *Depleted rowers 
(sFer<20.0 µg/L) significantly different from Normal rowers (sFer>20.0 µg/L), 
p=0.004. 
 
* 
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Discussion 
Our sample of collegiate female rowers is one of high risk for iron depletion 
due to their age and high training load, among other factors.  Although the exact 
mechanism by which endurance training results in decreased iron status remains 
unknown, possible explanations include poor dietary intake (7, 22-24); increased iron 
loss in sweat and urine (25); increased hemolysis (26, 27); the acute phase response 
(27, 28); or plasma volume expansion (29).  With the exception of the acute phase 
protein AGP (which was not used to exclude subjects from the analysis), these factors 
were not measured in the current sample.   
Strategies to easily screen and improve iron status may be useful for female 
endurance athletes at the beginning of a training season because data suggest that iron 
status of very active women may decrease with increased levels of physical training 
over time (30-33).   In a recent study, McClung et al (30) examined 94 female US 
Army recruits before and after 9 weeks of Basic Combat Training (BCT) and found 
that sFer decreased by 20% (p<0.01). In other longitudinal (5 weeks to 6 y) studies of 
female athletes, sFer decreased by ~25% after training (32, 33).   
Early screening and iron supplementation, both of which have been shown to 
improve resistance to fatigue and endurance capacity in IDNA non-athletes (16, 17), 
may be beneficial to female endurance athletes at the beginning of a season to thwart 
further decrements in iron status throughout the training and competitive seasons.  
Given the modest relationship between early season iron status and recent 
performance observed in this study, improving iron status may improve endurance 
athletes’ adaptation to training, as well as their performance in competition. 
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The cross-sectional design of this study limits our ability to examine factors 
that account for differences in iron status between schools, which could be the result 
of differences in iron-related variables other than rowing training.  Not all potential 
confounders could be measured in this survey.  Due to logistic considerations of the 
current survey, a self-reported measure of performance (2K PR) during the previous 2-
3 months was used as an outcome, and although the self-reported measure was highly-
correlated with lab-derived values in a subsample of 48 rowers, results should be 
interpreted with caution.  Although a limitation, the observed effect of IDNA on a 
non-concurrent measure of physical performance is consistent with laboratory data 
showing that IDNA impairs endurance performance in non-athletic women (16, 34).  
It would be important to confirm these results in a longitudinal study, preferably 
following the same rowers periodically throughout both seasons of the academic year.  
Future research should examine the prevalence, risk factors, and mechanisms of IDNA 
in female athletes, including plasma markers of hemolysis, accurate measures of 
athletes’ menstrual blood loss, dietary iron intake/absorption, as well as other markers 
of iron metabolism, such as hepcidin.   
Conclusions: The 30% prevalence of IDNA among the female rowers in this 
study was similar to that previously reported for other female athletes participating in 
endurance sports, as well as female soldiers (5-10). Results from this study add to the 
evidence that iron status is an important issue facing female endurance athletes at the 
beginning of a training season.  The prevalence of iron depletion is higher in female 
endurance athletes compared to the general population of young women due to many 
factors.  Female endurance athletes should be screened for iron deficiency and 
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depletion using serum ferritin cut-off of 20.0 µg/L to identify iron depletion before it 
leads to anemia or frank iron deficiency, thus reducing the adverse affects that iron 
depletion may have on their training and performance.  Athletes with a history of 
anemia or iron deficiency should receive counseling regarding supplementation and 
food choices, as well as serial monitoring of their iron status (Hgb, sFer).  
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CHAPTER 5 
 
HOW IS IRON STATUS ASSOCIATED WITH ENDURANCE PRFORMANCE 
AND TRAINING IN FEMALE COLLEGIATE ROWERS? 
 
Abstract 
 
Introduction:  Studies in both animals and humans have shown a relationship between 
iron depletion without anemia (IDNA) and physical performance. Consequences of 
IDNA relevant to endurance athletes include reduced work capacity, endurance, and 
energetic efficiency.  We conducted a cross-sectional study to investigate the 
relationship between iron status and endurance performance and training in non-
anemic female collegiate rowers. 
Methods: The iron status (hemoglobin, serum ferritin, soluble transferrin receptor) of 
165 female rowers from five colleges and universities in central New York, USA was 
assessed at the beginning of a training season.  Twenty-seven percent (n=44) of rowers 
were identified as IDNA (sFer<20.0 µg/L) and 10% as anemic (n=16, Hgb<12.0 
g/dL).  Forty-eight (n=24 Normal, n=24 Deplete) non-anemic rowers volunteered to 
have their body composition measured and physical performance assessed (VO2 peak, 
4K time, gross energetic efficiency).  Rowers also recorded their training (time, type 
and intensity) for 7 days, and daily training load was calculated using the session RPE 
method (training duration-by- intensity rating).  
Results: There were no significant differences between the two iron status groups in 
any of the potential confounders of the association between iron status and 
performance that were tested.  Compared to rowers with Normal iron status, Depleted 
rowers trained ~10 minutes less per day (p=0.02), and had a 0.3 L/min lower VO2peak 
83 
 
(p=0.03). With multiple regression analysis both sFer and training group (high versus 
low based on session-RPE cut-off of 3200) were significantly positively related to 
VO2peak. Less highly-trained rowers with poor iron status had a lower VO2peak (-
0.32 L/min, p=0.02), and were less energetically-efficient (-1.7%, p=0.09) compared 
to more highly-trained rowers with poor iron status, and improved performance with 
improved iron status was only observed in less well-trained subjects. 
Conclusion: Impaired iron status is a prevalent problem among female endurance 
athletes. The performance of less highly-trained rowers was poorer among those with 
low iron status than that of more highly-trained rowers.  IDNA may prevent rowers 
from training as hard, directly impacting their performance. 
Key words: iron depletion, athletes, physical performance, VO2peak, energetic 
efficiency  
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Iron status and endurance performance in female collegiate rowers  
 
Introduction 
Iron deficiency (ID) is the most prevalent nutrient deficiency in the world, 
including the US, where iron deficiency with anemia (IDA) affects 3-5%, and iron 
deficiency without anemia (IDNA) affects ~16% of young women (1).  Changes in 
energy metabolism and physical work capacity have been described in humans and 
animals with iron depletion (2).  Compared to their sedentary counterparts, female 
athletes are more susceptible to iron depletion, with prevalence as high as 25-35% (3-
7).  Although the exact mechanism is unknown, the increased prevalence of IDNA in 
active and training females may be due to a combination of factors, including: 
hemolysis (foot strike, impact); increased blood loss (gastrointestinal tract, hematuria, 
sweat); change in iron absorption due to inflammation of training; and/or poor dietary 
iron intake (8-11).  
Iron plays an essential role in oxygen transport and energy production during 
aerobic exercise.  Individuals with anemia (hemoglobin (Hgb) <12.0 g/dL) experience 
decreased maximal oxygen consumption (VO2max), an indicator of physical work 
capacity (2). Individuals with IDNA (serum ferritin (sFer) <20.0 µg/L, Hgb >12.0 
g/dL) are expected to have adequate O2-carrying Hgb but impaired O2 utilization, and 
thus suffer the functional consequences of tissue iron depletion, which results in 
reduced physical performance (12).  
Despite the inability to identify the exact mechanism in humans, endurance 
capacity, energetic efficiency, and time trial (TT) performance have been shown to be 
impaired in laboratory studies of IDNA human research subjects (13-16).  Studies of 
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how iron status affects non-anemic endurance athletes are limited, but research 
suggests that female endurance athletes and military soldiers with IDNA also have 
impaired physical performance (17-21).  It is has been suggested in animal and human 
studies that iron status is related to physical training, but the causal direction of this 
relationship is unclear (22-28).  In a sample of 149 non-anemic female rowers, we 
found that sFer was a significant predictor of reported 2K Personal Record (PR) time, 
and that iron-depleted rowers reported 2K times that were ~21 sec slower (p<0.001) 
compared to rowers with normal iron status (Chapter 4).  The strong relationship 
between rowers’ iron status and reported performance, as well as the limitation of self-
reported performance led us to perform the current study in which we were able to 
examine the relationship between iron status and performance measures assessed in a 
laboratory setting.   
The objective of this study was to examine the effects of iron depletion without 
anemia (IDNA, sFer <20.0 µg/L, Hgb >12.0 g/dL) on female collegiate rowers’ 
endurance training and exercise capacity as assessed by VO2peak, gross energetic 
efficiency, and time to complete a 4K time trial (TT), as well as reported training 
intensity and duration.  We hypothesized that rowers with IDNA would have a lower 
VO2peak, be less energetically efficient, have poorer 4K TT performance, and train 
less than rowers with normal iron status.    
Methods 
Recruitment of subjects: This study was approved by the Institutional Review 
Boards of the following colleges/universities: Binghamton University, Cornell 
University, Hobart and William-Smith Colleges, Ithaca College, and Syracuse 
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University. All rowers provided written informed voluntary consent prior to 
participating in the study.  Subjects were recruited at the beginning of the conditioning 
phases of their competitive rowing seasons (fall 2008, spring 2009, and fall 2009, 
upon arrival to campus post- summer and post-winter break). All varsity and second-
semester novice female rowers were eligible to participate in the screening if greater 
than 18 years of age, non-smoking, and were able to begin regular training for their 
sport. Training activities during this time included general aerobic conditioning 
(cycling, running, rowing on ergometer), resistance training, and high intensity 
rowing.  
Team coaches were instrumental in recruitment and screening efforts. Initial 
meetings with each coach were conducted prior to the start of each season to discuss 
the study and assess coach/team interest.  Coaches approached his/her team during 
their initial pre-season team meetings to assess interest in participating in the iron 
status screening.  A medical screening (required by the National Collegiate Athletic 
Association, NCAA) prior to our study excluded all athletes not healthy enough to 
participate in their rowing team training (current, acute or chronic illness, severe 
asthma, musculoskeletal problems, etc).   
A total of 165 female rowers from the five schools completed the iron status 
screening.  All 149 non-anemic subjects with and without iron depletion were invited 
to participate in the physical performance and body composition testing.  A total of 24 
IDNA rowers and 24 rowers with normal iron status participated in the present study 
(n= 12 Binghamton, 14 Cornell, 9 Ithaca, 8 Syracuse, and 5 William-Smith).  Subjects 
received iron status, body composition, and fitness testing results as a benefit of 
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participation, along with referral/recommendations to improve iron status as 
necessary.   
Assessment of iron status: Iron status variables measured from non-fasting 
venous blood samples (antecubital venipuncture, into two evacuated tubes, EDTA and 
serum-separator) included hemoglobin (Hgb), hematocrit (Hct), red blood cell count 
(RBC, Beckman Coulter, Fulerton, CA); serum ferritin (sFer, Immulite 2000, Siemens 
Healthcare Diagnostics, Deerfield, IL);  soluble transferrin receptor (sTfR, Ramco 
Laboratories, Stafford, TX); alpha-1-acid glycoprotein (AGP, radial immunodiffusion 
plate, Kent Labs, Bellingham, WA).  Total body iron (TBI, mg/kg) was calculated 
using the ratio of sTfR to sFer as described by Cook et al (29).  Iron status was 
analyzed immediately after blood sampling.  Rowers were classified as either iron 
depleted (sFer<20.0 µg/L), normal (sFer>20.0 µg/L), or anemic (Hgb<12.0 g/dL).  All 
anemics were notified of their status immediately after blood test results (within 1 
week of analysis), referred to their respective campus health services for further 
instruction/monitoring, and excluded from further participation in the study.  All 
laboratory assays were done in the Human Metabolic Research Unit at Cornell 
University. 
Questionnaires: Information about current dietary supplement use, health and 
menstrual status, usual physical activity, and eating habits and attitudes was obtained 
using questionnaires and a 7-day food diary (see Appendix 3-6).  Rowing training 
regimen, as well as leisure-time physical activity (LTPA, Appendix 8) outside of 
rowing training was quantified for 7 days via detailed training and activity records 
(Appendix 11).  Questions in the daily log addressed sleep and nap duration and 
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quality, soreness and fatigue, and training/physical activity frequency, intensity, time, 
and type.  Questions were presented in the format of a Visual Analog Scale (VAS) 
(30).  Subjects were asked to rate each question by placing a solid vertical line on a 
100mm scale anchored by opposing descriptors (see Figure 5.1).  All VAS questions 
were “scored” by measuring the rating with a ruler (mm).   
 
Daily Log Instructions 
This training log should be completed on a daily basis for the next 7 days.  Initial use 
of this log may take up to 5 minutes/day. For some questions, please rate each factor, 
as you feel today by placing a solid vertical line on the scale. 
 
Example:  Happy:  How happy do you feel right now? 
 
Not at all happy                                                                                                  Extremely happy 
 
Figure 5.1.  Visual Analog Scale (VAS) instructions and format of daily training log 
 
The session rating of perceived exertion (RPE) method (31) was used to 
quantify daily training load.  VAS Intensity score for each training session was 
multiplied by training session duration (time).  This method has been used by others to 
quantify training in athletes (32-34).  We validated the session RPE method using our 
VAS-format with the summated heart rate zone method (35)  during two weeks of 
training on a separate sample of thirteen female rowers and found a significant 
positive correlation between the two methods (r=0.85, p<0.001, Appendix 1).  In the 
current study, rowers were classified as either “High” trainers or “Low” trainers based 
on the session-RPE cutoff of 3200, which was the median (50
th
 percentile) Session 
RPE of the sample.    
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Body composition: Anthropometric and body composition measurements were 
determined at the site of exercise testing.  Body weight and height were measured with 
standard procedures and equipment (36).  For athletes for whom it was accessible 
(n=31), body fat and composition was assessed via air-displacement plethysmography 
(BodPod, Life Measurement, Inc, Concord. CA).  For all subjects, percent body fat 
was calculated from tricep, suprailiac, and thigh skinfold thickness (SF, Lange, 
Cambridge, MD) (37) and bioelectrical impedance analysis (BIA, RJL Systems, BIA-
101) (38).  The Siri equation (39) was used to calculate percent fat from body density. 
For those athletes without access to the BodPod (n=17), an average of their percent 
body fat values calculated from BIA and SF was used.  In the sample with both 
BodPod and BIA-SF average (n=31), the two methods were highly correlated (r=0.83, 
p<0.001), and not significantly different from each other (paired t-test, p=0.40).  The 
mean difference between percent body fat calculated from BodPod and the BIA-SF 
average was -0.48 3.15% (95% confidence interval of difference: -1.64, +0.67).  
There were no significant differences in either body fat measurement method between 
schools.   
 
Physical performance testing methods: Physical fitness and endurance 
performance was assessed using a rowing ergometer (Concept2, Morrisville, VT) 
equipped with a digital readout monitor (PM2), displaying work (watts, W), stroke 
rate (spm), distance (m), and elapsed time (min:sec).  A computerized metabolic cart 
(TrueMax 2400, ParvoMedics, Salt Lake City, Utah) was used to measure VO2 and 
other physiological measures during all testing. Concentrations of O2 and CO2 in 
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expired air were analyzed with gas analyzers (which are routinely calibrated with 
gases of known O2 and CO2 concentration).  Respiratory volume (VE) was measured 
with a respiratory pneumotachograph (Fitness Instrument Technologies, Farmingdale, 
NY) through a two-way breathing valve (Hans Rudolph, Kansas City, MO).   
Energy expenditure was assessed via indirect calorimetry during exercise 
testing using a standard protocol that measured expired gases for VE, VO2, VCO2, and 
respiratory exchange ratio (RER), all monitored continuously throughout testing (40).  
Heart rate (HR, Polar FS2, Polar Electro, Inc, Lake Success, NY) was also 
continuously monitored throughout testing.  Cadence (spm) and work rate (WR, watts 
(W) resistance) were monitored and recorded every 30 seconds.   
Blood samples were obtained by finger or ear punctures immediately before 
testing, and every 1000m during testing, as well as 5- and 10- min post-testing.  Blood 
lactate concentrations were determined by the Lactate Pro analyzer (FaCT Canada, 
Quesnel, British Columbia, Canada) (41), which we have concluded to be valid and 
accurate against an enzymatic assay (r=0.64, p<0.001, Sigma Diagnostics, St. Louis, 
MO), as is consistent with the peer-reviewed literature (42-45).   
Subjects were instructed to not consume food or beverages other than water, or 
to perform any strenuous physical activities 2 h prior to testing.  To control for the 
effects of dietary intake and hydration status, subjects were instructed to record all 
food and fluid intake 7d prior to testing, as well as the day of exercise testing 
(Appendix 7).  Subjects had the opportunity to warm-up for at least 10 min prior to all 
testing.   
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Rowers performed two tests in the lab.  The first was a pre-test done in order to 
acclimate subjects to testing protocol and laboratory procedures, as well as to establish 
a VO2peak and target WR of 85% of their maximal work rate (WRmax) for the 
subsequent 4K TT.  VO2peak was determined by a modified version of the maximum 
aerobic power (MAP) test, which is a ramped protocol used by rowing coaches to 
assess training progress (46). 
Rowers’ MAP in split-time was converted into watts (W = 2.8/pace per 500 
m
3
), and the test began 100 W below the predicted maximum.  Each stage of the test 
lasted 90s, with a 10s “gear-up” period between each stage (Appendix 12).  Every 90 
s, the rower was asked to increase her WR by 20 W, until she was no longer able to 
maintain the WR.  This test was designed to last between 8-10 min.  VO2peak was 
identified as the highest VO2 value achieved, and was confirmed by at least one of the 
following: 1) VO2 increased by <150 ml/min with an increase in WR; 2) RER >1.10; 
or 3) HRmax was within 10 beats of age-predicted maximum (220-age) (47).  A 15-
min cool-down period followed testing at a self-selected WR, and HR was monitored 
for 10 min post-test.  Blood sampling for lactate was collected pre- and post test, as 
well as at 5- and 10-min post-test.  Complete test time was about 45 min (10-15 min to 
acclimate to equipment; 10 min for actual testing; 15 min cool-down).  Participants 
were able to stop the test at any time, and the investigator was able to stop the test at 
any time (equipment malfunction; subject symptoms of severe fatigue).  
Endurance capacity was assessed by time to complete a 4K TT, and was 
administered within 3 days of the pre-test.  This test consisted of a 4K ergometer row 
at a sub-maximal WR prescription (WRRx) of 85% of rowers’ VO2peak reached in the 
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pre-test. This WR was maintained for 3600m of the test, and the rowers were then 
asked to sprint the final 400m of the test to simulate on-water racing (Appendix 12).  
The 4K TT was designed to last about 20-25 min.  Subjects received standardized 
verbal encouragement during testing.  Complete testing time was ~ 60 min total (15 
min to acclimate to equipment; 5 min warm-up; 25 min actual testing; 15 min cool-
down).  VO2peak and other performance outcome variables were obtained from the 
4K TT.  
 
Calculations: 
Work output (kcal/min) was calculated as: 
Formula 5.1: Work output = [Work (W) * 0.014 kcal/min]. 
 
Energy expenditure (EE) input was calculated as: 
Formula 5.2: EE = [VO2 (L/min) * non-protein respiratory quotient 
(kcal/min)]. 
 
Gross energetic efficiency (EF) was calculated as(48) : 
Formula 5.3: Gross EF = [Work output (kcal/min) / EE input (kcal/min)] 
*100 
 
 
Deviation from the target WR Rx of 85% of their pre-test WRmax (W) was calculated 
as: 
Formula 5.4: Deviation from WRRx= [WR Rx - average W maintained]. 
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Data Analysis: All data were analyzed using SPSS Statistics version 18.0 
(Chicago, IL). Descriptive statistics are presented as means ± standard deviations 
(SD).  Student’s T-test and ANOVA was used to analyze differences between iron 
status groups (Normal: sFer>20.0 µg/L vs Depleted: sFer<20.0 µg/L) with respect to 
all variables measured.  Pearson’s correlations were used to examine associations 
between variables.  To investigate the plausible effects of iron status on endurance 
performance, multiple regression analyses (MIXED procedure with School as a 
random effect) of the relationship between measures of physical performance (VO2 
peak, gross EF, 4K TT time) and total body iron stores was conducted, controlling for 
potential confounders.  Those variables correlated with physical performance (p<0.05) 
or significantly different between groups of iron status were designated as potential 
confounders and included as covariates in the development of regression models.  A 
statistical significance level of p<0.05 was accepted for testing main effects, and 
p<0.10 for testing interaction effects of the primary hypotheses.   
 
Results 
Body size and composition in the two iron status groups is shown in Table 5.1.  
There were no significant differences between groups for any measure of body size or 
body composition tested.  On average, rowers were 19.8±1.1 years of age, 170.7±7.3 
cm tall, and weighed 69.5±8.1kg (BMI 23.7±3.3 kg/m
2
).   
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Table 5.1: Anthropometry and body composition (mean± SD) of non-anemic female 
collegiate rowers at the beginning of training season, between groups*  
 Normal (n=24) Depleted (n=24) p-value (T-
test) 
Weight (kg) 
 
68.3±7.1 67.5±9.6 0.72 
Height (cm) 
 
170.5±5.9 170.2±8.9 0.88 
Body mass index (kg/m
2
) 
 
23.5±2.1 23.3±2.7 0.80 
Sitting height (cm) 
 
86.8±5.7 87.0±10.7 0.93 
Arm span (cm) 
 
168.7±8.6 169.1±10.5 0.91 
Percent body fat (%) 
 
24.6±5.0 26.3±5.3 0.26 
Fat-free mass (kg) 
 
51.3±5.0 49.5±6.1 0.27 
*Normal = sFer>20.0 µg/L, Hgb>12.0 g/dL; Deplete = sFer<20.0 µg/L, Hgb>12.0 
g/dL 
 
There were also no significant differences between the groups in any of the 
potential confounders of the association between iron status and performance that 
were tested (Table 5.2).  Across the sample, rowers had 3.2±2.2 years rowing 
experience; a 2K PR time of 7 minutes and 48 seconds (471±28 sec); and spent ~5.5 
(5.5±3.9 hours/week) hours per week in combined moderate and vigorous physical 
activity.  There was, however, a marginal difference in rowers’ reported 2K personal 
record from the previous season.  The 24 rowers who were Depleted reported 2K PRs 
that were ~18 seconds slower than those 24 with Normal iron status (8.0±0.6 versus 
7.7±0.4 min, respectively; p=0.07).  
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Table 5.2.  Rowing experience and dietary characteristics (Mean ± SD) of subjects 
 Normal 
(n=24) 
Depleted 
(n=24) 
p-
value 
Age (y) 
 
20.1±1.1 19.6±1.1 0.12 
Rowing experience (y) 
 
3.5±2.3 2.9±2.2 0.37 
2K personal record (min) 
 
7.7±0.4 8.0±0.6 0.07 
Dietary iron intake (mg/d)* 16.3± 5.9 
 
16.3±7.1  0.99 
Energy intake (kcal/d)* 
 
1988.5±622.0 1759.2±526.3 0.26 
Current use of supplement (%) 
 
9/22 = 40.9% 8/23 = 34.8% 0.76 
Number of days since first day of 
last menstrual period (d) 
 
18.5±12.2 17.4±13.5 0.77 
2
n=15 in Normal, n=18 in Deplete groups. 
 
 There were no differences between the two iron status groups in dietary iron 
intake, energy intake, or current supplement use.  Rowers who completed the 7d food 
diary reported consuming ~16 mg of dietary iron per day, 1900 kcal/d, and 38% of 
rowers in the study reported consuming a multivitamin/mineral supplement prior to 
the study.  
Iron status of the Normal and Depleted rowers is shown in Table 5.3.  There 
were significant differences between the two groups in sFer and TBI, which was 
expected due to classification of subjects based on a sFer cut-off of 20.0 µg/L.  One 
subject in the Depleted group had an AGP greater than the normal reference range 
(55-140 mg/dL).  The two groups did not differ in sTfR, Hgb, or any other red cell 
indicators.   
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Table 5.3: Iron status (mean± SD) of non-anemic female collegiate rowers at the 
beginning of training season, between groups*  
 
 Normal  
(n=24) 
Depleted  
(n=24) 
p-value 
Hemoglobin (Hgb, g/dL) 
 
13.1±0.7 13.0±0.7 0.720 
Serum Ferritin (sFer, µg/L) 
 
43.0±20.3 13.9±5.1 <0.001 
Log sFer (µg/L) 
 
1.1±0.2 1.6±0.2 <0.001 
Soluble Transferrin Receptor (sTfR, mg/L) 
 
6.4±2.5 6.4±2.1 0.958 
Total Body Iron (TBI, mg/kg) 
 
5.2±2.0 1.2±2.3 <0.001 
Hematocrit (Hct, %) 
 
40.1±2.1 40.2±2.1 0.90 
Mean Cell Volume (MCV, fL) 
 
88.8±3.6 87.9±4.6 0.34 
Red Cell Distribution Width (RDW, %) 
 
12.8±0.7 13.6±2.0 0.07 
Alpha-1-acid glycoprotein (AGP, mg/dL) 79.6±23.3 
 
79.4±33.0 0.98 
*Normal = sFer>20.0 µg/L, Hgb>12.0 g/dL; Deplete = sFer<20.0 µg/L, Hgb>12.0 
g/dL 
 
Results of the 4K ergometer test are shown in Table 5.4.  There were no 
significant differences in maximal HR, WR, or average gross EF between the two 
groups.  Depleted rowers had a lower absolute VO2peak (p=0.03), and tended to have 
a lower VO2peak/ kg FFM (p=0.10) than rowers with Normal iron status.  Depleted 
rowers also tended to perform the fist 3600m of the 4K at a lower workload than the 
Normal rowers (p=0.07). 
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Table 5.4.  Physical Performance (Mean± SD) over 4K at the beginning of a training 
season for female rowers with normal and depleted iron status 
 Normal 
(n=24) 
Depleted 
(n=24) 
p-value, 
unadjusted 
for 
covariates* 
Work rate Rx (W) 
 
180.0±30.1 163.3±31.5 0.07 
Deviation from Work rate Rx (W) 
 
0.9±4.5 -0.4±3.8 0.28 
Average Work rate for 3600m WR (W) 
 
179.0±29.0 163.7±30.7 0.08 
 
4K TT time (min) 
 
17.2±1.1 17.7±1.2 0.12 
3600m time (min) 
 
15.6±1.0 16.1±1.2 0.13 
400m time (sec) 
 
94.9±9.4 97.13±7.7 0.38 
 
VO2peak (l/min) 
 
3.4±0.4 3.1±0.4 0.03 
VO2peak (ml/kg/min) 
 
49.5±5.6 46.6±5.6 0.08 
VO2peak (ml/kg FFM/min) 
 
65.9±5.3 63.2±6.0 0.10 
Maximal work rate (W) 
 
236.7±41.4 225.0±44.4 0.35 
Maximal heart rate (bpm) 
 
188.6±14.3 191.08±9.4 0.49 
    
Average rate Energy expenditure (EE, kcal/min) 
 
13.75±2.0 12.89±1.8 0.12 
Total EE (kcal) 
 
235.0±22.8 226.8±18.6 0.18 
Average Gross energetic efficiency (%) 
 
17.8±1.6 17.5±2.0 0.60 
*ANOVA 
Rowers with Depleted iron stores had significantly higher pre-test lactate 
concentration (p=0.02, Figure 5.2), as well as higher lactate concentrations at the 
1000m and 2000m segments of the 4K TT (p=0.04 and p=0.02, respectively), and 10-
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min post-test. There was no significant difference between the two groups in maximal 
lactate concentration achieved.  When expressed as a percent of maximum lactate 
achieved, there were no significant differences between the two groups at any time 
point during the 4K TT.   
 
 
 
Figure 5.2.  Lactate concentration (mmol/L) between Normal and Depleted rowers 
during 4K time trial (TT) 
 
There was a significant difference in training session duration (Table 5.5). 
Depleted rowers trained ~11 min/d less than Normal rowers (57.9±9.2 versus 
68.8±21.0 min/d, respectively, p=0.02), and thus tended to have a lower average daily 
training load as calculated by session-RPE (p=0.07). There were no significant 
differences between the two groups in other variables measured over 7d. 
 
 
 
 
Pre-test     1000m            2000m 3000m  4000m    5-min      10-min  
* 
* 
* 
* 
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Table 5.5.  Training quality at the beginning of a training season 
 Normal (n=24) Depleted (n=24) p-
value 
Sleep time (hrs) 
 
6.8±0.7 7.2±1.0 0.16 
Nap time (min) 
 
64.0±34.9 64.3±78.3 0.99 
Motivation 
 
55.3±12.4 52.8±16.8 0.57 
Soreness 
 
35.6±15.5 31.2±15.3 0.33 
Fatigue 
 
45.4±14.8 39.5±13.8 0.16 
Intensity 
 
54.9±11.6 51.7±15.1 0.42 
Total training days recorded 
 
7.3±1.5 7.2±1.6 0.71 
Average training time (min/d) 
 
68.8±21.0 57.9±9.2 0.02 
Average sessionRPE 
 
3805.2 ±1570.8 3059.1±1207.3 0.07 
Total training load 
 
33508.0±18422.4 29222.9±19180.2 0.43 
 
Simple bivariate correlations between iron status and 4K performance, and 
between training variables and 4K performance are shown in Tables 5.6 and 5.7, 
respectively.  There was a significant positive correlation only between sFer and gross 
EF, but not between any other measures of iron status (Hgb, sTfR, TBI) and 4K 
performance.  There were significant positive associations between body composition 
variables and 4K performance, but none between 4K performance and rowing 
experience, training time, or session RPE.  Rowers’ reported 2K personal records 
(PRs) were significantly related to the three outcome measures (VO2peak, L/min: r=-
0.69, p<0.001; 4K time, min: r=+0.64, p<0.001; gross EF, %: r=-0.58, p<0.001), 
validating this measure used in previous analyses (Chapter 4).  Many of these 
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variables were tested as potential confounders, and no cause-effect relationships (or 
lack thereof) between training and performance are implied by these correlations. 
Table 5.6:  Bivariate correlations (r) between physical performance and iron status 
 4K time (min) VO2peak (L/min) Gross Energetic 
Efficiency (%) 
 r p-value r p-value r p-value 
Hemoglobin (g/dL) 
 
-0.14 0.34 -0.08 0.58 +0.10 0.52 
Serum Ferritin (µg/L) 
 
-0.24 0.10 +0.29 0.05 +0.22 0.14 
Log sFer (µg/L) 
 
-0.25 0.09 +0.22 0.13 +0.25 0.09 
Soluble transferrin receptor 
(mg/L) 
 
-0.22 0.14 +0.23 0.12 +0.11 0.45 
Total Body Iron (mg/kg) 
 
-0.11 0.46 +0.10 0.49 +0.14 0.33 
 
 
Table 5.7:  Bivariate correlations (r) between physical performance and training 
 4K time (min) Gross Energetic 
Efficiency (%) 
VO2peak (L/min) 
 r p-value r p-value r p-value 
Height (cm) 
 
-0.59 <0.001 +0.36 0.01 +0.58 <0.001 
Weight (kg) 
 
-0.49 <0.001 +0.30 0.04 +0.50 <0.001 
Fat-free mass (kg) 
 
-0.65 <0.001 +0.43 0.002 +0.71 <0.001 
Rowing Experience 
(y) 
 
-0.26 0.07 +0.15 0.30 +0.16 0.29 
2K Personal Record 
(PR, sec) 
 
+0.78 <0.001 -0.58 <0.001 -0.67 <0.001 
Training time 
(min/day) 
 
-0.12 0.42 -0.17 0.26 +0.12 0.42 
SessionRPE 
 
-0.04 0.78 -0.24 0.10 +0.06 0.69 
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ANOVA was then conducted for the main performance outcomes after 
adjusting for important covariates (Table 5.8).  After adjustment, iron-depleted rowers 
completed the 4K TT 30 seconds slower, had a 0.3 L/min lower VO2peak, and on-
average, were 0.6% less efficient compared to rowers with normal iron status. 
Table 5.8.  Physical performance outcomes during 4K TT (mean ±SD), adjusted for 
covariates* 
 Normal Depleted p-value 
4K TT time (min) 
 
17.43±0.67 17.92±0.87 0.030 
VO2peak (L/min) 
 
3.38±0.33 3.08±0.38 0.005 
Gross energetic efficiency (%) 
 
17.71±1.00 17.14±1.02 0.057 
*4K TT adjusted for training group, height, deviation from work load; VO2peak 
adjusted for training group, fat-free mass; gross EF adjusted for training group, 
average WR for 3.6K 
 
In order to test for differences in performance between iron status groups, 
multiple regression analysis was performed to control for potential confounders.  The 
results of this analysis are shown in Tables 5.9, 5.10, and 5.11.  Only in the modeling 
of iron status on VO2peak was sFer group (0=Depleted, 1=Normal, based on sFer 
cutoff of 20.0 µg/L) a significant predictor of performance.  Rowers with Depleted 
iron stores had a VO2peak that was 0.25 L/min lower than rowers with Normal iron 
stores (p<0.001, Table 5.9). sFer group alone was not a significant predictor of 4K 
time (p=0.12, Table 5.10) or gross EF (p=0.38, Table 5.11).  Training group alone 
(0=Low, 1=High, based on the average daily training load session RPE cut-off of 
3200) was not significantly related to VO2peak (p=0.06), 4K time (p=0.26) or gross 
EF (p=0.73).   
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Table 5.9.  Regression models to test the effects of iron status on VO2peak (L/min) 
 VO2peak  
 (L/min) 
VO2peak  
(L/min, with interaction) 
 β p β p 
Intercept 
 
+0.26 0.49 +0.26 0.44 
Serum ferritin Group (sFer group) 
 
+0.25 <0.001 +0.42 <0.001 
Training group* 
 
+0.12 0.06 +0.27 0.003 
sFer*Training group 
 
--------- --------- -0.32 0.02 
Fat-free mass (FFM, kg) 
 
+0.05 <0.001 +0.05 <0.001 
%Variance explained by Fixed effects 
Within School (residual) variance 75.0% 83.3% 
Between School variance 42.9% 57.1% 
% of total Variance between (due to) schools 36.4% 36.8% 
*Training group based on average daily load (0=<3200, 1=>3200) 
sFer group: 0=Depleted (sFer<20.0 µg/L), 1=Normal (sFer>20.0 µg/L) 
 
Table 5.10.  Regression models to test the effects of iron status on 4K TT time (min) 
 4K TT time  
(min) 
4K TT time  
(min, with interaction) 
 β p β p 
Intercept 
 
+29.8 <0.001 +29.7 <0.001 
Serum ferritin Group (sFer group) -0.48 0.12 
 
-0.70 0.13 
Training group* 
 
-0.34 0.26 -0.55 0.19 
sFer*Training group 
 
--------- --------- +0.47 0.46 
Height (cm) 
 
-0.07 0.02 -0.07 0.02 
Deviation from Work rate Rx (W) 
 
-0.07 0.04 -0.07 0.04 
%Variance explained by Fixed effects 
Within School (residual) variance 34.4% 30.1% 
Between School variance 46.6% 60.3% 
% of total Variance between (due to) schools 38.4% 66.7% 
*Training group based on average daily load (0=<3200, 1=>3200) 
sFer group: 0=Depleted (sFer<20.0 µg/L), 1=Normal (sFer>20.0 µg/L) 
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Table 5.11.  Regression models to test the effects of iron status on gross energetic 
efficiency (EF, %) 
 Gross EF  
(%) 
Gross EF  
(%, with interaction) 
 β p β p 
Intercept 
 
+11.5 <0.001 11.51 <0.001 
Serum ferritin Group (sFer group) 
 
-0.45 0.38 -1.35 0.075 
Training group* 
 
-0.17 0.73 -0.91 0.17 
sFer*Training group 
 
--------- --------- +1.68 0.094 
Average work rate for 3.6 K (W) 
 
+0.04 0.001 +0.04 <0.001 
%Variance explained by Fixed effects 
Within School (residual) variance 29.6% 31.4% 
Between School variance 34.5% 75.9% 
% of total Variance between (due to) schools 53.9% 10.8% 
*Training group based on average daily load (0=<3200, 1=>3200) 
sFer group: 0=Depleted (sFer<20.0 µg/L), 1=Normal (sFer>20.0 µg/L) 
 
 
In order to test for the potential modifying effect of iron status on the 
relationship between training and performance, interaction terms for sFer group -by- 
training group were included in the multiple regression models (see Tables 5.9, 5.10, 
5.11).  This analysis revealed that training modified the relationship between iron 
status and performance such that each performance variable was more negatively 
affected by poor iron status in the “Low” trainers compared to the “High” trainers.  
While there was no significant interaction between sFer group and training group as it 
affected 4K TT time (p=0.46 for the interaction term, Figure 5.3), within the low-
training group rowers with poor iron status took 42 seconds longer to complete the 4K 
TT compared to rowers with normal iron status (p=0.05).  
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Figure 5.3.  Time to complete 4K TT (min) for Low and High trainers according to 
iron status group 
 
Additionally, less highly-trained rowers with poor iron status had VO2peak 
values that were 0.32 L/min lower (interaction p=0.02, Figure 5.4), and were 1.7% 
less energetically-efficient (interaction p=0.094, Figure 5.5) than less highly-trained 
rowers with normal iron status.  Improved performance with improved iron status was 
only observed in the less highly-trained subjects.  
 
 
 
 
 
 
 
 
 
 
 
 
17.6 0.7 
17.4 0.7 17.3 0.7 
18.3 0.8 
Depleted (sFer<20 µg/L) 
Normal (sFer>20 µg/L) 
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 Figure 5.4.  VO2peak (L/min) for Low and High trainers according to iron status 
group 
 
 
 
 Figure 5.5.  Gross energetic efficiency (%) for Low and High trainers according to 
iron status group 
 
2.96 0.39 
3.37 0.43 
3.28 0.28 
3.39 0.27 
Depleted (sFer<20 µg/L) 
Normal (sFer>20 µg/L) 
17.01 1.11 
18.11 1.22 
17.36 0.87 
17.47 0.79 
Depleted (sFer<20 µg/L) 
Normal (sFer>20 µg/L) 
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Discussion 
These data support our hypothesis that rowers with depleted iron stores 
(sFer<20.0µg/L) have a lower VO2peak and higher lactate concentration during the 4K 
TT compared to rowers with normal iron status.   We have also observed that among 
women reporting lower levels of training time and intensity, time to complete a 4K TT 
was slower in iron-depleted rowers after controlling for training, height, and deviation 
from workload prescription, but there was not a significant interaction (p=0.46) 
between iron status group and training group.  However, women in the low-training 
group completed the TT ~66 seconds (~30 sec adjusted for covariates) faster with 
normal iron status compared to those with depleted iron status.  These findings are 
consistent with our lab’s previous findings in non-athletes that showed that moderate 
training in previously untrained women with improved iron stores resulted in 
decreased 15 K TT time on a cycle ergometer by 10% (-3.4 min) compared to women 
with poorer iron status who decreased their time by 5% (-1.6 min) (16).   
An important finding of this study was that rowers’ training status 
differentially affected the relationship between iron status and performance (4K TT 
time, VO2peak and gross EF).  This finding could be interpreted in two ways.  The 
first and more plausible interpretation is that rowers who trained less hard benefitted 
more from better sFer status than did rowers who trained harder.  One can consider 
this a “ceiling effect,” as there is less of a potential to benefit from better iron status in 
the more-highly trained.  This could be why we did not see an effect of iron status on 
performance in the “High” training group.  Our “Low” training group may be more 
comparable to the non-athletic women adapting to training, for whom there is a large 
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margin for improvement in performance (energetic efficiency and VO2peak) with an 
improvement in iron status (12, 16).  In the current study, less highly-trained rowers 
with normal iron status had a greater VO2peak and were more energetically-efficient 
than those less highly-trained rowers with depleted iron stores, while there was no 
effect of iron status on performance in the more highly-trained group.  This suggests 
that the effects of low iron status on VO2peak can be overcome by training, as 
VO2peak is an outcome related to O2 transport at the end of the test.  In non-anemic 
rowers, therefore, training would be a more important factor in the achievement of a 
higher VO2peak compared to improved iron status.  On the other hand, iron status may 
be more important than training level to improve energetic efficiency, as this outcome 
is related to metabolism over the entire TT, during which iron plays a significant 
metabolic role. 
Another interpretation is that rowers that train harder are able to overcome the 
negative effects of poor iron status on performance.  Animal studies have 
demonstrated that endurance training of ID rats seems to attenuate the reduction of 
skeletal muscle oxidative enzymes due to iron deficiency.  In a study by Perkkio et al 
(49), although ID rats had poorer endurance performance, there was a significantly 
larger effect of endurance training in ID rats compared to non-ID rats. Although Hgb 
in this animal study was negatively affected by dietary iron deficiency, the activity of 
mitochondrial enzymes in the muscle of ID rats, as well as endurance capacity were 
partially remedied by endurance training. One possible explanation may be increased 
absorption of dietary iron in ID. As training increases and iron stores become depleted, 
the absorption of dietary iron may be up-regulated.  Furthermore, it is likely that the 
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more highly-trained have already adapted more to the training regimen in spite of their 
iron status, while the less highly-trained still have potential to increase their training 
and therefore, their performance.  Unmeasured behavioral and/or psychosocial 
characteristics of the rowers may explain this scenario, as prior training and rowing 
experience are important predictors of performance.  It could be that rowers with more 
experience are more likely to train harder despite their iron status.  If iron status 
affects the relationship between training and performance, it is only one of the many 
factors (physiological, psychological, environmental) to be considered.  
Self-motivation is also an important variable, as it drives the training stimulus, 
and consequently performance.  In a study of female college rowers, those who did not 
comply with the prescribed training regimens (e.g. comparable to our low training 
group) had lower self-motivation and poorer ergometer performance than those rowers 
who trained harder (e.g. comparable to our high training group) (50).  In the current 
study, motivation scores were no different between the Depleted and Normal rowers, 
but more highly-trained rowers reported significantly higher motivation scores 
(58.5 11.9) compared to less highly-trained rowers (49.6 15.9, p=0.03).  
A limitation of this study is the possible misclassification of rowers into study 
groups of Normal and Depleted based on sFer cutoff of 20.0 µg/L.  Any 
misclassification could have diluted the differences in physical performance between 
the two groups. Serum ferritin is the most common index of iron stores, and reflects 
iron stored in the liver.  However, it is also an acute phase protein and can be elevated 
in an inflammatory state (e.g. infection, post-exercise), potentially masking ID (51-
53).  However, an inflammatory marker such as C-reactive protein (CRP) or alpha-1-
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acid glycoprotein (AGP) can partially rule-out falsely-elevated sFer (54-56).  In our 
study, while all but one subject had AGP levels below the threshold indicative of 
inflammation/infection, some iron-depleted subjects may still have been misclassified 
as normal.   
Recent research has suggested that the iron regulatory protein hepcidin is the 
mediator between the inflammatory response and poor iron status (57).  During the 
acute-phase response, which is seen post-exercise, hepcidin is up-regulated and enters 
the circulation to negatively control the export of iron from the intestinal enterocyte 
and recycled iron from the macrophage. Thus, increases in hepcidin may lead to a 
decrease in the absorption of dietary iron (9, 10, 58).  Several studies have shown 
associations between or increases in urinary hepcidin and post-exercise inflammation, 
suggesting that high levels of training may negatively affect iron status (11, 59-64). 
This mechanism may explain the increased prevalence of iron deficiency in female 
athletes and/or changes in iron status with training. In the current study, hepcidin and 
iron absorption were not measured, while dietary iron intake was not significantly 
different between the two groups. 
Soluble transferrin receptor (sTfR), a trans-membrane protein regulated by 
cellular iron status, reflects ID at the tissue level and is a more sensitive index of 
functional ID, especially at higher values (sTfR>8.5 mg/L).  Unlike sFer, sTfR is 
unaffected by inflammation, and has been shown to have lower within-subject 
variability in intensely training athletes (3, 65).  Total body iron (TBI) can be 
calculated using both sFer and sTfR (29). This index represents the ratio of functional 
to storage iron.  However, in a population with a low prevalence of anemia, variation 
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in TBI is driven by variation in sFer. In the current study, only six rowers were in a 
state of severe iron deficiency (sTfR >8.5 mg/L), but were non-anemic, thus sTfR 
values were not significantly different between the Depleted and Normal rowers 
(mean sTfR 6.4 mg/L).   
Additionally, protocols used to test the effects of iron status on performance 
are important to consider.  The exercise protocol (eg. TT vs time to exhaustion) needs 
to be sensitive enough to detect a difference in performance due to iron status, as well 
as to adequately explore differences in energy metabolism.  Previous studies of IDNA 
athletes have found no effect of iron status on performance during a time to exhaustion 
protocol (66, 67).  The time to exhaustion protocol is not the best measure of athletic 
performance in endurance athletes for several reasons. The test becomes too long, 
especially for highly-trained athletes, and consequently motivation becomes a major 
factor affecting the outcome of the test (68).  Furthermore, this protocol does not 
mimic competitive event performance.  The 4K fixed length time trial (TT) was used 
in this study as a measure of endurance performance because it best represents rowers’ 
training and competitive event performance (races last <30 min, short-duration, high-
intensity).  The 4K TT protocol also allows us to study proxies of oxidative 
metabolism (VO2, energetic efficiency, lactate) throughout the test in which iron plays 
an important role, as mentioned previously (16).  
Additionally, the measure of training needs to be sensitive enough to show 
difference between groups of iron status.  In the current study, the session-RPE 
method was used to quantify training.  Although this method has been used with 
various groups of athletes, and has been validated in our lab during rowing training, it 
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is possible that it inadequately captures the intermittent and varied nature of collegiate 
rowers’ training activities.  Much of rowing training revolves around repeated short 
bouts of high-intensity effort with intermittent rest (either on a rowing ergometer or in 
a boat on the water).  It may have been more difficult for rowers to adequately gauge 
the intensity of an entire 2-hour workout if activity bouts were short with adequate rest 
between bouts of activity.   
Conclusions: Despite the limitations of this cross-sectional study design, we 
found that in non-anemic rowers, iron depletion was associated with poorer physical 
performance at the beginning of a training season.  The effects of iron status on 
performance were more pronounced in rowers who trained less hard compared to 
those who trained harder.  Further studies that include more sensitive measurements of 
both training (e.g. HR and EE) and oxidative capacity (e.g. iron-dependent oxidative 
enzymes in muscle) are needed to better control for potential confounders and 
investigate the mechanism by which IDNA affects endurance performance.  These 
results should be confirmed with a randomized controlled iron supplementation trial 
designed to establish causal pathways for the role of iron depletion on training and 
performance.  Given the roles that iron plays in exercise, accurately determining iron 
status in female endurance athletes is critical. At the beginning of the training season, 
endurance athletes should be screened for iron deficiency with and without anemia, 
using both Hgb and sFer.  Treatment and/or nutrition counseling should be provided as 
necessary to assure sufficient dietary iron intakes, and prevent further decrements in 
iron status with training.   
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CHAPTER 6 
 
IRONSUPPLEMENTATION IMPROVES IRONSTATUS DURING TRAINING IN 
NON-ANEMIC FEMALE ROWERS 
 
Abstract   
Introduction:  Studies in both animals and humans have shown a relationship between 
iron depletion without anemia (IDNA) and physical performance.  Compared to their 
sedentary counterparts, female endurance athletes are at greater risk of IDNA.  
Consequences of IDNA in non-athletic women are especially relevant to female 
endurance athletes, especially reduced work capacity, endurance, and energetic 
efficiency.  We conducted a randomized placebo-controlled trial to investigate the 
effects of iron supplementation on iron status of female rowers during training.    
Methods: At the beginning of a training season, 43 non-anemic collegiate female 
rowers were randomized to receive 100 mg/d ferrous sulfate (n=22) or placebo (n=21) 
for 6 weeks using a double-blind design. Thirty-one rowers (n=15 iron, 16 placebo) 
completed the 6-week trial and all baseline and endpoint testing.  Subjects trained with 
their team as usual and completed daily training logs (time, type and intensity) and 
recorded compliance throughout the study. Iron status (hemoglobin, serum ferritin, 
soluble transferrin receptor, total body iron) was assessed at baseline and 6 weeks.   
Results: At baseline, there were no significant differences between the two treatment 
groups in iron status.  Rowers in both treatment groups increased their fat-free mass 
(p<0.001) and improved their VO2peak (p<0.001) after 6 weeks of training. Rowers in 
the iron supplemented group consumed 60% of the prescribed dose over the course of 
the study, and there was no difference in iron status between treatment groups at the 
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end of the study.  Multiple regression analyses revealed improvements in body iron 
stores (log ferritin, total body iron) in the iron treatment group after controlling for 
baseline iron stores, and those with most depleted stores at baseline showed the 
greatest improvement in iron stores (p=0.07 for the treatment-by-baseline sFer 
interaction term).   
Conclusion: Despite low compliance with the intervention and after controlling for 
baseline iron stores, iron supplementation improved iron stores in rowers training for 
their competitive season.  We conclude that female endurance athletes who consume 
~15 mg/d elemental iron during training can improve their iron stores, and those who 
are most depleted will benefit the most form supplementation.  Furthermore, iron 
supplementation during training may prevent loss of iron status in those rowers 
beginning a competitive season with marginal, but adequate, iron stores.   
Key words: iron depletion, athletes, rowers, iron supplementation 
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Iron supplementation improves iron status during training in non-anemic female 
rowers  
 
Introduction 
Iron deficiency (ID, clinically-defined as serum ferritin (sFer) <12.0 µg/L) is 
the most prevalent nutrient deficiency in the world, including the US, where iron 
deficiency with anemia (IDA, defined as ID plus hemoglobin (Hgb) <12.0 g/dL ) 
affects 3-5%, and iron depletion without anemia (IDNA, defined as sFer <20.0 µg /L) 
affects ~16% of premenopausal women (1).  Active females, including military 
soldiers, are especially susceptible, as surveys have shown even higher rates of IDNA 
(25-35%) (2-7).  Although the exact mechanism is unknown, the increased prevalence 
of IDNA in active and training females may be due to increased daily iron 
requirements as a result of one or more factors, including: hemolysis (foot strike, 
impact); increased blood loss (gastrointestinal tract, hematuria, sweat); reduced iron 
absorption (8-11).  These increased daily iron requirements of active and training 
women may not be met by dietary iron intake alone.  Surveys of female athletes show 
that more than 50% use some type of supplement, and iron or iron-containing 
multivitamins are among the most popular (12-14).    
It is has been suggested from animal and human studies that iron status is 
related to physical training, but the direction of this relationship is unclear (15-21).  
Athletes’ hematological adaptation to training has been reported, indicating increased 
mobilization of iron away from ferritin (storage) for the increased production of 
erythrocytes and increased demand for O2-carrying capacity (Hgb) and functional 
tissue iron (soluble transferrin receptor, sTfR) (22, 23).  Training sessions may also 
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cause an inflammatory response leading to increased hepcidin expression, and 
consequently decreased iron absorption and iron release from macrophages (24, 25).  
Additionally, researchers have also shown that sTfR is affected by muscle growth 
(26), which is a beneficial result of endurance training, and a factor that may play a 
role in diminishing the effects of supplementation on measures of iron status.  
Previous work from our laboratory, as well as from others, has shown that iron 
supplementation of IDNA non-athletic women improves iron status, although results 
have varied due to dose used, as well as demand during training (27-31).  Iron 
supplementation of female military soldiers has been shown to prevent declines in iron 
status that had been observed over 8 weeks of basic combat training (32).  
Given the high prevalence of IDNA among female athletes, and the strong 
association between iron status and physical performance in both sedentary and active 
women, the current experimental study was designed to determine the efficacy of low-
dose iron supplementation to prevent decrements in iron status in female rowers 
during 6 weeks of training for the competitive season.  We hypothesized that iron 
supplementation would prevent training-related declines in iron status in female 
rowers, and that iron-supplemented rowers would improve their iron status after 6-
weeks of treatment (no significant change in Hgb, increased sFer, decreased sTfR, 
increased TBI) compared to a placebo group. 
Methods 
Recruitment of subjects: Subjects were recruited at the beginning of the 
conditioning phases of their competitive collegiate rowing seasons (fall 2008, spring 
2009, and fall 2009, upon arrival to campus post- summer and post-winter break). All 
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varsity and second-semester novice female rowers were eligible to participate in the 
screening if they were at least18 years of age, non-smoking, and were able to begin 
regular training for their sport. Training activities during this time included general 
aerobic conditioning (cycling, running, rowing on ergometer), resistance training, and 
high intensity rowing.  A medical screening required by the National Collegiate 
Athletic Association (NCAA) prior to our study excluded all athletes not healthy 
enough to participate in their rowing team training (current, acute or chronic illness, 
severe asthma, musculoskeletal problems, etc).  All rowers provided written informed 
voluntary consent prior to participating in the study. This study was approved by the 
Institutional Review Boards of the following colleges/universities: Binghamton 
University, Cornell University, Hobart and William-Smith Colleges, Ithaca College, 
and Syracuse University. 
A total of 165 female rowers from the five schools completed the iron status 
screening (Figure 3.2, pg 58). Ten percent of rowers (n=16) screened were identified 
as anemic and 30% as IDNA (sFer<20.0 µg/L, Hgb>12.0 g/dL).  All 149 non-anemic 
subjects with and without iron depletion (cut-off: sFer<20.0 µg/L) were invited to 
participate in the baseline physical performance and body composition testing 
(Chapter 5).  Forty-eight rowers (n=24 IDNA rowers and 24 normal iron status) 
participated in the baseline data collection (n=5 William-Smith, 14 Cornell, 9 Ithaca, 
12 Binghamton, and 8 Syracuse). Forty rowers were then randomized to receive 
supplemental iron (n=21, 12 with sFer<20.0 µg/L) or placebo (n=19, 11 with 
sFer<20.0 µg/L).  Subjects received iron status, body composition, and fitness testing 
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results as a benefit of participation, along with referral and recommendations to 
improve iron status as necessary.   
Design:  This study was a randomized, double-blind, placebo-controlled iron 
supplementation trial (RCT). Each subject was randomly assigned to a treatment 
group by a research assistant who was not involved in data collection or contact with 
subjects.  Randomization was done by assigning each subject a random number, with 
even and odd numbers being assigned to either treatment group.  After initial 
randomization, any imbalance in the distribution of treatment or representation of 
school or baseline iron status (sFer) was corrected by re-randomization. Rowers were 
randomly assigned to one of two groups: iron supplementation with 50 mg FeSO4 
twice per day or placebo in the form of identical red capsules. Subjects were provided 
with 18 capsules each week, and were instructed to consume 2 capsules per day. 
Subjects were instructed to consume one capsule each at their morning and evening 
meals to minimize potential gastrointestinal side-effects, and with a glass of citrus 
juice to enhance iron absorption.  Subjects were also instructed to avoid consumption 
of any other multivitamin/mineral supplements during the 6-week study period.  At the 
time of randomization, no rowers had been regularly consuming dietary supplements. 
Compliance with the iron treatment, as well as current health, menstrual status, 
and physical activity was assessed by daily training logs. Subjects were instructed to 
record the number of capsules they consumed daily in their log, even if they had 
consumed less than the prescribed amount per day.  Additionally, weekly capsule 
counts were conducted by the researcher.  
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Both iron and placebo capsules were prepared by a Registered Pharmacist 
(PharmD) at the Cornell University College of Veterinary Medicine Pharmacy (Ithaca, 
NY).  The iron supplement capsules contained 50 mg FeSO4 per capsule with lactose 
filler, and the placebo capsules contained only lactose.  The iron content of both 
placebo and iron capsules was analyzed via ICP mass spectrometry digestion by the 
USDA’s Robert Holley Center for Agriculture and Health (Ithaca, NY).  Twenty 
capsules were randomly selected for analysis from each of 2 batches.  No differences 
in the average iron content were found between the two batches of iron-containing 
capsules (15.8 ± 0.5 mg elemental iron per capsule), and no iron was detected in the 
placebo capsules.  
For all subjects, body composition and physical performance were measured 
immediately before and after the 6 week treatment period.  Thirty-one rowers finished 
the entire study protocol (all blood analyses and exercise testing) (see Figure 3.2).  Six 
subjects from the iron group and three from the placebo group dropped out of the 
study due to personal reasons (n=4), injury (n=3) or illness (n=2), all unrelated to the 
study.  Rowers who did not complete the study reported getting more and better 
quality sleep at baseline (p=0.01 and p=0.04, respectively), as well as feeling better in 
general (p=0.03) than rowers who did complete the study (n=31). Compared to the 31 
rowers who completed the study, the 9 rowers who did not complete the study had 
slower times to complete a simulated 4K time trial on a rowing ergometer at baseline 
(19.4±2.6 min vs 17.7±1.2 min, p=0.008). There were no other significant differences 
in baseline iron status, body composition, training, or performance measures between 
those who completed the study and those who did not complete the study. 
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Iron status variables measured from non-fasting venous blood samples 
(antecubital venipuncture, into two evacuated tubes, EDTA and serum-separator) 
included hemoglobin (Hgb), hematocrit (Hct), red blood cell count (RBC, Beckman 
Coulter, Fullerton, CA); serum ferritin (sFer, Immulite 2000, Siemens Healthcare 
Diagnostics, Deerfield, IL);  soluble transferrin receptor (sTfR, Ramco Laboratories, 
Stafford, TX); alpha-1-acid glycoprotein (AGP, radial immunodiffusion plate, Kent 
Labs, Bellingham, WA).  Total body iron (TBI, mg/kg) was calculated using the ratio 
of sTfR to sFer as described by Cook et al (33).  Every effort was made to obtain 
baseline, midpoint, and endpoint samples at the same time of day to control for diurnal 
variation in any measurement of iron status.  Immediately after blood sampling, Hgb 
and sFer status were analyzed. To control for potential variation in the non-automated 
sTfR assay conditions, both baseline and endpoint serum samples for the same subject 
were analyzed at the same time after the supplementation trial was completed. Rowers 
were classified as either iron depleted (sFer<20.0 µg/L), normal (sFer>20.0 µg/L), or 
anemic (Hgb<12.0 g/dL).  All anemics were notified of their status immediately after 
blood test results (within 1 week of analysis), referred to their respective campus 
health services for further instruction and/or monitoring, and excluded from further 
participation in the study.  All laboratory assays were done in the Human Metabolic 
Research Unit at Cornell University (Ithaca, NY).  
Body Composition: Anthropometric and body composition measurements were 
determined at the site of exercise testing.  Body weight and height were measured with 
standard procedures and equipment (34) .  For athletes for whom it was accessible 
(n=31), body fat and fat-free mass was assessed via air-displacement plethysmography 
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(BodPod, Life Measurement, Inc, Concord. CA).  For all subjects, percent body fat 
was calculated from tricep, suprailiac and thigh skinfold thickness (SF, Lange, 
Cambridge, MD) (35)  and bioelectrical impedance analysis (BIA, RJL Systems, BIA-
101) (36).  The Siri equation (37)  was used to calculate percent fat from body density. 
For those athletes without access to the BodPod (n=17), an average of their percent 
body fat values calculated from BIA and SF was used.  In the sample with both 
BodPod and BIA-SF average (n=31), the two methods were highly correlated (r=0.83, 
p<0.001), and not significantly different from each other (p=0.40).  The mean 
difference between percent body fat calculated from BodPod and the BIA-SF average 
was -0.48 3.15% (95% confidence interval of difference: -1.64, +0.67).  There were 
no significant differences in either body fat measurement method across schools.   
Data Analysis: All data were analyzed using SPSS Statistics version 18.0 
(Chicago, IL).  Based on an RCT of non-athletic women with good compliance, a 
sample size of 11 subjects per group was estimated to detect an effect size of 1.12 
standard deviation units (reflecting a 6.41 µg/L difference in sFer between treatment 
groups at the end of the 6-week trial (alpha=0.05, power=0.80) (30). We then used a 
smaller effect size (0.89) in order to account for the smaller margin for improvement 
in performance expected in athletes compared to untrained women (29, 30) due to 
their higher fitness level and training status at baseline, and estimated that a sample 
size of 17 rowers per treatment group should have been more than adequate to detect a 
difference in sFer between the two treatment groups. 
Data were examined to verify normality of distribution, and skewed 
distributions were log-transformed.  Results are reported as means  SDs.  All initial 
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analyses were performed on an “as-treated” basis to examine the effect of iron 
supplementation on both iron status and performance outcomes.  Additional subgroup 
analyses were then conducted on those subjects classified as IDNA at baseline.  
Independent Student’s T-test and ANOVA was used to examine treatment 
group differences at baseline; characteristics differing between treatment groups 
(p<0.05) were considered potential confounders and were included as covariates in 
subsequent regression models.  Mixed linear regression analysis, including both 
random and fixed effects, was used to assess the effects of iron supplementation on 
change in iron status.  School was treated as a random effect to control for unmeasured 
potentially confounding factors related to school differences in iron status.  A 
statistical significance level of p<0.05 was the level of statistical significance for main 
effects, and p<0.20 for testing interaction effects.   
Results 
Subject characteristics:  The placebo and supplemented groups were of similar 
age (19.8 1.1 and 19.7 0.9 years, respectively) and height (170.5 7.7 and 169.0 6.5 
cm, respectively), and had similar years of rowing experience (3.7 2.6 and 2.6 1.3 
years, respectively).  There was no significant difference in history of supplement 
usage, and there was no difference in the number of days since last menstrual period at 
baseline between treatment groups (17.2 10.2 and 22.9 16.2 days in placebo and iron 
groups, respectively). Body weight and composition did not differ between the two 
groups before or after the study (Table 6.1).  Rowers in both groups significantly 
increased their fat-free mass (FFM) by 1.2 1.2 kg and decreased their percent body fat 
by 1.5 1.8 % after 6 weeks of training (p<0.001).     
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Table 6.1. Anthropometry and body composition of rowers before and after 6 weeks of 
training and treatment (those who finished the trial) 
 Pre-treatment Post-treatment Change 
Weight (kg)    
          Placebo (n=16) 67.7 9.5 67.8 9.4 0.09 1.2 
          Iron (n=15) 67.0 6.6 67.3 7.1 0.25 1.6 
Body fat (%)    
          Placebo 25.8 4.3 24.2 3.7* -1.6 1.7 
          Iron 25.2 5.1 23.9 4.5* -1.4 1.9 
Fat-free mass (FFM, kg)    
          Placebo 50.0 5.6 51.2 5.9* 1.2 1.1 
          Iron 50.0 4.9 51.1 5.1* 1.1 1.3 
*Significantly different from baseline, p<0.001 
 
Compliance:  There were no significant group differences in the number of 
recorded training days during the study period.  The amount of capsules consumed, 
however, was 25% greater (but not significantly) in the placebo group (Table 6.2).  
There were no differences between the two groups in treatment-associated symptoms, 
as no adverse events or symptoms related to the supplementation were reported during 
the study.   
Table 6.2.  Compliance as measured by training log days recorded, weekly capsule 
count (n=31) 
 Placebo Iron 
Training log days recorded, n 51 10 47 19 
Capsules consumed, n 80 20 64 34* 
Total FeSO4 consumed, mg 0 3200 1699 
Percent of total prescribed dose consumed, % 75.6 17.7 60.3 30.2** 
Between treatment groups: *p=0.11, **p=0.09 
 
Response to iron treatment:  Results of the blood analyses measured at 
baseline and endpoint (0 and 6 weeks) of the study are presented in Table 6.3.  No 
significant group differences in any iron status measure was observed at baseline.  
After 6 weeks of training and iron supplementation, intent-to-treat analysis revealed 
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there were no differences in iron status between the two treatment groups, although all 
major indicators of body/tissue iron stores changed in the predicted direction in the 
iron-supplemented group.  Among those rowers with greater than 50% compliance 
(n=24), there were no significant differences in change in iron status between the two 
treatment groups.  We did not find any significant correlations between the amount of 
iron supplement consumed and change in iron status in the iron treatment group. 
Table 6.3.  Iron status (Hgb, Hct, sFer, sTfR, etc) at baseline and endpoint of trial 
(n=31) 
 Baseline 
(n=31) 
Endpoint 
(n=31) 
Change
1
 
Hemoglobin, g/dL    
          Placebo (n=16) 13.1 0.7 13.4 0.8 0.3 0.4 
          Iron (n=15) 13.1 0.7 13.3 0.6 0.2 0.7 
Ferritin, µg/L    
          Placebo 28.5 22.8 27.5 13.1 -1.0 14.8 
          Iron 25.0 15.8 28.0 8.6 3.0 15.3 
Log sFer    
          Placebo 1.3 0.3 1.4 0.2 +0.1 0.3 
          Iron 1.3 0.3 1.4 0.2 +0.1 0.3 
Soluble transferrin receptor, 
mg/L 
   
          Placebo 6.3 2.0 6.2 1.7 -0.1 2.2 
          Iron 6.2 1.9 5.4 1.7 -0.8 2.4 
Total body iron, mg/kg    
          Placebo 3.1 3.3 3.6 2.1 0.4 2.5 
          Iron 3.1 2.8 4.4 1.8 1.3 3.0 
1.  Change=endpoint minus baseline 
 
Initial multiple regression analyses (not including interaction terms) showed no 
effect of iron supplementation on change in iron stores after controlling for baseline 
iron stores (treatment group: β =0.04 (p=0.53); β =-0.78 (p=0.21); β=0.85 (p=0.18) for 
change in log sFer, sTfR, and TBI, respectively).  After including the interaction term 
for treatment-by-baseline iron status, analyses showed that treatment group predicted 
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change in iron stores (as measured by log sFer and TBI) after controlling for baseline 
iron stores (Table 6.4).   
Table 6.4.  Regression models to test the effects of iron supplementation on change in 
iron stores (log sFer, sTfR, TBI) after 6 weeks of training and treatment (n=31) 
 
 Model 1 – log sFer Model 2 – sTfR Model 3 - TBI 
  P  P  P 
Constant 
 
0.81 <0.001 4.69 0.003 2.29 0.001 
Treatment (0=P, 1=I) 
 
0.53 0.06 -0.13 0.95 1.77 0.06 
Baseline log sFer (µg/L) 
 
-0.56 <0.001 ---------- ---------- ---------- ---------- 
Baseline sTfR (mg/L) 
 
---------- ---------- -0.76 0.002 ---------- ---------- 
Baseline TBI (mg/kg) 
 
---------- ---------- ---------- ---------- -0.59 <0.001 
Treatment*BL log sFer  
 
-0.37 0.07 ---------- ---------- ---------- ---------- 
Treatment*BL sTfR 
 
---------- ---------- -0.10 0.75 ---------- ---------- 
Treatment*BL TBI 
 
---------- ---------- ---------- ---------- -0.30 0.18 
R
2
 (adjusted R
2
) 0.68 (0.65) 0.49 (0.43) 0.65 (0.61) 
 
The interaction between treatment group and iron status at baseline was 
significant, such that rowers with the lowest log sFer at baseline had the greatest 
improvement in iron stores in the iron group compared to the placebo group (p=0.07, 
see Figure 6.1).  There was also a modest interaction effect of treatment-by-baseline 
TBI (p=0.18).  Dose was not a significant predictor of change in sFer status in the 
entire sample of rowers, and was not included in the regression model.  Furthermore, 
there was no significant interaction between treatment and dose as it affected change 
in stores (β=0.003, p=0.40).   
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Figure 6.1.  Relationship between log sFer at baseline and change in log sFer (Model 
1 from Table 6.4) after 6 weeks of treatment (n=31).  Interaction significant at 
p=0.07. 
 
Additional plausibility analyses revealed a moderate relationship between 
supplemental iron consumed (mg elemental iron per kg of body weight) and change in 
total body iron (mg/kg) in the entire sample (n=14 iron, 16 placebo). After excluding 
one outlier who was a non-compliant rower in the iron treatment group with a large 
increase in TBI and controlling for TBI at baseline (β=-0.58, p<0.001), total 
supplemental iron consumed (0 mg in the placebo group) was a moderately significant 
predictor of change in TBI (β=0.07, p=0.13; R2=0.56).  Examining those rowers in the 
Placebo 
Iron 
 
-----
____
___ 
____ 
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iron group separately (n=14), total supplemental iron consumed remained a 
moderately significant predictor of change in TBI (β=0.12, p=0.18; R2=0.51).   
Subgroup analyses of rowers with IDNA at baseline  
As a result of the significant interaction presented in Table 6.4 suggesting that 
the iron supplementation would be most beneficial to the rowers who were iron 
depleted at baseline, we separately examined the subgroup of rowers who started the 
study with sFer<20.0 µg/L.  In these subjects, those randomized to the iron group were 
not significantly different from the placebo group in any baseline characteristics or 
measure of anthropometry or body composition (Table 6.5).  Among this subgroup, 
there were no significant differences in compliance between the two treatment groups 
(Table 6.6).   
Table 6.5. Anthropometry and body composition of rowers before and after 6 weeks of 
training and treatment  
 
 Pre-treatment Post-treatment Change 
Weight (kg)    
          Placebo (n=8) 68.1 11.9 68.4 12.0 0.4 1.2 
          Iron (n=8) 65.3 6.0 65.1 6.2 -0.2 1.7 
Body fat (%)    
          Placebo 24.8 4.1 23.0 3.7 -1.8 1.9 
          Iron 26.7 5.2 24.8 4.3 -1.9 2.3 
Fat-free mass (kg)    
          Placebo 50.9 7.1 52.4 7.8 1.6 1.0 
          Iron 47.7 4.1 48.8 3.7 1.1 1.5 
 
 
Table 6.6.  Compliance as measured by training log days recorded, weekly pill count 
(n=16) 
 Placebo (n=8) Iron (n=8) 
Training log days recorded, n 51.9 11.8 44.6 21.8 
Capsules consumed, n 83.4 23.0 58.8 39.1 
Total FeSO4 consumed, mg 0 2887.5 1871.0 
Percent of total prescribed dose consumed, % 76.1 16.9 55.2 33.5 
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Response to iron treatment:  Iron status of rowers with IDNA at baseline is 
presented in Table 6.7.  After 6 weeks of training and iron supplementation, there were 
no differences in iron status between the two treatment groups, although all major 
indicators of body/tissue iron stores changed in the predicted direction in the iron-
supplemented group.  We did not find any significant correlations between the amount 
of iron supplement consumed and change in iron status in the iron treatment group.   
 
Table 6.7.  Iron status (Hgb, Hct, sFer, sTfR, etc) at baseline and endpoint of trial for 
rowers with IDNA at baseline (n=16) 
 Baseline 
(n=16) 
Endpoint 
(n=16) 
Change 
Hemoglobin, g/dL    
          Placebo (n=8) 12.9 0.6 13.2 0.7 +0.3 0.2 
          Iron (n=8) 13.3 0.6 13.4 0.8 +0.2 0.8 
Ferritin, µg/L    
          Placebo 12.8 5.5 20.7 9.3 +7.9 9.4 
          Iron 14.3 4.8 25.1 9.5 +10.9 13.0 
Log sFer    
          Placebo 1.1 0.2 1.3 0.2 +0.2 0.3 
          Iron 1.1 0.2 1.4 0.2 +0.2 0.3 
Soluble transferrin receptor, mg/L    
          Placebo 6.0 1.8 6.6 1.0 +0.6 1.4 
          Iron 5.9 1.8 5.7 1.6 -0.2 2.3 
Total body iron, mg/kg    
          Placebo 1.1 2.6 2.3 1.7 +1.2 2.4 
          Iron 1.6 2.5 3.8 1.8 +2.1 3.5 
 
Multiple regression analysis of the IDNA subgroup showed that baseline iron 
stores predicted change in iron status (as measured by log sFer, sTfR, and TBI, Tables 
6.8, 6.9, 6.10), but there was no significant effect of treatment on change in iron status 
before including the treatment-by-dose interaction term.  There was a significant 
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interaction between treatment group and dose consumed (Table 6.8, Model 1) for 
change in log sFer, and there were no significant interactions between treatment group 
and dose for the other measures of iron status. 
 
Table 6.8.  Regression models to test the effects of iron supplementation on change in 
log serum ferritin (log sFer) after 6 weeks of training and treatment in IDNA 
subgroup (n=16) 
 
 Model 1 – log sFer  Model 2 – log sFer, 
without interaction 
Model 3 – log sFer, 
without dose 
  P  P  P 
Constant 
 
1.85 0.002 1.30 0.002 1.38 0.001 
Treatment  
(0=P, 1=I) 
-0.44 0.26 0.13 0.29 0.10 0.34 
Dose 
 
-0.005 0.27 0.001 0.58 ------------ ------------ 
Log sFer at baseline 
 
-1.17 0.001 -1.11 0.001 -1.10 0.001 
Treatment*Dose  
 
0.008 0.14 ------------ ------------ ------------ ------------ 
       
R
2 
(adjusted R
2
) 0.67 (0.55) 0.59 (0.49) 0.59 (0.51) 
 
Table 6.9.  Regression models to test the effects of iron supplementation on change in 
soluble transferrin receptor (sTfR) after 6 weeks of training and treatment in IDNA 
subgroup (n=16) 
 
 Model 1 - sTfR Model 2 – sTfR, 
without interaction 
Model 3 – sTfR, 
without dose 
  P  P  P 
Constant 
 
5.21 0.07 4.15 0.02 5.36 0.001 
Treatment  
(0=P, 1=I) 
-1.89 0.47 -0.58 0.43 -0.92 0.19 
Dose 
 
0.002 0.95 0.017 0.23 ------------ ------------ 
Baseline sTfR 
 
-0.79 0.002 -0.80 0.001 -0.79 0.002 
Treatment*Dose  0.02 0.60 ------------ ------------ ------------ ------------ 
       
R
2 
(adjusted R
2
) 0.63 (0.50) 0.62 (0.53) 0.57 (0.51) 
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Table 6.10.  Regression models to test the effects of iron supplementation on change in 
total body iron ( TBI) after 6 weeks of training and treatment in IDNA subgroup 
(n=16) 
 
 Model 1 - TBI Model 2 – TBI, 
without interaction 
Model 3 – TBI, 
without dose 
  P  P  P 
Constant 
 
5.49 0.12 2.29 0.18 2.26 0.005 
Treatment  
(0=P, 1=I) 
-2.33 0.52 1.42 0.19 1.43 0.14 
Dose 
 
-0.04 0.34 -0.0004 0.98 ------------ ------------ 
TBI Baseline 
 
-0.99 <0.001 -0.96 <0.001 -0.96 <0.001 
Treatment*Dose  0.05 0.29 ------------ ------------ ------------ ------------ 
       
R
2 
(adjusted R
2
) 0.70 (0.60) 0.67 (0.59) 0.67 (0.62) 
 
The relationship between supplement dose and change in log sFer is shown in 
Figure 6.3 A and B.  Iron-supplemented rowers who were more compliant (consumed 
more of the supplement) had the greatest improvement in iron stores (log sFer) 
compared to the placebo group (β =+0.008, p=0.14, see Figure 6.2A).  These results 
persisted after excluding four subjects who did not consume at least 50% of the 
prescribed dose (β=+0.013, p=0.15 for the treatment-by-dose interaction, Figure 
6.2B). 
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Figure 6.2 A.  Relationship between supplement consumed (percent of total dose) and 
change in iron status (log sFer, Table 6.8, Model 1) after 6 weeks of treatment for all 
rowers IDNA at baseline (n=16;   
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Figure 6.2B.  Relationship between supplement consumed (percent of total dose) and 
change in iron status (log sFer, Table 6.8, Model 1) after 6 weeks of treatment for 
rowers IDNA at baseline consuming more than 50% of prescribed dose (n=12); 
y=1.47 -0.92(treatment group)-0.72 (log sFer at baseline)-0.006(total dose consumed) 
+0.013 (treatment*dose), R
2
=0.55 (adjusted R
2
=0.29) 
 
Additional plausibility analyses revealed a moderate relationship between 
supplemental iron consumed (mg elemental iron per kg of body weight) and change in 
total body iron (mg/kg) in the IDNA subgroup sample (n=7 iron, 8 placebo). After 
excluding one outlier who was a non-compliant rower in the iron treatment group with 
a large increase in TBI, and controlling for TBI at baseline (β=-0.68, p=0.002), total 
supplemental iron consumed was a moderately significant predictor of change in TBI 
Placebo 
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(β=0.11, p=0.10; R2=0.59).  Examining those IDNA rowers in the iron group 
separately (n=6), total supplemental iron consumed became a significant predictor of 
change in TBI (β=0.23, p=0.05; R2=0.79).   
Discussion 
The purpose of this randomized, double-blind, placebo-controlled trial was to 
examine the effects of iron supplementation on change in iron status in non-anemic 
female rowers training for their competitive season.  Serum ferritin and Hgb were used 
to identify those to include in the supplementation trial, as done previously (29, 30).  
Additionally, we measured sTfR and calculated total body iron to differentiate those 
with low total iron stores from those with low tissue (functional) iron (38-40).  This 
study showed that 6 weeks of iron supplementation during training did lead to a 
greater improvement in iron stores (sFer, TBI) compared to placebo, after controlling 
for baseline iron stores.  These findings are important to training female endurance 
athletes, as well as all physically-active women.   
Other researchers have reported deterioration of iron status with moderate to 
high levels of physical activity.  These decrements in iron status have been shown to 
affect physical performance, especially in those women who begin training with poor 
iron status (32, 40, 41), and iron supplementation has been shown to prevent a 
deterioration in sFer during periods of moderate to heavy physical training (32).  In the 
present study, we did observe a positive effect of iron supplementation on sFer and 
TBI, especially in those rowers with low sFer at baseline.  We did not, however, 
observe this positive effect on sTfR. 
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The rowers in our study were not anemic, therefore, there were few with sTfR 
>8.0 mg/L (n=6 at baseline).  At the end of the study, sTfR was not significantly 
different between treatment groups (p=0.20), although rowers in the placebo group 
tended to have higher sTfR compared to the iron group.  Researchers have shown that 
sTfR is affected by muscle growth (26, 40), and in the current study, after 6 weeks of 
training all rowers increased their FFM by ~1.2 kg.  Although we observed no 
correlation between change in FFM and change in sTfR, it is possible that this factor 
may have played a role in diminishing the effects of supplementation on this measure 
of iron status. 
In the current study, rowers with the lowest sFer at baseline (who had the 
greatest potential for improvement) did benefit the most from iron supplementation, 
which was expected.  Depleted iron stores at the beginning of the training season, 
coupled with increased iron requirements during heavy training would result in 
negative iron balance.  Increased intake of highly bio-available iron (dietary or 
supplemental) would be the only way to replace losses and meet increased demands of 
training (FFM, Hgb, etc).  Conversely, if iron stores are adequate (or even marginally-
adequate) at the beginning of a training season, they may be used to meet increased 
demands, thus leading to depletion over the course of a training period.   
It is possible that rowers’ training may have decreased (or overshadowed) the 
response to iron supplementation. Endurance exercise does increase body iron 
turnover, and may increase basal iron loss (sweat, urine, etc).  It has been suggested 
that physical training may increase the estimated average requirement (EAR) for iron 
in female athletes by 30-70% -- from 8 mg to 10-14 mg/d (42).  The level of iron 
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supplementation used in this study was more than the RDA for women (18 mg/d), and 
should have been adequate to improve iron stores if taken as directed.  In previous 
studies, 100 mg FeSO4 over the course of 6-8 weeks was sufficient to improve iron 
stores (sFer) in compliant, non-athletic women (29, 30).  In our sample, although 
rowers in the iron group consumed on-average only 60% of the prescribed iron dose 
(~15 mg elemental iron/d), we still saw an improvement in iron status with iron 
supplementation, and no side-effects were reported with this dose.  
Although women in this study were not clinically anemic, criteria used to 
identify anemia (Hgb <12.0 g/dL) may be insufficient for female athletes during 
training.  At the end of the sutyd, Hgb of rowers in both groups increased by 0.2 g/dL.  
The potential for functional (non-clinical) anemia is much greater in this population 
due to intense training, which may further increase demand for O2-carrying capacity 
(Hgb) and functional tissue iron (sTfR).  This prioritization of iron for Hgb synthesis 
over storage may be another reason for the small sFer response to supplementation.   
A limitation of our subgroup analysis is the use of the sFer cut-off of 20.0 µg/L 
to identify rowers as IDNA.  Any misclassification of baseline iron status in these 
subjects could have diluted the differences in change in iron status between the two 
treatment groups. Although sFer is the most common index of iron stores, and reflects 
iron stored in the liver, it is an acute-phase protein and can be elevated in an 
inflammatory state (e.g. infection, post-exercise), potentially masking ID (43-45). 
However, an inflammatory marker such as C-reactive protein (CRP) or alpha-1-acid 
glycoprotein (AGP) can partially rule-out falsely-elevated sFer (46-48).  In our study, 
while there were no differences in AGP between the two treatment groups at the 
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beginning or end of the study, and only one subject had AGP levels above the 
threshold indicative of inflammation (140 mg/dL), some iron-depleted subjects may 
still have been misclassified as normal.  
Recent research has suggested that the iron regulatory protein hepcidin is the 
mediator between the inflammatory response and poor iron status (49).  During the 
acute-phase response, which is seen post-exercise, hepcidin is up-regulated and enters 
the circulation to negatively control the export of iron from the intestinal enterocyte. 
Thus, acute increases in hepcidin may lead to a decrease in the absorption of dietary 
iron (24). This mechanism may explain the increased prevalence of iron deficiency in 
female athletes and/or changes in iron status with training, as well as the reduced 
potential for improved sFer with iron supplementation in athletes.  Several studies 
have shown associations between or increases in urinary hepcidin and inflammation 
post-exercise, suggesting that high levels of training may negatively affect iron status 
(11, 50-54).  Researchers found that although serum hepcidin was not affected by 
basic combat training in female military soldiers, it was positively associated with sFer 
and CRP levels before and after training, demonstrating its association with 
inflammation (55). In the current study, hepcidin and iron absorption were not 
measured.  
Conclusions:  Despite our limitations, this randomized placebo-controlled 
study did show a significant effect of low-dose iron supplementation on change in sFer 
during training after controlling for baseline sFer, and adds to the growing body of 
evidence that iron supplementation improves the iron status of active women, which 
may ultimately impact training and physical performance.  Based on the results from 
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this study, we conclude that female endurance athletes that consumed ~15 mg/d 
elemental iron during training can improve their iron status, and those who are most 
depleted will benefit the most form supplementation.  Future studies should focus on 
ways to improve supplement compliance in training female athletes in order to confer 
maximum benefit to athletes’ iron status, and to assess the effects of iron 
supplementation on training and physical performance in this population.    
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CHAPTER 7 
 
IRON SUPPLEMENTATION IMPROVES LACTATE RESPONSE AND 
ENERGETIC (WORK) EFFICIENCY AFTER TRAINING IN NON-ANEMIC 
FEMALE ROWERS 
 
Abstract 
Introduction:  Studies in both animals and humans have shown a relationship between 
iron deficiency without anemia (IDNA) and physical performance. Twice as many 
active females (30%) are IDNA, compared to their sedentary counterparts.  
Consequences of IDNA demonstrated in non-athletic women are especially relevant to 
female endurance athletes (e.g. reduced work capacity, endurance, and energetic 
efficiency).  We conducted a trial to investigate the effects of IDNA on endurance 
performance in female rowers during training.    
Methods: At the beginning of a training season, 43 non-anemic rowers were 
randomized to receive 100 mg/d FeSO4 (n=22) or placebo (n=21) for 6 weeks using a 
double-blind design. Thirty-one rowers (n=15 iron, 16 placebo) completed the 6-week 
trial and all baseline and endpoint testing.  Subjects trained with their team as usual 
and completed daily logs of training time, type and intensity throughout the study.  
Iron status (hemoglobin, serum ferritin, soluble transferrin receptor, total body iron), 
body composition, and laboratory tests of physical performance (4K time trial (TT), 
VO2peak, energetic efficiency, blood lactate) were assessed at baseline and after 
training.   
Results: There were no significant differences at baseline between the two treatment 
groups for iron status or performance.  After controlling for baseline iron status, 
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multiple regression analyses revealed improvements in log sFer in the iron treatment 
group compared to placebo, and the more iron depleted at baseline, the greater benefit 
from supplementation.  After 6 weeks of training, while rowers in both treatment 
groups increased their fat-free mass and improved their endurance performance  
(VO2peak, energetic efficiency, lactate response), lactate (as %lactate max) during the 
first 2000m of the TT and after 5 min of recovery was significantly lower in the iron- 
supplemented group compared to the placebo group (p=0.05).  Multiple regression 
analyses revealed that after controlling for baseline performance and dose of 
supplement consumed, the rowers in the iron group who consumed more of the 
prescribed dose had a greater improvement in work efficiency compared to placebo 
(p=0.15 for the interaction treatment -by- dose).  Additionally, the energetic efficiency 
of those rowers with poorer baseline iron stores (sFer<20.0 ug/L) benefitted more 
from iron supplementation. 
Conclusion: After 6 weeks of iron supplementation, rowers had improved lactate 
response during the first half of a 4K TT and 5 min post-test.  After controlling for 
baseline performance and supplement dose, iron supplementation improved female 
rowers’ energetic efficiency during a 4K TT after 6 weeks of training, but there was 
no effect on VO2peak or 4K TT time.  
 
Key words: iron depletion, athletes, physical performance, energetic efficiency, 
lactate, rowers, iron supplementation 
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Introduction 
Iron deficiency (ID, serum ferritin (sFer) <12.0 µg/L) is the most prevalent 
nutrient deficiency in the world, including the US, where iron deficiency with anemia 
(IDA, ID plus hemoglobin (Hgb) <12.0 g/dL) affects 3-5%, and iron deficiency 
without anemia (IDNA, sFer <20.0 µg/L) affects ~16% of young women (1). Active 
females, including military soldiers, are especially susceptible, as surveys have shown 
even higher rates of IDNA (25-35%) (2-7).  Although research has clearly shown the 
effects of IDA on physical performance (8-10), the high prevalence of IDNA in 
female athletes requires investigation into its effects on physical performance in this 
group.  Though the exact mechanism is unknown, the increased prevalence of IDNA 
in active and training females may be due to one or more factors beyond poor dietary 
iron intake, including: hemolysis (foot strike, impact); increased blood loss 
(gastrointestinal tract, hematuria, sweat); change in iron absorption (11-14).  We have 
previously shown that daily iron supplementation for six weeks improves the iron 
status of female collegiate rowers (Chapter 6).   
Despite the inability to identify the exact mechanism in humans, endurance 
capacity, energetic efficiency, and time trial (TT) performance have been shown to be 
impaired in laboratory studies of IDNA humans (15-18).  Studies of how iron status 
affects non-anemic endurance athletes are limited, but research suggests that female 
endurance athletes and military soldiers with IDNA have impaired physical 
performance (19-24).  It is has been suggested that the iron status of experimental 
animals and humans is related to their physical training, but the direction of this 
relationship is unclear (8, 25-30).   
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Energetic efficiency and blood lactate metabolism are two measures of 
endurance performance. Energetic (work) efficiency (%) is defined as work output per 
kcal expended and is expressed as a percent relative to VO2peak (ml/kg/min), or to 
work (W) performed. It is hypothesized that IDNA affects iron-containing enzymes of 
the TCA cycle, which are involved in the transformation of chemical to mechanical 
energy to do work (produce work output). Blood lactate concentration is positively 
correlated with the amount of lactate produced in muscle, which is an indication of the 
degree of anaerobic metabolism at the muscle tissue level.  Blood lactate measured 
during exercise is the result of lactate production, release, and removal from the 
muscle.  Although researchers have shown that ID and anemic humans and animals 
display an earlier increase in lactate production and decreased rate of lactate clearance 
(31, 32), results in IDNA humans are not clearly understood. 
Previous work from our laboratory, as well as from others, has shown that 
IDNA reduces endurance capacity of non-athletes (both untrained women and 
untrained women participating in an aerobic training program) by improving energetic 
efficiency (15, 17, 18, 20).  Additionally, our group and others have shown 
improvements in lactate metabolism in iron-supplemented women, especially during 
the earlier phases of endurance TTs (15, 17, 33).  In a study of female athletes, we 
found that sFer status was a significant predictor of rowers’ reported performance (2K 
Personal Record (PR) time, Chapter 4) and measured performance (VO2peak, 
energetic efficiency, Chapter 5). Despite the strong cross-sectional associations 
between IDNA and performance, there is inadequate evidence demonstrating how iron 
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repletion affects performance in highly-trained IDNA endurance athletes, who have 
much less potential to benefit from improvements in iron status. 
The high prevalence of IDNA among female athletes, and the strong 
association between both iron status and physical performance led us to perform the 
current study in which we aimed to test for a causal relationship between iron status 
and performance in trained female athletes who are beginning their competitive 
season’s training program.  The objectives of this study were to: 1) examine the effects 
of iron supplementation on female collegiate rowers’ metabolic adaptations to rowing 
(endurance) training during a 4K TT (VO2peak, gross energetic efficiency, lactate 
concentration, and time to complete TT); and 2) to investigate the relation of change in 
iron status indicators and changes in endurance capacity and energy metabolism 
during a TT after 6 weeks of training.   We hypothesized that iron-supplemented 
rowers would be more energetically-efficient and have improved blood lactate 
response during the 4K TT, complete the TT faster, and have a higher VO2peak than 
rowers in the placebo group.   
Methods 
Recruitment of subjects: Subjects were recruited at the beginning of the 
conditioning phases of their competitive rowing seasons (fall 2008, spring 2009, and 
fall 2009, upon arrival to campus post- summer and post-winter break). All varsity and 
second-semester novice female rowers were eligible to participate in the screening if 
at least 18 years of age, non-smoking, and were able to begin regular training for their 
sport. Training activities during this time included general aerobic conditioning 
(cycling, running, rowing on ergometer), resistance training, and high intensity 
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rowing.  Detailed reports of training and physical activity will be reported elsewhere 
(Chapter 8).  A medical screening (NCAA-required) prior to our study excluded all 
athletes not healthy enough to participate in their rowing team training (current, acute 
or chronic illness, severe asthma, musculoskeletal problems, etc).  All rowers provided 
written informed voluntary consent prior to participating in the study. This study was 
approved by the Institutional Review Boards of the following colleges/universities: 
Binghamton University, Cornell University, Hobart and William-Smith Colleges, 
Ithaca College, and Syracuse University.  
A total of 165 female rowers from the five schools completed the iron status 
screening (see Figure 3.2, pg 58). Ten percent of rowers (n=16) screened were 
identified as anemic and 30% as IDNA (sFer<20.0 µg/L, Hgb>12.0 g/dL).  All 149 
non-anemic subjects with and without iron depletion (cut-off: sFer<20.0 µg/L) were 
invited to participate in the baseline physical performance and body composition 
testing.  Forty-eight non-anemic rowers (n=24 IDNA and 24 rowers with normal iron 
status) participated in the baseline data collection (n=5 William-Smith, 14 Cornell, 9 
Ithaca, 12 Binghamton, and 8 Syracuse). Forty rowers were then randomized to 
receive supplemental iron (n=21, 12 with sFer<20.0 µg/L) or placebo (n=19, 11 with 
sFer<20.0 µg/L).  Subjects received iron status, body composition, and fitness testing 
results as a benefit of participation, along with referral and recommendations to 
improve iron status as necessary.   
Design: This study was a randomized, double-blind, placebo-controlled iron 
supplementation trial. Each subject was randomly assigned to a treatment group by a 
research assistant who was not involved in data collection or contact with subjects.  
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Randomization was done by assigning each subject a random number, with even and 
odd numbers being assigned to either treatment group.  After initial randomization, 
any imbalance in the distribution of treatment or representation of school or baseline 
iron status (sFer) was corrected by re-randomization. Rowers were randomly assigned 
to one of two groups: iron supplementation with 50 mg FeSO4 twice per day or 
placebo in the form of identical red capsules. Subjects were provided with 18 capsules 
each week, and were instructed to consume 2 capsules per day. Subjects were 
instructed to consume one capsule each at their morning and evening meals to 
minimize potential gastrointestinal side-effects, and with a glass of citrus juice to 
enhance iron absorption.  Subjects were also instructed to avoid consumption of any 
other multivitamin/mineral supplements during the 6 week study period. 
Compliance with the iron treatment, as well as current health, menstrual status, 
and physical activity was assessed by daily training logs. Subjects were instructed to 
record the number of capsules they consumed daily in their log, even if they had 
consumed less than the prescribed amount per day.  Additionally, weekly capsule 
counts were conducted by the researcher.  
Both iron and placebo capsules were prepared by a Registered Pharmacist 
(PharmD) at the Cornell University College of Veterinary Medicine Pharmacy (Ithaca, 
NY).  The iron supplement capsules contained 50 mg FeSO4 per capsule with lactose 
filler, and the placebo capsules contained only lactose.  The iron content of both 
placebo and iron capsules was analyzed via ICP mass spectrometry digestion by the 
USDA’s Robert Holley Center for Agriculture and Health (Ithaca, NY).  Twenty 
capsules were randomly selected for analysis from each of 2 batches.  No differences 
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in the average iron content were found between the two batches of iron-containing 
capsules (15.8 ± 0.5 mg elemental iron per capsule), and no iron was detected in the 
placebo capsules.  
For all subjects, body composition and physical performance were measured 
immediately before and after the 6 week treatment period.  Thirty-one rowers finished 
the entire study protocol (all blood analyses and exercise testing) (see Figure 3.2).  Six 
subjects from the iron group and three from the placebo group dropped out of the 
study due to personal reasons (n=4), injury (n=3) or illness (n=2), all unrelated to the 
study.  Rowers who did not complete the study reported getting more and better 
quality sleep at baseline (p=0.01 and 0.04, respectively), as well as feeling better in 
general (p=0.03) than rowers who did complete the study (n=31). Compared to the 31 
rowers who completed the study, the 9 rowers who did not complete the study had 
slower times to complete a simulated 4K time trial on a rowing ergometer at baseline 
(19.4±2.6 min vs 17.7±1.2 min, p=0.008). There were no other significant differences 
in baseline iron status, body composition, training, or performance measures between 
those who completed the study and those who did not complete the study. 
Assessment of iron status: Iron status variables measured from non-fasting 
venous blood samples (antecubital venipuncture, into two evacuated tubes, EDTA and 
serum-separator) included hemoglobin (Hgb), hematocrit (Hct), red blood cell count 
(RBC, Beckman Coulter, Fullerton, CA); serum ferritin (sFer, Immulite 2000, 
Siemens Healthcare Diagnostics, Deerfield, IL);  soluble transferrin receptor (sTfR, 
Ramco Laboratories, Stafford, TX); alpha-1-acid glycoprotein (AGP, radial 
immunodiffusion plate, Kent Labs, Bellingham, WA).  Total body iron (TBI, mg/kg) 
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was calculated using the ratio of sTfR to sFer as described by Cook et al (34).  Every 
effort was made to obtain baseline, midpoint, and endpoint samples at the same time 
of day to control for diurnal variation in any measurement of iron status.  Immediately 
after blood sampling, Hgb and sFer status were analyzed. To control for potential 
variation in the non-automated sTfR assay conditions, both baseline and endpoint 
serum samples for the same subject were analyzed at the same time after the 
supplementation trial was completed. Rowers were classified as either iron depleted 
(sFer<20.0 µg/L), normal (sFer>20.0 µg/L), or anemic (Hgb<12.0 g/dL).  All anemics 
were notified of their status immediately after blood test results (within 1 week of 
analysis), referred to their respective campus health services for further instruction 
and/or monitoring, and excluded from further participation in the study.  All 
laboratory assays were done in the Human Metabolic Research Unit at Cornell 
University (Ithaca, NY).  
Body Composition: Anthropometric and body composition measurements were 
determined at the site of exercise testing.  Body weight and height were measured with 
standard procedures and equipment (35).  For athletes for whom it was accessible 
(n=31), body fat and fat-free mass was assessed via air-displacement plethysmography 
(BodPod, Life Measurement, Inc, Concord. CA).  For all subjects, percent body fat 
was calculated from tricep, suprailiac and thigh skinfold thickness (SF, Lange, 
Cambridge, MD) (36) and bioelectrical impedance analysis (BIA, RJL Systems, BIA-
101) (37).  The Siri equation (38) was used to calculate percent fat from body density. 
For those athletes without access to the BodPod (n=17), an average of their percent 
body fat values calculated from BIA and SF was used.  In the sample with both 
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BodPod and BIA-SF average (n=31), the two methods were highly correlated (r=0.83, 
p<0.001), and not significantly different from each other (p=0.40).  The mean 
difference between percent body fat calculated from BodPod and the BIA-SF average 
was -0.48 3.15% (95% confidence interval of difference: -1.64, +0.67).  There were 
no significant differences in either body fat measurement method across schools.   
Questionnaires: Information about current dietary supplement use, health and 
menstrual status, usual physical activity, and eating habits and attitudes was obtained 
using questionnaires and a 7-day food diary.  Rowing training regimen, as well as 
leisure-time physical activity (LTPA) outside of rowing training was quantified daily 
throughout the trial via detailed training and activity records (Appendix 11). Eleven 
questions in the daily log addressed sleep and nap duration and quality, soreness and 
fatigue, motivation, concentration, and training/physical activity frequency, intensity, 
time, and type.  Questions were presented in the format of a Visual Analog Scale 
(VAS) (39).  Subjects were asked to rate each question by placing a solid vertical line 
on a 100mm scale anchored by opposing descriptors.  Data on training outcomes are 
presented elsewhere (Chapter 8). 
The session-RPE method (40)  was used to quantify daily training load.  VAS 
Intensity score for each training session was multiplied by training session duration 
(time).  This method has been used by others to quantify training in athletes (41-43).  
We validated the session RPE method using our VAS-format with the summated heart 
rate zone method (44) during two weeks of training on a separate sample of thirteen 
female rowers and found a significant positive correlation between the two methods 
(r=0.85, p<0.001, Appendix 1).  In the current study, rowers were classified as either 
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“High” trainers or “Low” trainers based on the Session-RPE cutoff of 3200, which 
was the median (50
th
 percentile) sessionRPE of the sample.    
Physical Performance Testing Methods: Physical fitness and endurance 
performance was assessed using a rowing ergometer (Concept2, Morrisville, VT) 
equipped with a digital readout monitor (PM2), displaying work (W), stroke rating 
(SPM), distance (m), and time (min:sec).  A computerized metabolic cart (TrueMax 
2400, ParvoMedics, Salt Lake City, Utah) was used to measure VO2 and other 
physiological measures during all testing. Concentrations of O2 and CO2 in expired air 
were analyzed with each breath, and respiratory volume (VE) was measured with a a 
respiratory pneumotachograph (Fitness Instrument Technologies, Farmingdale, NY) 
through a two-way breathing valve (Hans Rudolph, Kansas City, MO).   
Energy expenditure was assessed via indirect calorimetry during exercise 
testing using a standard protocol that monitors expired gases for VE, VO2, VCO2, and 
respiratory exchange ratio (RER) continuously throughout testing (45, 46).   Heart rate 
(HR, Polar FS2, Polar Electro, Inc, Lake Success, NY) was also continuously 
monitored throughout testing.  Cadence (strokes per minute, spm) and work rate (WR, 
watts (W) resistance) were monitored and recorded every 30 seconds.   
 Capillary blood samples were obtained by finger or ear punctures immediately 
before testing, and every 1000m during testing, as well as 5- and 10- min post-testing.  
Blood lactate concentrations were determined by the Lactate Pro analyzer (FaCT 
Canada, Quesnel, British Columbia, Canada) (47), which we have concluded to be 
valid and accurate against an enzymatic assay (r=0.64, p<0.001, Sigma Diagnostics, 
St. Louis, MO), as is consistent with the peer-reviewed literature (48-51).   
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Subjects were instructed to not consume food or beverages other than water, or 
to perform any strenuous physical activities 2 h prior to testing.  To control for the 
effects of dietary intake and hydration status, subjects were instructed to record all 
food and fluid intake 7d prior to testing, as well as the day of exercise testing.  
Subjects had the opportunity to warm-up for at least 10 min prior to all testing.   
Rowers performed two tests in the lab.  The first was a pre-test done to 
acclimate subjects to testing protocol and laboratory procedures, as well as to establish 
a VO2peak and target WR prescription of 85% of their maximal work rate (WRmax) 
to be used in the subsequent 4K TT.  VO2peak was determined by a modified version 
of the maximum aerobic power (MAP) test, which is a ramped protocol used by 
rowing coaches to assess training progress (52). 
Rowers’ MAP in split-time was converted into watts (W = 2.8/pace per 500 
m
3
), and the test began 100 W below the predicted maximum.  Each stage of the test 
lasted 90s, with a 10s “gear-up” period between each stage (Appendix 12).  Every 90 
s, the rower was asked to increase her WR by 20 W, until she was no longer able to 
maintain the WR.  This test was designed to last between 8-10 min.  VO2peak was 
identified as the highest VO2 value achieved, and was confirmed by at least one of the 
following: 1) VO2 increased by <150 ml/min with an increase in WR; 2) RER >1.10; 
or 3) HRmax was within 10 beats of age-predicted maximum (220-age) (46).  A 15-
min cool-down period followed testing at a self-selected WR, and HR was monitored 
for 10 min post-test.  Blood sampling for lactate was collected pre- and post test, as 
well as at 5- and 10-min post-test.  Complete test time was about 45 min (10-15 min to 
acclimate to equipment; 10 min for actual testing; 15 min cool-down).  Participants 
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were able to stop the test at any time, and the investigator was able to stop the test at 
any time (equipment malfunction; subject symptoms of severe fatigue). The pre-test 
was only performed at baseline. 
Endurance capacity was assessed at both baseline and endpoint by time to 
complete a 4K TT, which was administered within 3 days of the baseline pre-test.  
This test consisted of a 4K ergometer row at a sub-maximal WR prescription (WRRx) 
of 85% of rowers’ VO2peak reached in the pre-test. This WR was maintained for 
3600m of the test, and the rowers were then asked to sprint the final 400m of the test 
to simulate on-water racing (Appendix 10.12).  The 4K TT was designed to last about 
20-25 min.  Subjects received standardized verbal encouragement during testing.  
Complete testing time was ~ 60 min total (15 min to acclimate to equipment; 5 min 
warm-up; 25 min actual testing; 15 min cool-down). The 4K TT was performed at 
baseline and endpoint at the same WR Rx.  VO2peak and other reported performance 
outcome variables were obtained from the 4K TT.  
 
Calculations 
Work output (kcal/min) was calculated as: 
Formula 7.1:  Work output = [Work in Watts (W) * 0.014 kcal/min]. 
 
Energy expenditure (EE) input was calculated as: 
Formula 7.2:  EE = [VO2 (L/min) * non-protein respiratory quotient 
(kcal/min)]. 
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Gross energetic efficiency (EF) was calculated as(53) : 
Formula 7.3:  Gross EF = [Work output (kcal/min) / EE input (kcal/min)] *100 
 
 
Deviation from the target WR Rx of 85% of their pre-test WRmax (W) was calculated 
as: 
Formula 7.4:  Deviation from WRRx= [WR Rx - average W maintained]. 
 
Data Analysis: All data were analyzed using SPSS Statistics version 18.0 
(Chicago, IL).  A sample size of 26 subjects per group was estimated as required to 
detect an effect size of 0.70 SD units for change in TT time and 29 subjects per group 
to detect an effect size of 0.65 SD units for change in VO2max between treatment 
groups (alpha=0.05, power=0.80).  Data were examined to verify normality of 
distribution, and skewed distributions were log-transformed.  Results are reported as 
means  SDs.  All initial analyses were performed on an “as-treated” basis to examine 
the effect of iron supplementation on both iron status and performance outcomes.  
Additional subgroup analyses were then conducted on those subjects classified as 
IDNA at baseline.  
Independent Student’s T-test and ANOVA were used to examine treatment 
group differences at baseline; characteristics differing between treatment groups 
(p<0.05) were considered potential confounders and were included as covariates in 
subsequent regression models.  Those variables significantly correlated with physical 
performance outcomes (p<0.05) were designated as potential confounders and 
included as covariates in the regression models.  Pearson’s correlations were used to 
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examine the relation between change in iron status and change in performance 
outcomes.   
Mixed effects linear regression analysis, including both random and fixed 
effects, was used to assess the effects of iron supplementation on performance.  School 
was treated as a random effect to control for unmeasured potentially confounding 
factors related to school differences in iron status, training and performance. A 
statistical significance level of p<0.05 was the level of statistical significance for main 
effects, and p<0.20 for exploratory testing of interaction effects.   
Results 
Subject characteristics: Thirty-one rowers completed the performance testing 
at the end of the supplementation trial (see Figure 3.2).  The placebo and 
supplemented groups were of similar age (19.8 1.1 and 19.7 0.9 years, respectively) 
and height (170.5 7.7 and 169.0 6.5 cm, respectively), and had similar years of 
rowing experience (3.7 2.6 and 2.6 1.3 years, respectively).  Body weight and 
composition did not differ between the two groups before or after the study (Table 
7.1).  Rowers in both groups significantly increased their FFM by 1.2 1.2 kg and 
decreased their percent body fat by 1.5 1.8 % after 6 weeks of training (p<0.001).     
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Table 7.1. Anthropometry and body composition of rowers before and after 6 weeks of 
training and treatment (n=31) 
 Pre-treatment Post-treatment Change 
Weight (kg)    
          Placebo (n=16) 67.7 9.5 67.8 9.4 0.09 1.2 
          Iron (N=15) 67.0 6.6 67.3 7.1 0.25 1.6 
Body fat (%)    
          Placebo 25.8 4.3 24.2 3.7 -1.6 1.7 
          Iron 25.2 5.1 23.9 4.5 -1.4 1.9 
Fat-free mass (kg)    
          Placebo 50.0 5.6 51.2 5.9 1.2 1.1 
          Iron 50.0 4.9 51.1 5.1 1.1 1.3 
Differences between treatment groups not significant. 
 
 
Compliance: There were no significant group differences in the number of 
recorded training days (51 10 and 47 19 d in Placebo and Iron groups, respectively) 
during the study period.  The amount of supplement consumed, however, was 25% 
greater (not statistically significant) in the placebo group (Table 7.2).  There were no 
differences between the two groups in treatment-associated symptoms (no adverse 
events or symptoms related to the supplementation were reported).  
 
Table 7.2.  Compliance as measured by training log days recorded, weekly pill count 
 Placebo Iron 
Training log days recorded, n 51 10 47 19 
Capsules consumed, n 80 20 64 34 
Total FeSO4 consumed, mg 0 3200 1699 
Percent of total Rx consumed, % 75.6 17.7 60.3 30.2 
 
 
Response to iron treatment: Results of the blood analyses have been reported 
elsewhere (Chapter 6).  Multiple regression analyses revealed improvements in body 
iron stores (log sFer, total body iron) in the iron treatment group after controlling for 
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baseline iron status, and those with most depleted stores at baseline showed the 
greatest improvement in iron status.   
4K endurance time trial (TT): Results of the 4K TT before and after 6-weeks 
of training and treatment are shown in Table 7.3.  After 6 weeks of training, rowers in 
both treatment groups improved VO2peak (+0.2 0.2 l/min, p<0.001) and maximal 
workload (+22.0 36.3 W, p=0.002), however, there were no significant differences 
between the two treatment groups.  While average gross efficiency during the entire 
4K TT was not significantly different after 6 weeks of training in either treatment 
group (p=0.39), efficiency at the end of the test was significantly improved in both 
groups (+1.2 2.4%, p=0.006).  There were no significant correlations between 
measures of iron status or change in iron status and change in performance in the total 
sample.  As expected, there were significant positive correlations between change in 
performance and training variables in the total sample, which will be presented in 
Chapter 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 
 
Table 7.3.  Physical performance measures (4K time, Total VO2, % VO2, RER, WR) 
before and after 6 weeks of training and treatment 
 Pre-treatment Post-treatment Change 
4K time, min    
          Placebo (n=16) 18.0 1.0 17.7 1.4 -0.2 0.9 
          Iron (n=15) 17.4 1.3 17.8 1.9 0.4 1.3 
Absolute VO2 peak, L/min    
          Placebo 3.1 0.4 3.3 0.4* 0.2 0.2 
          Iron 3.3 0.4 3.4 0.4 0.2 0.2 
Relative VO2 peak, ml/kg FFM/min    
          Placebo 62.9 5.1 65.1 6.2 2.3 4.5 
          Iron 65.2 5.7 66.5 5.4 1.3 5.0 
Maximal work rate, W    
          Placebo 225.8 51.1 243.1 64.6** 17.3 35.0 
          Iron 227.3 25.9 254.3 43.7 27.0 38.2 
Maximal heart rate, bpm    
          Placebo 190.8 8.9 190.8 9.8 0.1 4.7 
          Iron 192.8 14.7 195.8 7.8 3.0 15.6 
Maximal RER    
          Placebo 1.00 0.04 1.04 0.07 0.04 0.08 
          Iron 1.03 0.07 1.05 0.07 0.02 0.07 
Gross energetic efficiency, %    
          Placebo 17.3 2.0 17.1 1.9 -0.2 1.3 
          Iron 16.9 1.1 17.5 1.3 0.6 1.2 
No significant differences between treatment groups; t-test significantly different from 
BL, *p<0.001, **p=0.002 
 
Change in gross energetic efficiency: The effect of iron supplementation on 
change in performance as measured by VO2peak, 4K TT time, and energetic 
efficiency was tested using multiple regression analyses after controlling for baseline 
performance, training, and supplement dose consumed.  There were no significant 
effects of iron supplementation on 4K TT time or VO2peak, but there were 
relationships between supplementation and gross energetic efficiency.  Results of 
these analyses testing the effects of treatment group on energetic efficiency are shown 
in Table 7.4.   
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Table 7.4. Regression models to test the effects of iron supplementation on change in 
gross efficiency (%) after 6 weeks of training and treatment in entire sample of rowers 
(n=31)  
 
 Model 1 Model 2 Model 3 Model 4 
(n=24 consuming </= 
50% of prescribed dose) 
  p  p  p  p 
Constant 
 
3.15 0.14 6.3 0.01 7.9 0.005 7.6 0.02 
Treatment  
(0=Placebo, 
1=Iron) 
0.37 0.33 0.02 0.97 -1.7 0.17 -3.90 0.17 
Dose 
 
------ ------- -
0.02 
0.04 -
0.04 
0.02 -0.04 0.07 
Baseline EF 
 
-
0.22 
0.08 -0.3 0.012 -0.3 0.008 -0.28 0.09 
Training group  
(0=Low, 1=High) 
1.32 0.002 1.5 <0.001 1.5 <0.001 1.6 0.003 
Treatment*Dose 
 
------ ------- ------ ------- 0.02 0.15 0.05 0.15 
         
 R
2
=0.45 
Adj=0.38 
R
2
=0.53 
Adj=0.46 
R
2
=0.57 
Adj=0.49 
R
2
=0.56 
Adj=0.44 
 
In the three regression models, while training and dose of supplement were 
significant predictors of change in efficiency, iron treatment alone was not (Table 7.4, 
Models 1 and 2, p>0.05). There was a significant interaction between treatment group 
and dose consumed (Table 7.4, Model 3, p=0.15).  The more supplement that was 
consumed in the Iron group, the greater positive change in gross efficiency after 6 
weeks of training and treatment (see Figure 7.1, B).    
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Figure 7.1 A and B.  Relationship between dose of supplement consumed and change 
in gross energetic efficiency in non-anemic rowers.  A: complete sample (n=31, Model 
3); B: subgroup consuming >50% of dose (n=24, Model 4); both A and B adjusted for 
treatment group, baseline efficiency, training, dose 
 
 
A 
B 
Placebo 
Iron 
 
-----
____
___ 
____ 
 
Placebo 
Iron 
 
-----
____
___ 
____ 
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To further assess the relative effect of change in iron status on rowers’ change 
in gross energetic efficiency, multiple linear regression analyses were performed with 
change in gross efficiency as the dependent variable and change in log sFer as the 
independent variable, controlling for potential confounders such as training, baseline 
efficiency and supplement dose consumed.  Results of the multiple regression analyses 
testing the effects of change in log sFer are shown in Table 7.5.   
Table 7.5. Regression models to test the effects of change in log serum ferritin (sFer) 
on change in gross efficiency (%) after 6 weeks of training and treatment in entire 
sample of rowers (n=31) 
 
 Model 4 Model 5 Model 6 
  p  p  p 
Constant 
 
3.15 0.15 6.10 0.013 6.05 0.015 
Change log sFer from baseline  
 
0.47 0.51 0.44 0.50 0.99 0.48 
Dose 
 
------ ------- -0.02 0.02 -0.02 0.03 
Baseline EF 
 
-0.21 0.09 -0.31 0.01 -0.31 0.015 
Training group  
(0=Low, 1=High) 
1.44 0.001 1.55 <0.001 1.57 <0.001 
Change log sFer*dose ------ ------- ------ ------- -0.01 0.66 
       
 R
2
=0.44 
Adj=0.37 
R
2
=0.54  
Adj=0.47 
R
2
=0.55 
Adj=0.45 
 
In the three regression models, while training and dose of supplement were 
significant predictors of change in efficiency, there was no independent effect of 
change in log sFer (Table 7.5, Models 4 and 5 p>0.05). There was no significant 
interaction between change in log sFer and dose consumed (Table 7.5, Model 6, 
p=0.66). 
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Analysis of IDNA subgroup: In order to explain further the plausibility of the 
relationship between iron status and performance, additional analyses were performed 
for change in gross efficiency in a subset of rowers (n=16) with baseline sFer <20.0 
µg/L (IDNA).  Iron status measures for this subgroup are presented in Chapter 6, and 
show that iron supplementation of IDNA rowers improved sFer after controlling for 
baseline sFer. There were no significant correlations between change in efficiency and 
any measures of iron status or change in iron status in this subgroup.  In the subgroup 
of those who were IDNA at baseline, those randomized to the iron group were not 
significantly different from the placebo group in any measure of body composition, 
training, or performance variable at baseline, with the exception that rowers 
randomized to the iron group reported significantly less sleep at baseline compared to 
the placebo group (6.4±0.7 vs 7.3±0.4 hours, p=0.03).  
Results of the IDNA subgroup’s 4K TT before and after 6-weeks of training 
and treatment are shown in Table 7.6.  After 6 weeks of training, IDNA rowers in both 
treatment groups improved VO2peak (+0.2 0.2 l/min, p=0.01) and maximal workload 
(+20.6 30.9 W, p=0.02), however, there were no significant differences between the 
two treatment groups except for a change in efficiency in favor of improvement in the 
iron-supplemented group over the placebo group (p=0.03).  There was a significantly 
positive correlation between change in gross efficiency from baseline to endpoint and 
total supplement consumed (r=+0.65, p=0.007) in the IDNA subgroup.  
 
 
 
 
170 
 
Table 7.6.  Physical performance measures (4K time, Total VO2, % VO2, RER, WR) 
before and after 6 weeks of training and treatment (n=16 rowers IDNA at baseline) 
 
 Pre-treatment Post-treatment Change 
4K time, min    
          Placebo (n=8) 17.9 1.4 17.7 1.7 -0.2 0.7 
          Iron (n=8) 17.9 1.3 18.5 2.3 0.6 1.8 
Absolute VO2 peak, L/min    
          Placebo 3.1 0.5 3.3 0.6 0.2 0.2 
          Iron 3.1 0.3 3.2 0.3 0.1 0.2 
Relative VO2 peak, ml/kg FFM/min    
          Placebo 60.9 4.5 63.2 5.5 2.2 4.3 
          Iron 64.8 7.2 65.0 5.6 0.2 5.2 
Maximal work rate, W    
          Placebo 227.8 60.3 253.1 86.9 25.4 35.0 
          Iron 218.0 21.6 233.9 38.2 15.9 27.7 
Maximal heart rate, bpm    
          Placebo 187.7 9.6 189.5 9.3 1.8 4.2 
          Iron 195.2 6.9 194.5 6.9 -0.8 4.4 
Maximal RER    
          Placebo 1.00 0.04 1.02 0.05 0.02 0.06 
          Iron 1.03 0.07 1.05 0.07 0.02 0.05 
Gross energetic efficiency, %    
          Placebo 17.4 2.5 16.9 2.1 -0.5 1.0* 
          Iron 16.7 1.5 17.5 1.2 0.8 1.1 
No significant differences between treatment groups, except for *p=0.03 t-test 
significantly different between treatment groups. 
 
 
Multiple regression analyses of the rowers with IDNA at baseline are presented 
in Tables 7.7 and 7.8.  Analyses performed with change in gross efficiency as the 
dependent variable and treatment group as the independent variable showed that after 
controlling for training, rowers supplemented with iron had 1.1% greater improvement 
in gross efficiency after 6 weeks of training than did the placebo group (Table 7.7, 
Model 3, p=0.02; w/out training in Model, 1.3% greater than Placebo, p=0.01).  
171 
 
Baseline efficiency was not a significant predictor of change in gross efficiency in this 
subgroup and was left out of subsequent regression models. 
Table 7.7. Regression models to test the effects of iron treatment on change in gross 
efficiency after 6 weeks of training and treatment in subgroup of rowers with Baseline 
sFer<20.0 (n=16) 
 
 Model 1 Model 2 Model 3 
  p  p  p 
Constant 
 
-0.50 0.57 3.03 0.23 -0.72 0.45 
Treatment  
(0=P, 1=I) 
1.30 0.01 1.16 0.02 1.08 0.02 
Baseline EF 
 
------ ------- -0.20 0.16 ------ ------- 
Training group  
(0=Low, 1=High) 
------ ------- ------ ------- 0.87 0.06 
%Variance explained by Fixed effects 
Within School and Season (residual) variance 
 
75% 75% 59% 
Between-School and between-Season variance 
 
72% 27% 74% 
% of total Variance between (due to) schools and season 33% 62% 32% 
 
Further analysis with change in gross efficiency as the dependent variable and 
change in log serum ferritin as an independent variable showed that after controlling 
for training, change in log serum ferritin did not predict change in efficiency in this 
subgroup of rowers when used in place of treatment group (Table 7.8, Model 1, 
ß=1.01, p=0.31).   There were, however, significant interactions between change in log 
serum ferritin and the amount of supplemental iron consumed, and change in log 
serum ferritin and training group (Table 7.8, Models 5 and 6, respectively).   
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Table 7.8. Regression models to test the effects of change in log serum ferritin and the 
amount of supplemental iron consumed on change in gross efficiency after 6 weeks of 
training and treatment in subgroup of rowers with Baseline sFer<20.0 (n=16) 
 
 Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
  p  p  p  p  p  p 
Constant 
 
-0.56 0.47 -0.53 0.48 -0.65 0.43 -1.16 0.04 -1.13 0.05 -0.86 0.334 
Change log sFer 
(µg/L) 
 
1.01 0.31 0.90 0.40 0.57 0.53 1.64 0.08 1.51 0.08 0.62 0.45 
Dose of 
supplemental iron 
(mg) 
------ ------- ------ ------- 0.002 0.06 0.004 0.009 0.004 0.001 0.003 0.015 
Training group  
(0=Low, 1=High) 
1.27 0.03 1.03 0.17 0.56 0.35 0.45 0.41 ------ ------- 0.75 0.20 
Change log sFer * 
dose of 
supplemental iron  
------ ------- ------ ------- ------ ------- -0.006 0.095 -0.006 0.06 ------ ------- 
Training * change 
log sFer 
 
------ ------- 1.39 0.61 ------ ------- ------ ------- ------ ------- -5.15 0.12 
%Variance explained by Fixed effects 
Within School and 
Season (residual) 
variance 
23% 17% 41% 58% 62% 54% 
Between-School 
and between-
Season variance 
36% 47% 52% 100% 100% 30% 
% of total Variance 
between (due to) 
schools and season 
61% 73% 
 
56% 63% 62% 36% 
 
Rowers who improved their sFer status and consumed more than 600 mg of the 
supplemental iron during the 6-week study (n=5 in iron treatment group) increased 
their gross energetic efficiency more than those who consumed less than 600 mg of 
the supplement (n=11, three of those in Iron treatment group; Table 7.8, Model 5, 
p=0.06 for the interaction, Figure 7.2).  Additionally, rowers who improved their sFer 
status and trained harder over the course of the 6-week trial increased their gross 
energetic efficiency more than those who trained less (Table 7.7, Model 6, p=0.12 for 
the interaction, Figure 7.3).   
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.  
 
Figure 7.2.   Relationship between change in dose of supplement consumed and 
change in gross energetic efficiency in non-anemic rowers who were depleted at 
baseline (n=11 in Low consumption group and n=5 in High consumption group).  
Adjusted for change in log sFer, supplemental iron consumed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
High 
 
-----
___
___
_ 
___
_ 
 
Iron consumption group 
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Figure 7.3.   Relationship between change in log sFer and  change in gross energetic 
efficiency in non-anemic rowers who were depleted at baseline (n=10 in Low training 
group and n=6 in High training group).  Adjusted for change in log sFer, 
supplemental iron consumed and training.  
 
Blood lactate: Changes in blood lactate concentration over the course of the 
4K TT are shown in Table 7.9.  There were no significant differences between the 
treatment groups in baseline or endpoint pre-test lactate levels.  At baseline, after 
1000m, lactate increased ~2 - 2.5 fold above pre-test levels during the 4K TT test in 
the iron and placebo groups, respectively, and remained elevated for the duration of 
the 4K test.  After 6 weeks of training, blood lactate concentrations at all time points 
during the endpoint 4K TT were significantly lower compared to baseline in both 
treatment groups (p<0.05).   
Low 
High 
 
-----
___
___
_ 
___
_ 
 
Training group 
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Table 7.9.  Endpoint blood lactate concentration (mmol/dL) during 1K segments of 4K 
TT before and after 6 weeks of training and treatment 
Lactate concentration, mmol/L 
 Pre-test 1000m 2000m 3000m 4000m 5-min post-
test 
10-min post-
test 
Baseline 
Placebo 2.3 1.1 8.0 2.2 9.6 2.9 10.4 3.6 13.5 2.0 11.9 2.6 10.0 3.7 
Iron 2.8 1.5 7.9 2.6 9.7 3.4 11.2 2.4 13.1 1.2 13.1 1.2 11.2 2.0 
Endpoint* 
Placebo 1.9 0.9 5.7 2.0 6.3 2.6 6.7 3.0 11.4 2.1 9.9 2.1 8.3 2.0 
Iron 2.2 1.3 5.0 1.8 5.7 2.3 7.0 2.3 12.2 1.7 9.8 3.0 9.0 2.7 
* Endpoint lactate values during 4K TT (1000m thru 10-min post-test) significantly 
different form baseline (p<0.05) 
 
When blood lactate concentration is expressed as a percent of maximal lactate 
concentration, there was a significant negative correlation between consumption of 
supplemental iron (total mg) and percent of maximal lactate at the 1000m mark (r=-
0.39, p=0.03).  Further examining lactate expressed as a percent of maximal lactate 
achieved, there were significant differences between the two treatment groups.  
Rowers supplemented with iron had a slower rise in blood lactate during the first half 
of the 4K TT (10% lower than the placebo group), and a faster recovery five minutes 
after completing the TT compared to the placebo group (8% lower than the placebo 
group; see Figure 7.4).   
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Figure 7.4.  Lactate concentration as a percent of maximal lactate at Endpoint (%) 
between the two treatment groups (n=31; adjusted for treatment group and baseline 
values).  *p=0.001 between Treatment groups (50.6 5.1 in Placebo vs 40.3 9.6% in 
Iron); **p=0.006 between Treatment groups (55.1 5.4 in Placebo vs 45.4 9.8% in 
Iron); ***p=0.001 (86.9 5.4 in Placebo vs 79.3 6.4% in Iron). 
 
 
In the subgroup of rowers with baseline sFer<20.0 µg/L, as a percent of 
maximal lactate concentration after 6 weeks of training, the Iron-supplemented group 
had 1000 and 2000 m lactate concentrations that were 12.5% and 13.4% lower, 
respectively compared to the placebo group, after controlling for values at baseline 
(1000m: 54.7 9.1 in Placebo vs 42.2 12.8% in Iron, p=0.04; 2000m: 62.3 7.4 in 
Placebo vs 48.9 9.1% in Iron, p=0.006).  
 
 
 
 
* 
Pre-test         1000m   2000m          3000m        4000m  5-min     10-min 
** 
*** 
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Discussion 
The purpose of this experiment was to examine the effects of iron 
supplementation on endurance performance and training in non-anemic female rowers.  
Serum ferritin and Hgb were used to identify those to include in the supplementation 
trial, as done previously (17, 18).  Additionally, we measured sTfR and calculated 
total body iron to differentiate those with low liver iron stores from those with low 
tissue (functional) iron.  After 6 weeks of iron supplementation, rowers were able to 
improve iron status, after controlling for baseline iron status, and the iron status of 
rowers with poorest iron status at baseline benefitted the most from supplementation 
(Chapter 6).   
In our previous cross-sectional analyses, we found that rowers with IDNA at 
the beginning of the training season reported slower 2K personal records for the 
previous season (Chapter 4) and had a lower concurrent VO2peak and reduced 
energetic efficiency compared to rowers with normal iron status (Chapter 5).  In the 
current analyses, time to complete the 4K TT was unaffected by iron supplementation.  
However, the iron-supplemented rowers were able to significantly increase their 
energetic efficiency after controlling for baseline efficiency and supplement dose 
consumed.  Furthermore, analysis of data from the subsample of rowers with baseline 
serum ferritin <20.0 µg/L showed that iron-supplemented rowers clearly increased 
their energetic efficiency by 1.3% after 6 weeks of training compared to the placebo 
group.  
This means that after being supplemented with iron for 6 weeks, non-anemic 
rowers were able to perform the same workload at a lower energy cost (lower level of 
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physical exertion = more energetically efficient).  This finding is consistent with 
similar iron supplementation studies of non-anemic women.  Researchers have found 
that O2 consumption (as % VO2max) during an endurance test was significantly less (-
3%) after iron supplementation and significantly greater (+3%) in placebo (15).  Zhu 
& Haas showed that after 8 weeks of iron supplementation, non-athletic women 
increased their efficiency by decreasing their energy expenditure by 5.1% (p=0.016) 
compared with women in the placebo group, and that this treatment effect on 
%VO2peak was mediated by a change in Hgb (17).   
Hinton et al found that after a 4-week training program imbedded in a 6-week 
iron supplementation trial, although both placebo and iron treatment groups increased 
their work efficiency (through training), there were no significant differences in 
efficiency between the treatment groups, however, the iron group decreased their O2 
consumption by 5% (as a %VO2peak) during the last 5K of 15 K TT. (18).  Another 
study of untrained IDNA Mexican women reported 5.2% greater efficiency during a 
cycle ergometer test after 6 weeks of supplementation with18 mg of iron (54).  Most 
recently, Hinton et al found that after 6 weeks of iron supplementation, post-trial work 
efficiency in recreational athletes’ was significantly increased (+1.1%) compared to 
placebo (+0.7%) (20).  
The 4K TT test protocol was designed to give rowers an incentive to finish 
“the race” as they would on the water, similar to the manner in which they train.  This 
familiar format should have minimized the influence of motivational status on test 
time and level of exertion that is a common problem in time-to-exhaustion protocols.  
However, there was still a subjective component of the TT protocol, as it was up to 
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each rower to control her work rate on the ergometer at all times, so despite WRRx 
given (85% of max), it was up to each rower to maintain that WR using the monitor on 
the ergometer.  However, deviation from WRRx was not significantly different 
between the two treatment groups at baseline or endpoint.  Additionally, the difference 
in energetic efficiency should not have been due to differences in psychological 
factors between the two treatment groups, as motivation scores measured throughout 
the trial were not significantly different between the two treatment groups at baseline 
and endpoint (reported elsewhere, Chapter 8).  
After six weeks of training, all rowers improved their lactate response during 
the 4 K TT, however, the iron supplemented group had much slower rise from pre-test 
lactate (10% lower, as a percentage of maximal lactate) during the first two phases of 
the TT, and a faster recovery five minutes after completing the test compared to the 
placebo group.  Although many researchers have found no effect of iron 
supplementation on lactate concentration during exercise in IDNA women (18, 22, 55-
57), results from the current study are similar to those of Zhu and Haas who found that 
IDNA women supplemented with iron showed a slower rise in lactate concentration 
during the first leg of a 15K TT (5 K mark) on a cycle ergometer, as well as an inverse 
association between lactate concentration at the 5 K and Hgb, even in marginal iron 
deficiency  (17).  Even in the absence of frank anemia (Hgb <12.0 g/dL), impaired O2 
transport capacity due to IDNA appears to affect lactate metabolism, resulting in 
impaired oxidative metabolism, and ultimately increased reliance on anaerobic 
metabolism to produce energy (greater lactate production at an earlier stage of 
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exercise). In a state of IDNA, lactate metabolism may be directly affected, resulting in 
the prevention or slowing of lactate clearance (31, 32).  
Conclusions:  Within the limitations of this study, we conclude that IDNA was 
not found to affect rowers’ time to complete a 4K TT on the rowing ergometer.  
However, after 6 weeks of iron supplementation, rowers’ energetic efficiency during 
the 4K TT was improved compared with the placebo group, after controlling for 
baseline efficiency and treatment dose.  This effect was most evident in the subgroup 
analyses of rowers with IDNA at baseline.  This indicates that IDNA increases rowers’ 
exertion and energy cost to do the same load of work, and that iron supplementation 
enhanced rowers’ adaptation to training.  In addition, rowers supplemented with iron 
showed slower lactate response during the early phase of the 4K TT, and a faster 
recovery post-TT, indicating that iron depletion affects lactate metabolism, in the 
absence of frank anemia.  Both the energetic efficiency and lactate effects observed 
are likely manifestations of the same phenomenon related to energy production during 
exercise.    
These results are important for female endurance athletes whose dietary 
patterns and physical training levels increase their risk of IDNA, and suggest that iron 
supplementation may maximize the benefits of endurance training. Future studies 
should focus on implementation of iron status screening programs for female athletes 
in-training, as well as ways to improve supplement compliance in athletes.  
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CHAPTER 8 
 
IRON SUPPLEMENTATION IMPROVES TRAINING QUALITY IN  
NON-ANEMIC FEMALE ROWERS 
 
Abstract 
Introduction:  Compared to their sedentary counterparts, female athletes are more 
susceptible to iron deficiency without anemia (IDNA).  Studies in both animals and 
humans demonstrate a relationship between IDNA and physical performance, however 
it is unclear how IDNA affects the quality of endurance athletes’ physical training, 
which is integral to athletic performance.    
Purpose:  To examine the relationship between iron status and training quality, as well 
as the effects of iron supplementation on the training quality of non-anemic rowers 
during a competitive season.  
Methods: At the beginning of a season, non-anemic collegiate female rowers were 
randomized to receive either 100 mg/d ferrous sulfate (n=22) or placebo (n=21) for 6 
weeks using a double-blind design.  Subjects trained with their team as usual and 
completed daily logs using the Visual Analog Scale (VAS) format to rate aspects of 
training quality (intensity, concentration, speed, stress). Iron status (hemoglobin, 
serum ferritin, soluble transferrin receptor, total body iron) was assessed at baseline 
and at 6 weeks.  A training quality score was created for each of the six weeks of 
training.  Change in training quality score (week 6 score minus week 1 score) was 
used as the dependent variable in mixed multiple regression analyses to examine the 
impact of iron supplementation on change in training quality.   
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Results: Twenty-four rowers (n=12 iron, 12 placebo) completed all 6 weeks of 
training data.  After controlling for baseline training quality, multiple regression 
analysis revealed that rowers in the iron group had an improved training quality score 
(ß=+77.5, p=0.03) compared to those in the placebo group, however, change in iron 
status (sFer, sTfR, or TBI) did not affect this relationship.  
Conclusion: After controlling for baseline training quality, rowers supplemented with 
iron improved their training quality after 6 weeks of training and treatment compared 
to those in the placebo group.  
 
Keywords:  Iron depletion, athletes, endurance training, rowers, iron 
supplementation 
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Iron supplementation improves training quality in non-anemic female rowers. 
 
Introduction 
Iron deficiency (ID) is the most prevalent nutrient deficiency in the world, 
including the US, where iron deficiency with anemia (IDA) affects 3-5%, and iron 
deficiency without anemia (IDNA) affects ~16% of young women (1).  Compared to 
their sedentary counterparts, female athletes are more susceptible to IDNA (25-35%) 
(2-7). Although the exact mechanism is unknown, the increased prevalence of IDNA 
in active/training females may be due to a combination of factors, including: 
hemolysis (foot strike, impact); increased blood loss (gastrointestinal tract, hematuria, 
sweat); change in iron absorption and/or poor dietary iron intake (8-11). 
The iron status of experimental animals and humans is related to their physical 
training, but the direction of this relationship is unclear (12-18).  Animal studies have 
shown a relationship between ID and physical activity time, frequency, and distance 
moved (14, 19, 20), and iron’s role in the dopaminergic system has been implicated in 
these activity-related behavior changes.  Researchers have also demonstrated 
decrements in iron status with increased physical training in humans (21-23), though 
training in these studies had not been quantified or controlled. It has been 
hypothesized that these declines in iron status with increased training may be related 
to decreased iron absorption due to inflammation (24, 25), and/or poor dietary intake 
during training (22, 23).  Additionally, we have previously shown that IDNA non-
athletic women adapt less to aerobic training (26), and have lower levels of physical 
activity (27), but evidence in athletes is lacking.   
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The high prevalence of IDNA among female athletes and the strong 
association between athletes’ iron status and physical performance led us to conduct 
the current study in which we aimed to provide evidence about a causal relationship 
between iron status and training in female athletes at the beginning of their 
competitive season’s training program.  The objective of this study was to examine the 
effects of iron supplementation on female collegiate rowers’ endurance training.  We 
hypothesized that iron-supplemented rowers would benefit from improved iron status, 
and that supplementation would prevent or reduce the negative effects of training on 
iron status, allowing for improved training quality.   
Methods  
Design:  This study was a randomized, double-blind, placebo-controlled iron 
supplementation trial. Each subject was randomly assigned to a treatment group by a 
research assistant who was not involved in data collection or contact with subjects.  
Randomization was done by assigning each subject a random number, with even and 
odd numbers being assigned to either treatment group.  After initial randomization, 
any imbalance in the distribution of treatment or representation of school or baseline 
iron status (sFer) was corrected by re-randomization. Rowers were randomly assigned 
to one of two groups: iron supplementation with 50 mg FeSO4 twice per day or 
placebo in the form of identical red capsules. Subjects were provided with 18 capsules 
each week, and were instructed to consume two capsules per day (four extra capsules 
were provided). Subjects were instructed to consume one capsule each at their 
morning and evening meals to minimize potential gastrointestinal side-effects, and 
with a glass of citrus juice to enhance iron absorption.  Subjects were also instructed to 
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avoid consumption of any other multivitamin/mineral supplements during the 6 week 
study period. 
Compliance with the iron treatment, as well as current health, menstrual status, 
and physical activity was assessed by daily training logs. Subjects were instructed to 
record the number of capsules they consumed daily in their log, even if they had 
consumed less than the prescribed amount per day.  Additionally, weekly capsule 
counts were conducted by the researcher.  
Both iron and placebo capsules were prepared by a Registered Pharmacist 
(PharmD) at the Cornell University College of Veterinary Medicine Pharmacy (Ithaca, 
NY).  The iron supplement capsules contained 50 mg FeSO4 per capsule with lactose 
filler, and the placebo capsules contained only lactose.  The iron content of both 
placebo and iron capsules was analyzed via ICP mass spectrometry digestion by the 
USDA’s Robert Holley Center for Agriculture and Health (Ithaca, NY).  Twenty 
capsules were randomly selected for analysis from each of two batches.  No 
differences in the average iron content were found between the two batches of iron-
containing capsules (15.8 ± 0.5 mg elemental iron per capsule), and no iron was 
detected in the placebo capsules.  
For all subjects, body composition and physical performance were measured 
immediately before and after the 6 week treatment period.  Thirty-one rowers finished 
the entire study protocol (all blood analyses and exercise testing) (see Figure 8.1).  Six 
subjects from the iron group and three from the placebo group dropped out of the 
study due to personal reasons (n=4), injury (n=3) or illness (n=2), all unrelated to the 
study.  Rowers who did not complete the study reported getting more and better 
191 
 
quality sleep at baseline (p=0.01 and 0.04, respectively), as well as feeling better in 
general (p=0.03) than rowers who did complete the study. Compared to the 31 rowers 
who completed the study, the 9 rowers who did not complete the study had slower 
times to complete a simulated 4K time trial on a rowing ergometer at baseline 
(19.4±2.6 min vs 17.7±1.2 min, p=0.008). There were no other significant differences 
in baseline iron status, body composition, training, or performance measures between 
those who completed the study and those who did not complete the study. 
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Figure 8.1.  Timeline and flow of subjects through randomized, placebo-controlled 
iron supplementation trial 
Screening of Iron status 
n= 165 female collegiate rowers 
(10% Anemic, 30% IDNA) 
 
Baseline data collection: 
n=56 
n=48 non-anemic 
 
Randomization to treatment groups 
 
n=40 non-anemics 
 
(n=23 w/sFer<20 µg/L) 
 
100 mg/d FeSO4 
n=21 
(n=12 sFer <20.0 µg/L) 
 
Placebo 
n=19 
(n=11 sFer<20.0 µg/L) 
 
Lost to follow-up: 
(n=6) 
Sick (n=2) 
Injured (n=2) 
Unknown reasons (n=2) 
 
4 of 6 drop outs w/sFer <20.0 
µg/L) 
Analyzed 
n=12 completed placebo group  
(n=6 sFer<20.0 µg/L) 
 
Lost to follow-up: 
(n=3) 
Quit team (n=1) 
Injured (n=1) 
Unknown reasons (n=1) 
 
2 of 3 drop-outs had sFer<20.0 µg/L) 
Analyzed 
n=12 completed Iron group 
(n=5 sFer <20.0 µg/L) 
 
Week 0-1 of training: 
Beginning of  training 
season 
 
Week 1 of training: 
Baseline data 
collection (body 
composition, 
performance testing, 
training) 
 
n=24 completed entire 6-week protocol and all baseline and endpoint 
testing 
 
(n=11 sFer<20.0 µg/L, 13 sFer>20.0 µg/L) 
 
Excluded: 
 
Anemic subjects (n=8) 
 
Declined further participation 
(n=8) 
Excluded: 
 
Declined further participation 
(n=109) 
Weeks 1-6: 
Training 
 
 
Week 3: 
Iron status 
assessment 
 
 
Week 6: 
Iron status 
assessment 
 
Performance, 
body 
composition 
testing 
Randomization 
to treatment 
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Assessment of iron status:  Iron status variables measured from non-fasting 
venous blood samples (antecubital venipuncture, into two evacuated tubes, EDTA and 
serum-separator) included hemoglobin (Hgb), hematocrit (Hct), red blood cell count 
(RBC, Beckman Coulter, Fullerton, CA); serum ferritin (sFer, Immulite 2000, 
Siemens Healthcare Diagnostics, Deerfield, IL);  soluble transferrin receptor (sTfR, 
Ramco Laboratories, Stafford, TX); alpha-1-acid glycoprotein (AGP, radial 
immunodiffusion plate, Kent Labs, Bellingham, WA).  Total body iron (TBI, mg/kg) 
was calculated using the ratio of sTfR to sFer as described by Cook et al (28).  Every 
effort was made to obtain baseline, midpoint, and endpoint samples at the same time 
of day to control for diurnal variation in any measurement of iron status.  Hgb and 
sFer status were analyzed immediately after blood sampling. To control for potential 
variation in the non-automated sTfR assay conditions, both baseline and endpoint 
serum samples for the same subject were analyzed at the same time after the 
supplementation trial was completed. Rowers were classified as either iron depleted 
(sFer<20.0 µg/L), normal (sFer>20.0 µg/L), or anemic (Hgb<12.0 g/dL).  All anemics 
were notified of their status immediately after blood test results (within one week of 
analysis), referred to their respective campus health services for further instruction 
and/or monitoring, and excluded from further participation in the study.  All 
laboratory assays were done in the Human Metabolic Research Unit at Cornell 
University (Ithaca, NY).  
Body Composition: Anthropometric and body composition measurements were 
determined at the site of exercise testing.  Body weight and height were measured with 
standard procedures and equipment (29).  For athletes for whom it was accessible, 
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body fat and fat-free mass was assessed via air-displacement plethysmography 
(BodPod, Life Measurement, Inc, Concord. CA).  For all subjects, percent body fat 
was calculated from tricep, suprailiac and thigh skinfold thickness (SF, Lange, 
Cambridge, MD) (30) and bioelectrical impedance analysis (BIA, RJL Systems, BIA-
101) (31).  The Siri equation (32) was used to calculate percent fat from body density. 
For those athletes without access to the BodPod (n=10), an average of their percent 
body fat values calculated from BIA and SF was used.  In a larger sample of subjects 
with both BodPod and BIA-SF average (n=31), the two methods were highly 
correlated (r=0.83, p<0.001), and not significantly different from each other (p=0.40).  
The mean difference between percent body fat calculated from BodPod and the BIA-
SF average was -0.48 3.15% (95% confidence interval of difference: -1.64, +0.67).  
There were no significant differences in either body fat measurement method across 
schools.   
Assessment of physical performance: Physical fitness and endurance 
performance was assessed using a rowing ergometer (Concept2, Morrisville, VT) 
equipped with a digital readout monitor (PM2), displaying work (watts, W), stroke 
rating (spm), distance (m), and time (min:sec).  A computerized metabolic cart 
(TrueMax 2400, ParvoMedics, Salt Lake City, Utah) was used to measure VO2 and 
other physiological measures during all testing. Heart rate (HR, Polar FS2, Polar 
Electro, Inc, Lake Success, NY) was also continuously monitored throughout testing.  
Cadence (strokes per minute, spm) and work rate (WR, (W) resistance) were 
monitored and recorded every 30 seconds.  Endurance capacity was assessed at both 
baseline and endpoint by time to complete a 4K TT, consisting of a 4K ergometer row 
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at a sub-maximal WR prescription (WRRx) of 85% of rowers’ VO2peak reached in the 
pre-test. This WR was maintained for 3600m of the test, and the rowers were then 
asked to sprint the final 400m of the test to simulate on-water racing (Appendix 12).  
The 4K TT was performed at baseline and endpoint at the same WR Rx.  Detailed 
methods and analysis of laboratory assessments of physical performance (gross 
energetic efficiency, VO2peak, 4K TT time) have been reported elsewhere (Chapter 
7).   
Assessment of Training Quality: Information on compliance with capsule 
consumption, current health and menstrual status, usual leisure-time physical activity, 
and rowing training regimen was quantified each day for 6 weeks via detailed training 
and activity diaries (Appendix 11).  Twenty-four rowers (n=12 iron, 12 placebo) had 
complete training log data at baseline and after 6 weeks of training and treatment.  
Questions in the daily log addressed sleep and nap duration and quality, motivation, 
concentration, soreness and fatigue, and training/physical activity frequency, intensity, 
time, and type.  Eleven questions were presented in the format of a Visual Analog 
Scale (VAS).  Subjects were asked to rate each question by placing a solid vertical line 
on a 100mm scale anchored by opposing descriptors (see Figure 8.2).  All VAS 
questions were “scored” by measuring the rating with a ruler (mm).   
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Daily Log Instructions 
This training log should be completed on a daily basis for the next 7 days.  Initial use 
of this log may take up to 5 minutes/day. For some questions, please rate each factor, 
as you feel today by placing a solid vertical line on the scale. 
 
 
Example:  Happy:  How happy do you feel right now? 
 
Not at all happy                                                                                                  Extremely happy 
 
Figure 8.2.  Visual Analog Scale (VAS) instructions and format of training log 
 
 
 
Data Analysis: All data were analyzed using SPSS Statistics version 18.0 
(Chicago, IL).  Data were examined to verify normality of distribution, and skewed 
distributions were log-transformed.  Results are reported as means  SDs.  All initial 
analyses were performed on an “as-treated” basis to examine the effect of iron 
supplementation on both iron status and training outcomes.  Independent Student’s T-
test and ANOVA was used to examine treatment group differences at baseline; 
characteristics differing between treatment groups (p<0.05) were considered potential 
confounders and were included as covariates in subsequent regression models.   
Exploratory principal component analyses (SPSS, Principal Components, 
Varimax Rotation) was conducted on all training log variables measured weeks one 
through six to reduce the number of independent variables and improve the strength of 
the underlying constructs related to quality of endurance training.   Data from those 
variables that loaded together (see Table 8.1, Quality/Intensity Factor, eigenvalue 4.8; 
6 items) were then summed, to create a Training Quality score for each of the 6 weeks.  
The same two factors and similar loadings were observed when analyses were 
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performed on training data from each individual week.  The Soreness/Fatigue factor 
was not used in any of the present analyses.   
 
Table 8.1.  Rotated factor loadings of training variables for all training measures 
weeks 1 through 6 (average of all ratings from baseline through endpoint)  
 Quality/ Intensity Factor Soreness/Fatigue Factor 
Intensity 0.95 ------------ 
Motivation 0.82 ------------ 
Discomfort 0.77 ------------ 
Concentration 0.91 ------------ 
Speed 0.95 ------------ 
Stress 0.93 ------------ 
Soreness ------------ 0.84 
Fatigue ------------ 0.85 
Percent of variance explained 87.4 12.6 
 
Repeated-measured ANOVA was then performed on the Training Quality 
scores to test group and time effects, as well as group-by-time interaction effects for 
iron status outcomes (baseline, week 3, and endpoint, unless otherwise noted).  
Repeated measures models of training quality included weeks 1-6 (baseline through 
endpoint).   Pearson’s correlations were used to examine the relation between change 
in iron status and change in training quality.   
Mixed linear regression analysis, including both random and fixed effects, was 
used to assess the effects of iron supplementation on change in training quality.  
School was treated as a random effect to control for unmeasured potentially 
confounding factors related to school differences in iron status.  A statistical 
significance level of p<0.05 was the level of statistical significance for main effects, 
and p<0.20 for testing interaction effects.   
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Results 
Subject characteristics: The placebo and supplemented groups were of similar 
age (19.9 1.2 and 19.8 0.8 years, respectively) and height (171.7 7.3 and 170.2 5.3 
cm, respectively), and had similar years of rowing experience (3.6 2.4 and 2.4 1.1 
years, respectively).  Body weight and composition did not differ between the two 
groups before or after the study (Table 8.2).  Rowers in both groups significantly 
increased their FFM by 1.0 1.2 kg and decreased their percent body fat by 1.1 1.6 % 
after 6 weeks of training (p<0.001).     
Table 8.2. Anthropometry and body composition of rowers before and after 6 weeks of 
training and treatment (those with training quality data at baseline and endpoint) 
 Pre-treatment Post-treatment Change 
Weight (kg)    
          Placebo (n=12) 69.7 8.9 69.6 8.6 0.2 1.3 
          Iron (n=12) 67.1 6.1 67.6 6.5 0.5 1.6 
Body fat (%)    
          Placebo 25.2 4.1 23.8 3.8 -1.4 1.8 
          Iron 23.7 3.9 22.9 3.9 -0.8 1.3 
Fat-free mass (kg)    
          Placebo 51.8 4.7 53.0 5.0 1.2 1.2 
          Iron 51.2 4.5 52.0 4.9 0.9 1.4 
NS differences between Tx groups 
 
Compliance: There were no significant group differences in the number of 
recorded training days (54 9 and 50 17 d in Placebo and Iron groups, respectively) 
during the study period.  The amount of supplement consumed, however, was 25% 
greater (not significantly) in the placebo group (Table 8.3).  There were no differences 
between the two groups in treatment-associated symptoms (no adverse events or 
symptoms related to the supplementation were reported).  
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Table 8.3.  Compliance as measured by training log days recorded, weekly pill count 
 Placebo 
(n=12) 
Iron  
(n=12) 
Capsules consumed, n 84 19 72 29 
Total FeSO4 consumed, mg 0 3629 1462 
Percent of total Rx consumed, % 78.6 16.7 68.3 25.5 
NS differences between Tx groups 
 
 
Response to iron treatment and relation of iron status to physical 
performance:  Results of the blood analyses have been reported elsewhere (Chapter 
6).  Multiple regression analyses revealed improvements in body iron stores (log sFer, 
total body iron) in the iron treatment group after controlling for baseline iron status, 
and those with most depleted stores at baseline showed the greatest improvement in 
iron status. Data described elsewhere revealed a significant interaction in the subgroup 
of rowers with IDNA at baseline between change in iron status and the amount of 
supplemental iron consumed on change in gross energetic efficiency (Chapter 7).   
Training quality: Individual characteristics of training quality at weeks one and 
six (baseline and endpoint) are presented in Table 8.4.  After six weeks of training, 
there was no significant difference between the placebo and iron-supplemented groups 
in daily training time (64.7 40.3 and 76.9 58.7 min/d, respectively) or session RPE, 
although the iron-supplemented group reported higher training intensity on average 
compared to the placebo group (61.0 16.8 versus 50.1 15.1, p=0.08).   
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Table 8.4.  Training quality characteristics before and after 6 weeks of training and 
treatment  
 Pre-treatment (n=24) Post-treatment (n=24) Change 
Sleep, hours    
          Placebo (n=12) 7.4 1.1  7.3 1.1  -0.1 0.7 
          Iron (n=12) 6.8 0.9  7.0 1.5  0.2 1.6 
Motivation    
          Placebo 52.5 17.4 54.0 13.0 1.5 14.0 
          Iron 57.8 13.8 56.6 20.4 -1.1 26.7 
Soreness    
          Placebo 44.7 12.8 30.5 19.1 -14.2 18.1  
          Iron 42.2 17.4 27.4 18.2 -14.8 15.4 
Fatigue    
          Placebo 45.1 17.2 41.7 12.8 -3.4 19.4 
          Iron 40.9 13.8 42.6 23.9 1.7 21.5 
Nap, minutes    
          Placebo 53.0 29.7 76.8 33.5 20.1 30.2 
          Iron 41.8 20.8 60.8 51.8 15.6 34.2 
Intensity    
          Placebo 50.8 20.9 46.3 14.4
#
 -4.6 21.6 
          Iron 51.8 15.1 59.6 15.5 7.7 16.2 
Training time/day, minutes    
          Placebo 62.3 27.1 53.8 28.0 -8.5 25.4 
          Iron 63.6 19.1 78.8 63.6 15.1 65.3 
SessionRPE    
          Placebo 4138.5 2126.3 3431.5 1769.5 -707.0 1761.7 
          Iron 4191.4 1814.0 5432.9 4207.2 1241.4 4172.3 
Concentration    
          Placebo 54.1 21.1 51.2 17.2* -3.0 19.5 
          Iron 60.4 18.9 70.9 18.9 +10.5 21.5 
Speed    
          Placebo 45.2 17.3 40.9 15.3** -4.4 19.7 
          Iron 48.1 19.2 59.4 16.4 +11.3 19.6 
Stress    
          Placebo 42.0 17.5 38.8 16.3*** -3.2 20.4 
          Iron 44.5 14.0 56.8 20.5 12.3 16.6*** 
Training Quality Score    
          Placebo 283.5 101.1 271.7 81.6 -11.7 101.5 
          Iron 303.8 80.6 355.5 95.6^ +51.8 105.5^^ 
ANOVA between Treatment groups:  
#
p=0.04; *p=0.014, **p=0.009, ***p=0.05; 
^p=0.03, ^^p=0.15 Group*Time 
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Rowers supplemented with iron increased their training intensity (+7.7 16.2 
versus -4.6 21.6 in the placebo group, p=0.13) and minutes of training per day 
(+15.1 65.3 versus -8.5 25.4 minutes in the placebo group, p=0.26) from baseline to 
endpoint, though not significantly different compared to the placebo group (p=0.13 
and 0.26, respectively). There were significant endpoint differences in measures of 
training between the two groups.  After 6 weeks of training, the iron-supplemented 
group reported higher concentration during training (p=0.03), as well as greater speed 
(p=0.02) compared to the placebo group.  When attributes of training quality were 
summed into the training quality score, iron-supplemented rowers increased their 
training quality score from baseline compared to those in the placebo group (*p=0.15 
for the group-by-time interaction, Figure 8.3).   
 
 
 
 Figure 8.3.  Estimated marginal means (EMMs) ± SE of Training Quality Score (sum 
of Intensity, motivation, concentration, discomfort, speed, stress) during the 6-week 
RCT   
 
* 
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Iron status and training quality: There was a significant correlation between 
change in Hgb from midpoint to endpoint and change in total training minutes per day 
(r=+0.82, p<0.001).   There was a significant negative correlation between change in 
sTfR and change in fatigue rating from baseline to endpoint (r=-0.45, p=0.03).  There 
were no significant correlations between change in log Fer or TBI and change in any 
other training variables examined, nor was there a significant correlation between 
change in iron status and change in training quality score. 
Training and performance: There were no significant correlations between 
change in training quality score (endpoint minus baseline) and change in gross 
energetic efficiency (r=0.16, p=0.46), change in 4K TT time (r=0.06, p=0.79), or 
change in VO2peak (r=0.11, p=0.60).  Change in motivation and soreness were 
moderately correlated with change in 4K TT time (r=0.35, p=0.09 and r=-0.36, 
p=0.09, respectively). Change in stress rating was moderately correlated (r=-0.35, 
p=0.09), and change in intensity rating was significantly related to change in energy 
expenditure during the 4K TT (r=-0.42, p=0.04).   
Additional mixed effects regression analyses of the entire sample reveal that 
after controlling for change in iron status (log sFer) and baseline performance, change 
in training quality is a moderate predictor of change in gross energetic efficiency 
(β=0.003, p=0.19, data shown in Chapter 9).  The interaction between change in iron 
status and change in training quality was not significant in the regression model. 
Analyses of the subgroup with IDNA at baseline show that after controlling for change 
in iron status (log sFer) and baseline performance, change in training quality is a 
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significant predictor of change in gross energetic efficiency (β=0.009, p=0.006, Figure 
8.4).   
 
Figure 8.4: Relationship between change in  training quality score and change in 
gross energetic efficiency in IDNA rowers randomized to placebo and iron treatment.  
Adjusted for change in log sFer and baseline performance. 
 
 
Change in training quality with iron treatment: To further assess the relative 
effect of iron supplementation on change in training, multiple linear regression 
analyses were performed with change in training quality score as the dependent 
variable and indicators of iron status as independent variables, controlling for potential 
Placebo 
Iron 
 
-----
____
___ 
____ 
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confounders such as baseline training and supplement dose consumed.  Results of the 
multiple regression analyses are shown in Table 8.5.  
Table 8.5.  Regression models to test the effects of iron supplementation on change in 
training quality/intensity (week 6 minus week1) after 6 weeks of training and 
treatment 
 Model 1 Model 2 Model 3 
  P  P  P 
Constant 
 
174.2 0.009 211.05 0.007 171.2 0.04 
Treatment  
(0=P, 1=I) 
77.5 0.03 ------------ ------------ 85.6 0.52 
Baseline 
training 
quality/intensity 
 
-0.67 0.002 -0.65 0.009 -0.66 0.02 
Baseline 
training 
quality/intensity 
* Treatment 
------------ ------------ ------------ ------------ -0.03 0.95 
Change log 
sFer from 
baseline  
------------ ------------ -38.1 0.66 ------------ ------------ 
Baseline 
training 
quality/intensity 
* change log 
sFer 
------------ ------------ ------------ ------------ ------------ ------------ 
%Variance 
explained by 
Fixed effects 
   
Within School 
and Season 
(residual) 
variance  
93.8% 91.9% 93.5% 
Between-
School and 
between-Season 
variance  
55.1% 69.3% 49.9% 
% of total 
Variance 
between (due 
to) schools and 
season  
37.0% 43.0% 34.8% 
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Rowers supplemented with iron significantly increased their training intensity 
from baseline to the end of the study compared to those treated with placebo (Figure 
8.5).  Dose consumed (β=-0.66, p=0.45), baseline log sFer (β=12.6, p=0.85) and 
change in iron status, as well as change in either sTfR or TBI, were not significant 
predictors of change in training, nor were there any significant interactions between 
iron status and training.   
 
Figure 8.5: Relationship between baseline training quality score and change in 
training quality score in non-anemic rowers randomized to placebo and iron 
treatment.  Adjusted for treatment group and baseline training quality score (Table 
8.5, Model 1). 
Mean training 
quality score  
at baseline 
Placebo 
Iron 
 
-----
____
___ 
____ 
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Discussion 
The purpose of this analysis was to examine the effects of iron 
supplementation on the training quality in non-anemic female rowers.  Serum ferritin 
and Hgb were used to identify those to include in the randomized, double-blind, 
placebo-controlled iron supplementation trial, as has been done previously (26, 33).  
Additionally, we measured sTfR and calculated total body iron to differentiate those 
with low total iron stores from those with low tissue (functional) iron.  
In previous cross-sectional analyses, we found that compared to rowers with 
normal iron status, depleted rowers trained ~10 minutes less per day at the beginning 
of a training season (p=0.02, Chapter 5). We have previously reported (Chapter 6) 
that after controlling for baseline iron status, iron supplementation improved iron 
stores (sFer, TBI).  We also found that after controlling for baseline performance, iron 
supplementation improved endurance performance as measured by gross energetic 
efficiency (Chapter 7).   
The relationship between iron status, training, and performance led us to 
conduct the current analysis, the major finding of which was that six weeks of iron 
supplementation improved rowers’ training quality, as assessed by daily self-report.  
These findings are important to female athletes because training quality ultimately 
affects performance.  Improvements in all performance and body composition 
measures indicate that the 6-week training regimens employed by the various rowing 
teams were successful to induce physiological adaptation.  Iron supplementation 
enhanced this adaptive response to training, as evidenced by greater training quality 
scores after controlling for baseline training quality.   
207 
 
Training itself has been implicated in changes in the iron stores of endurance 
athletes (21, 22, 34-36).  At the beginning of any type of training program, there is a 
transient decrease in Hgb and other RBC indices, termed “sports anemia”.  This is a 
temporary condition in which Hgb and RBC indices are diluted due to the rapid 
increase in plasma volume induced by training (hemodilution) (35, 37-39).  As a 
result, iron is mobilized to tissues to support the demand for RBC production and 
synthesis of Hgb over iron storage.  This condition resolves as the rower adapts to her 
training regimen during the first few weeks of the training season.  In a very small 
study of elite cross-country skiers (n=2 male and 1 female), training was quantified 
daily during a 33 week training season (40).  Serum ferritin was decreased resulting 
from either decreased iron stores, or from temporary effects of training adaptation, and 
MCV increased, reflecting an enhanced number of young RBCs with training.  The 
authors concluded that the large, rapid changes in sFer were likely not a reflection of 
total body iron stores, and proposed hemolysis and increased basal losses as an 
explanation, due to the fact that iron stores were not depleted enough to restrict 
erythropoiesis.   However, this may be due to the effect of training on the iron 
regulatory protein, hepcidin. 
Hepcidin has been recently identified as instrumental in iron metabolism (41, 
42), and a recent report has reviewed several studies examining the acute increase in 
hepcidin with intense training (mainly running) (25), and consequent decrease in iron 
status in active individuals.  Female soldiers reported no effect of basic combat 
training (BCT) on hepcidin activity, although hepcidin concentrations were associated 
with iron status and inflammation before and after BCT (43).  Liu et al found that after 
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5 weeks of training, rats had lower levels of iron and ferritin, as well as lower 
expression of DMT1, HCP1, and FPN1 compared to those who had not been trained.  
They also found that mRNA expressions of hepatic hepcidin and hemojuvelin in 
skeletal muscle were higher than rats in the control group (44).  This animal model 
shows how the inflammation of training affects iron metabolism via hepcidin’s 
inhibition of iron absorption.  Hepcidin was not measured in the current study of 
female rowers, but remains an important area of future research.  
To the best of our knowledge, this is the first report of the effect of iron 
supplementation on training quality.  Studies of military soldiers have reported 
decrements in iron status with basic combat training, but training outcomes were not 
reported (23, 45).  McClung et al did examine aspects of soldiers’ mood and found 
iron supplementation doubled soldiers’ vigor scores (indicator of cognitive status) 
compared to the placebo group, but there were no differences between treatment 
groups in any other subscale of the Profile of Mood States (POMS) (23).  In a 
longitudinal study of female runners, Banister and Hamilton showed that iron status 
varied with fatigue and training load over the course of 300 days (46).  Researchers 
suggest that iron’s role in the dopaminergic system may be responsible for effects of 
iron supplementation on ratings of fatigue, training stress and intensity, as well as 
those related to cognitive performance, such as motivation and concentration (9, 47).   
The training quality score combined several individual aspects of training 
quality into a single score and appears to perform well as a proxy for training 
intensity.  We did validate the subjective ratings against heart rate during rowing 
training in a separate sample of rowers (see Appendix 1).  However, more objective 
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methods to assess and quantify training, such as measured heart rate and 
accelerometry, may be more sensitive to changes in iron status and the effects of iron 
supplementation, and future studies examining the effects of iron on endurance 
training should employ these methods to quantify training intensity, frequency, and 
duration during the training season.   
At the beginning of the study, there were no differences between schools in 
training time or intensity ratings, and the training quality score based on PCA did not 
differ between the five schools.  Furthermore, variation in training and performance 
between schools was accounted for by using a mixed multiple regression model.  It is 
possible, however, that not all of the variance between schools was accounted for 
using this statistical method.  Randomization of rowers to treatment groups was 
balanced by school, baseline sFer status, and fitness level to minimize (equalize) the 
effects of group differences between treatment groups.  In addition to our small 
sample size and poor treatment compliance, the success of the training regimen, 
regardless of iron treatment, led to such significant improvements in fitness that the 
effect of heavy training may have reduced our ability to detect an effect of iron 
supplementation or improved iron status on training quality.  In previous cross-
sectional analyses, we found that iron status differentially affected early-season 
physical performance according to training level (“low” vs “high,” Chapter 5).  In the 
current study, we saw no such interaction between baseline training quality and 
change in iron status.  This may be partly explained by the fact that the margin for 
improvement with supplementation or improvement in iron status would have been 
much less in those who trained the hardest (“ceiling effect”).   
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Conclusions: Within the limitations of the present study, we conclude that six 
weeks of daily low-dose iron supplementation results in improved training quality in 
female collegiate rowers during a training season. Female athletes should be screened 
for iron status at the beginning of a training season.  After identification, anemic and 
IDNA athletes should be provided with supplemental iron, and their iron status should 
be monitored throughout the training season.  Additionally, coaches should take an 
active role in monitoring training quality over the season, and recommend health 
status screening as needed.   
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CHAPTER 9 
 
GENERAL DISCUSSION 
 
This final chapter has five sections.  The first summarizes results from the 
cross-sectional and randomized controlled trial (RCT) studies.  The second examines 
the internal and external validity of these two studies.  The third discusses the 
biological implications of the major findings from the two studies.  The fourth 
discusses recommendations to athletes, coaches, and collegiate athletic programs.  The 
final section discusses the direction of future research.   
 
Summary of results of Cross-sectional studies and RCT 
 Results from this study are consistent with previous reports, and add to the 
evidence that iron status is an important issue facing female endurance athletes.  In our 
cross-sectional study, we have shown that IDNA is prevalent among female collegiate 
rowers, and that rowers with IDNA reported slower 2K PRs from the previous season.  
We have also shown that iron status affected rowers’ VO2peak differentially, 
according to training status at the beginning of a season.  After adjusting for important 
covariates, rowers with depleted iron stores had a lower VO2peak, slower 4K time trial 
(TT) time, and tended to be less efficient during the 4K TT.  Performance of rowers 
who trained less hard at the beginning of a season was more adversely affected by 
IDNA.  There was no effect of poor iron status on performance in the group of rowers 
who reported training more at the beginning of a season.  
216 
 
In our RCT, we have also shown that rowers who consumed ~15 mg elemental 
iron per day improved their iron stores (sFer) during training (after controlling for 
baseline sFer), and that those rowers with the lowest iron stores at baseline benefitted 
the most from iron supplementation.  These findings add to the growing body of 
evidence that iron supplementation improves the iron status of active women, which 
may ultimately impact training and physical performance. Furthermore, our RCT has 
shown that IDNA in female collegiate rowers affects physical performance as 
measured by gross energetic efficiency. This indicates that compared to rowers with 
normal iron status, IDNA increases rowers’ exertion and energy cost to do the same 
load of work, and that iron supplementation enhanced rowers’ adaptation to training.  
In addition, rowers supplemented with iron showed lower lactate response during the 
early phase of the 4K TT, indicating that lactate metabolism is affected in the absence 
of frank anemia. Rowers supplemented with iron also showed a greater increase in 
training quality (from baseline to 6 weeks) compared to the placebo group.  By the end 
of 6 weeks, rowers supplemented with iron reported greater increases in training 
intensity, as well as ratings of concentration and motivation during training compared 
to the placebo group. 
In both studies, lactate response was augmented by normal iron status (cross-
sectional study) and by iron supplementation (RCT).  Time to complete the 4K TT 
was unaffected by IDNA status in the cross-sectional study, and by iron 
supplementation in the RCT.  A discrepancy between the two studies was the effect of 
IDNA on VO2peak, which was found to be lower in IDNA rowers who reported 
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training less in the cross-sectional study, yet was unaffected by iron supplementation 
in the RCT.   
 
Critique of validity of the cross-sectional study and RCT   
The main objective of these two studies was to investigate how IDNA impairs 
endurance performance and training in female rowers, and whether iron 
supplementation can improve iron status, performance and training in this population.  
To establish this causal relationship between IDNA and performance, three conditions 
must be met:   
1. There must be an association between iron status and performance. 
2. There must be a temporal sequence between change in iron status and change 
in performance. 
3. Potential confounders must be controlled. 
 
In this section, we will examine the following to evaluate the validity of the cross-
sectional study and supplementation trial in establishing the relationship between iron 
status and physical performance:  internal validity, biological plausibility, and external 
validity (1). 
Internal validity: cross-sectional study: In the cross-sectional study (Chapters 4 
and 5), we examined the effect of IDNA on performance by comparing performance 
outcomes (2K PR time, VO2peak, energetic efficiency, 4K TT time) between IDNA 
and normal rowers.  IDNA rowers reported slower 2K PRs, and those who trained less 
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at the beginning of a season had lower VO2peaks and lower work efficiency compared 
to IDNA rowers who trained harder.   
 The cross-sectional study design related performance outcomes to low body 
iron stores (sFer), but could not allow for establishment of a causal relationship 
between IDNA and poor performance.  A cross-sectional design cannot provide strong 
evidence about temporal sequence, and not all potential confounders can be excluded.  
Since this is not an RCT, confounders may not be evenly distributed between the two 
groups, causing potentially unmeasured bias.  Although we tried to control for factors 
such as height, FFM, and training, we were not able to control for all possible 
potential confounders between normal and depleted rowers.  Any unmeasured 
confounding factors may mask iron’s effects on performance by influencing the 
sensitivity or reliability of our outcome measurements.    
This cross-sectional study enabled us to investigate the plausibility of 
relationships between iron status, training and performance.  This plausibility analysis 
is useful when there are putative mechanisms to explain how iron status affects 
physical performance.  These analyses suggest relationships, but do not provide causal 
evidence, as temporal relationships between iron status and performance cannot be 
determined with the cross-sectional study design.  In our heterogenous sample of 
rowers, we attempted to control for the differences between schools (training 
regimens, level of competition, rowing experience) using a mixed-effects regression 
analysis, which included “school” as a random effect, but this only captures some of 
the unmeasured confounding. 
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 Being related to both iron status and performance, training was examined as a 
potential confounder, and indeed the IDNA rowers reported training ~10 min less per 
day, compared to the rowers with normal iron status. To control for the effect of 
training in the cross-sectional study, training was assessed quantitatively via daily 
training logs and quantified using the sessionRPE method, and was then controlled for 
as a covariate in the testing of group differences and in testing for a linear effect of 
sFer. We examined the rowers in terms of training load at the beginning of a season 
and divided them into “low” trainers and “high” trainers, based on a sessionRPE cut-
off of the 50
th
 percentile (3200).   
 When designing our study, we hypothesized that training would be a mediator 
in the relationship between iron status and performance.  ID may decrease training, 
which would then impair performance.  In this scenario, controlling for training as a 
covariate in the analysis of iron status group differences in physical performance 
would inappropriately over-control for training, and possibly mask the effect of IDNA.  
In our cross-sectional analysis, training was found to be a modifier of the relationship 
between iron status and performance, such that the performance of rowers who trained 
less was more adversely affected by IDNA compared to rowers who trained more.  
Because our cross-sectional study was conducted at the beginning of a training 
season, our “training” measure may be a proxy for another variable related to, but not 
a substitute for training itself.  Examples include motivation, experience, and time 
and/or accessibility to train off-season.  It is likely that those rowers reporting high 
training at the beginning of the training season are more likely to adapt to the training 
regimen in spite of their iron status, while those reporting less training still have 
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potential to increase their training and therefore, their performance. As expected, 
rowers in the high training group had higher VO2peak/kg FFM (p=0.01), and tended to 
have a faster 4K TT as tested in the lab (p=0.07). Unmeasured behavioral and/or 
psychosocial characteristics of the rowers may explain this scenario, as prior training 
and rowing experience are important predictors of performance.  It could be that 
rowers with more experience are more likely to train harder despite their iron status, 
however, there was no difference in rowing experience between the two training 
groups.  If iron status affects the relationship between training and performance, it is 
only one of the many factors (physiological, psychological, environmental) to be 
considered.  
As a measure of training load at the beginning of the season, sessionRPE 
(training session intensity rating  x  training session time) may be a proxy for who 
came into the season at a higher fitness level due to training on her own prior to the 
start of the season.  This could be related to self-motivation or any of the other factors 
mentioned previously. Self-motivation is also an important variable, as it drives the 
training stimulus, and consequently performance.  In a study of female college rowers, 
those who did not comply with the prescribed training regimens (e.g. comparable to 
our low training group) had lower self-motivation and poorer ergometer performance 
than those rowers who trained harder (e.g. comparable to our high training group) (2).  
In the current study, motivation scores were not different between the depleted and 
normal rowers, but more highly-trained rowers reported significantly higher 
motivation scores (58.5 11.9) compared to less highly-trained rowers (49.6 15.9, 
p=0.03).  Rowers in the high training group also reported higher ratings of 
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concentration during training (63.5 11.9) at the beginning of a training season 
compared to the low training group (52.3 14.2, p=0.005).  SessionRPE at the 
beginning of a training season may also be a proxy for who performed well during the 
previous season.  Rowers’ in the high training group reported 2K PRs from the 
previous season that were, on average, 17.2 seconds faster compared to the low 
training group (p=0.06).   
Internal validity: Given the limitations of the cross-sectional analysis, it was 
important to conduct a randomized, double-blinded, and placebo-controlled trial 
(RCT) to further examine the relationship between iron status and supplementation 
and performance in these athletes.  The RCT design lends to better internal validity 
than the cross-sectional study in establishing causal relationships, as the RCT design 
meets all three of the previously mentioned criteria.  Randomization was successful in 
that all potential confounders were theoretically evenly distributed between treatment 
groups, and there were no baseline differences in any performance outcome, iron 
status, or confounding variables.  Successful randomization could be an explanation 
for a lack of a training effect (as a mediator or modifier) in the RCT.  Our training 
variable was equally distributed between the two treatment groups at baseline.  
External validity: External validity is especially relevant for negative or non-
significant findings, which may be due to effect modifiers inherent to the study 
population.  These factors may have directly interfered with the effectiveness of the 
iron supplementation, making the treatment insufficient to cause changes in iron 
status, performance or training outcome measurements. The generalizability of these 
findings to other populations of women with IDNA is limited due to our inclusion 
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criteria, which limited participation to female collegiate rowers who agreed to 
participate in the study.  The results of the supplementation trial would not be 
appropriately applied to populations that have higher iron requirements due to 
excessive iron loss and/or poor iron absorption (unhealthy, clinical populations).  The 
duration of our RCT and dose of supplemental iron may not produce the same results 
in a clinical population.  
These results are consistent with results observed in other similar populations, 
and are likely applicable to other well-trained female endurance athletes (runners, 
swimmers, skiers, etc), due to the commonality of the college/university 
environments, and general nature and common outcomes of their training.   It is likely 
that well-trained female athletes across sports disciplines are more prone to IDNA for 
similar reasons (poor dietary intake, high training load), and that their mitochondrial 
respiratory potential (iron-containing enzymes involved in oxidative metabolism) 
would also be compromised.  Furthermore, well-trained athletes of all sports 
disciplines can be highly motivated during exercise testing, so the effect of large 
variation in motivation or other similar psycho-social characteristics would be 
minimized. The results from these studies may not be applicable to non-athletes, as 
underlying genetic, psychological or sociological characteristics between athletes and 
non-athletes may differ (eg. motivation, etc).   
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Does training act as a mediator of the effect of iron status or supplementation 
on performance?  To answer our main research question (refer to Chapter 2, Figure 
2.4, Conceptual diagram) four conditions must be met (3) : 1) Iron status is 
significantly associated with performance (establishes evidence that there is an effect 
that could be mediated by training); 2) Iron status is significantly associated with 
training (treating training as an outcome variable); 3) Training is significantly 
associated with performance (after controlling for iron status); 4) The significance of 
the impact of iron status on performance is reduced after controlling for training.  
These four conditions will now be individually-discussed, referring back to tables and 
figures from Chapters 6, 7, and 8. 
1) Iron status is significantly associated with performance :  Multiple 
regression analyses of the subgroup of rowers with IDNA at baseline revealed a 
significant interaction between change in iron status (log sFer) and the amount of 
supplemental iron consumed, and the change in iron status and training load (see 
Chapter 7, Table 7.7, Models 5 and 6; Figures 7.4 and 7.5).  These effects were not 
seen in the whole sample of rowers, likely due to the inclusion of rowers with normal 
iron status.  Results of the subgroup analysis provide evidence that there is a 
relationship between iron status and performance that may be mediated by training.   
2) Iron status is significantly associated with training: Change in training 
quality as the outcome was not significantly correlated with change in iron status, and 
multiple regression analyses revealed that change in iron status (as measured by log 
sFer, sTfR, or TBI) was not a significant predictor of change in training quality score 
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(see Chapter 8, Table 8.5, Model 2).  This remained true in the subgroup of rowers 
who were IDNA at baseline.   
3) Training is significantly associated with performance: Multiple regression 
analyses of the entire sample of rowers (n=31) revealed significant effects of rowers’ 
average training load, baseline energetic efficiency, and dose of supplement consumed 
on change in performance (energetic efficiency), but no significant effect of change in 
iron status (log sFer) on change in performance.  Furthermore, there was no interaction 
between change in iron status and average training load (see Chapter 7, Table 7.5).  
Additional mixed effects regression analyses of the entire sample reveal that after 
controlling for change in iron status (log sFer) and baseline performance, change in 
training quality is a moderate predictor of change in gross energetic efficiency 
(β=0.003, p=0.19).  The interaction between change in iron status and change in 
training quality was not significant in the regression model. Analyses of the subgroup 
with IDNA at baseline show that after controlling for change in iron status (log sFer) 
and baseline performance, change in training quality is a significant predictor of 
change in gross energetic efficiency (β=0.009, p=0.006).  Results of the subgroup 
analysis provide evidence that there is a relationship between training and 
performance.  The relationship between change in training quality and change in 
performance (gross EF) between treatment groups in the entire sample (A) and the 
IDNA subgroup (B) is presented in Figure 9.1.   
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Figure 9.1A.  Relationship between change in training quality score and change in 
gross energetic efficiency between treatment groups in the complete sample (n=31). 
 
   
Figure 9.1B.  Relationship between change in training quality score and change in 
gross energetic efficiency between treatment groups in the subgroup of rowers with 
IDNA at baseline (n=16); both A and B adjusted for change in iron status, baseline 
efficiency 
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4) The significance of the impact of iron status on performance is reduced 
after controlling for training:  Further analyses suggest that the effect of change in iron 
stores or iron supplementation on change in gross energetic efficiency may be 
partially-mediated by change in training quality.  This is evidenced by a decrease in 
the effect of change in log sFer (ß =-0.53, p=0.64 without training , versus ß=-0.82, 
p=0.46 with training), as well as a decrease in the effect of treatment group (without 
change in iron stores in model, ß=0.64, p=0.15 without training , versus ß=0.37, 
p=0.54 with training) after adding change in training quality to the mixed effects 
multiple regression models controlled for baseline training quality.  Although these 
effects were not statistically significant, it is important to further examine the simple 
relationships between the independent variable (change in sFer), mediator (change in 
training quality), and the dependent variable (change in gross energetic efficiency), 
which are presented in Figure 9.2.   
 
 
 
 
 
 
 
 
Figure 9.2.  Regression analysis to test for mediation 
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The Sobel method (3, 4)  is one way to test whether change in training quality 
carries any of the influence of the effect of change in sFer on change in gross EF.  
Although the un-standardized ß-coefficients are not different from zero, results of the 
analysis reveal that ~ 25% of the direct effect (change sFer  change gross EF) is 
mediated by change in training quality (Sobel test = 2.65, p=0.008, ratio of 
indirect/direct effect=0.32).  However, the Sobel method is very conservative, and our 
small sample size may affect the validity of (add bias to) this estimate.   
Especially in a small sample, multi-colinearity, or strong correlation between 
change in iron stores (independent variable) and change in training quality (proposed 
mediator) may bias regression coefficients and thus interpretation of the mediation 
effect.  However, the correlation between change in iron stores (log sFer) and change 
in training quality was not significant (r=0.07, p=0.74), so this was not a major 
concern in this analysis.  Furthermore, if our measure of training quality (proposed  
mediator) is not completely free of error, estimates of the regression coefficients will 
be biased (effects of b and c’).  Analysis of our training quality score over the 6-week 
study showed high internal consistency (Crohnbach’s alpha = 0.82, n=21 with 
complete data for training weeks 1 through 6). 
After controlling for baseline training, change in gross EF was a significant 
predictor of change in training quality (ß=26.74, p=0.047).  When change in iron 
stores (log sFer) is added to this model, there is no change in gross EF’s effect on 
change in training; when treatment group is added to the model, the effect of  change 
in gross EF on training  is decreased (ß=19.02, p=0.15), and treatment has a modest 
effect (ß=60.31, p=0.09).  Theoretically, this reverse causality (change EF  change 
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in training) does not make sense -- those rowers who improved their EF, should have 
done so only after training (temporality).  There may be a different variable that is 
known to cause each of these two variables independently (a variable that causes 
change in training, but not change in EF, and vice-versa).  Examination of 
instrumental variables would help us to better estimate mediation.  Alternatively, 
omission of any variables that cause both change in EF and change in training will 
bias the estimates, but since this was a RCT, this should not be the case.   
Although the RCT is a strong study design, it is not immune to limitations, 
introducing insult to the study’s validity.  It is possible that the physical performance 
and/or training measures used in this study may not have been sensitive enough to 
demonstrate any improvements in highly-trained IDNA athletes.  A ceiling effect at 
this moderate (non-clinical) stage of ID on performance is possible.  Additionally, an 
overwhelming response to heavy training may have masked effect the effect of iron 
treatment or change in iron status.  Other possible limitations include selection bias 
(recruitment and attrition of study subjects), measurement bias, confounding bias, and 
power, which are discussed below.   
Selection bias and recruitment and attrition of study subjects:  We expected a 
5-10% refusal rate of potential subjects during subject recruiting, and a 10% drop-out 
rate during the 6 week RCT.  Out of 199 possible rowers from the 5 schools, 83% 
participated in the screening (13% refusal rate, Chapter 4).  From the 165 that were 
screened, only 34% (n=56, across range of iron status) opted to participate in the 
cross-sectional testing (Chapter 5), and 24% (n=40 non-anemics) were randomized 
into the 6-week study (Chapters 6-8).  A possible explanation for the low response 
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rate and participation in the baseline laboratory testing and RCT may be the initial 
time required at baseline.  Although obtaining the blood sample for analysis of iron 
status took less than 5 minutes, completion of the screening questionnaire packets took 
about 30 min, and may have been perceived as burdensome.  Also, commitment to 
participation in the baseline laboratory testing required 2 separate visits to the lab 
(VO2peak and 4KTT tests).  Although our subjects received all iron status, body 
composition, and fitness test results, we did not financially-compensate our subjects, 
and this may have deterred participation.  At the end of the study, subjects who 
completed the trial were debriefed and asked if monetary compensation would have 
increased participation; 84% of these participants answered “No.”   
For the RCT, the attrition rate was 23%, but the 9 rowers who did not complete 
the trial were no different from those who did complete the trial regarding their 
baseline characteristics (for variables we could examine).  Bias may occur when those 
who refuse to participate in the study or drop out during the study are different from 
those that joined and remained in the 6 week study, relevant to risk factors and 
behaviors associated with the outcomes.  We attempted to minimize attrition by 
frequent contact with research subjects via bi-weekly email reminders of testing 
appointments, supplement and training log completion, and weekly face-to-face 
contact to collect/distribute capsules and logs, as well as to remind subjects of the 
availability of investigator(s) to answer questions prior to and during the trial, and 
regular, personalized interaction between research staff and subjects.    
Additionally, we attempted to maximize clarity of subject instruction with 
regards to training logs and supplement intake.  Furthermore, accommodations were 
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made for transportation to/from and parking at the HMRU, as necessary for blood 
samples, exercise testing and body composition assessments.  Selection bias was also 
partially controlled through successful randomization to treatment and placebo groups, 
and the double-blinded design protected our study against treatment-associated biases, 
helping us to avoid subjectivity in outcome measurements, treating subjects differently 
based on treatment, etc. However, even after randomization, there is still the 
possibility that unmeasured confounders were not uniformly distributed between 
groups. 
Measurement bias: Recall bias is inherent in the FFQ and other self-reported 
dietary and behavioral assessment methodology.  To help mitigate the effects of this 
bias, detailed instructions and formats were provided for the diet and training logs.   
Researcher bias during testing and anthropometric measurements was minimized by 
blinding the data collector to the participant’s treatment assignment and using 
structured interview guides as necessary.   
Confounding bias: There was a risk of confounding due to the interrelated 
nature of the multiple determinants of iron status in female collegiate athletes.  Some 
of this potential confounding was controlled through the exclusionary criteria (women 
younger than 18 and older than 30 y; women using substances known to affect 
outcome variables (smoking, alcohol, etc).  We attempted to measure potential 
confounders related to dietary intake, supplement intake, and intervention compliance, 
and adjusted for these as appropriate during statistical analysis.  Our randomization 
was successful in regards to measured confounders, and should have accounted for 
unmeasured confounders.  
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We attempted to adjust for any unmeasured potential confounders using mixed 
effects multiple regression analyses, which takes into account the heterogeneity 
between subjects.  In a mixed model, intra-individual (random variation within an 
individual) and inter-individual (random variation among individuals) variability are 
characterized.  We used school and season as our random effects, as it was inevitable 
that there be inherent differences in factors affecting training and performance at the 
school and season levels, however, this only captures some of the unmeasured 
confounding.   
  Power and statistical analysis: Though we expected similar effects of IDNA 
on endurance as we have observed in our previous studies (5-8), the current study was 
underpowered to detect differences less than 1 SD of change in endurance 
performance, due to our small sample size of IDNA rowers.  Additionally, athletes 
would be expected to have a smaller margin for improvement in endurance training 
and performance due to their continuous high levels of training.  Furthermore, 
compliance (amount of supplement consumed) was low, and we had fewer IDNA 
rowers complete the trial than we had anticipated.  Due to the exploratory nature of 
many of our analyses, numerous statistical tests were performed, increasing our 
susceptibility to Type I error. 
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Plausibility 
 In both the cross-sectional study and the RCT, significant associations between 
change in physical performance and iron status or change in iron status were observed, 
making it plausible that iron status affects physical performance in female rowers.  In 
the cross-sectional study, there were significant group differences (IDNA vs normal) 
in VO2peak, which was strongest in those rowers who reported the least intense 
training at the beginning of a season. This difference was seen using a sFer cut-off of 
<20.0 µg/L.  Furthermore, there was a significant positive association between 
VO2peak and sFer (r=0.29, p=0.05), making it not only plausible that the group 
difference in VO2peak was due to group differences in sFer, but it also strongly 
supports the inference that VO2peak may be impaired in IDNA, despite non-clinical 
diagnosis.   
If there were a significant correlation between change in iron stores (TBI) and 
number of iron capsules consumed in the iron supplemented group, this would confirm 
that the observed change in iron status was due to the iron supplementation, further 
increasing the plausibility of the results.  Rowers in the iron group, on average, 
consumed 76% of the total prescribed dose of iron (4200 mg FeSO4), which may not 
have been enough to see significant differences in iron stores (sFer) over 6 weeks of 
supplementation.  sTfR did decrease in the iron-supplemented group, though not 
significantly so.   Consequently, there was an insignificant change in TBI in both 
groups (Placebo group +0.45±2.5 mg/kg; Iron group +1.3±3.0 mg/kg, p=0.37), though 
it appears to be in the expected direction.   
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 The relationship between supplemental iron consumed (mg elemental iron per 
kg of body weight) and change in total body iron (mg/kg) was discussed in Chapter 6, 
and is shown in Figure 9.3 A and B.  Figure A shows the entire sample of rowers 
(n=14 iron, 16 placebo), less one outlier who was a non-compliant rower in the iron 
treatment group with a large increase in TBI. After controlling for TBI at baseline (β=-
0.58, p<0.001), total supplemental iron consumed (0 mg in the placebo group) was a 
moderately significant predictor of change in TBI (β=0.07, p=0.13; R2=0.56).  
Examining those rowers in the iron group separately (n=14), total supplemental iron 
consumed remained a moderately significant predictor of change in TBI (β=0.12, 
p=0.18; R
2
=0.51).  Figure B shows the subgroup of rowers (n=7 iron, 8 placebo), less 
the same outlier who was a non-compliant rower in the iron treatment group with a 
large increase in TBI. In the subgroup of rowers who were IDNA at baseline, after 
controlling for TBI at baseline (β=-0.68, p=0.002), total supplemental iron consumed 
was a moderately significant predictor of change in TBI (β=0.11, p=0.10; R2=0.59).  
Examining those IDNA rowers in the iron group separately (n=6), total supplemental 
iron consumed became a significant predictor of change in TBI (β=0.23, p=0.05; 
R
2
=0.79).   
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Figure 9.3A. Relationship between supplemental iron intake (mg/kg) to change in total body iron 
(mg/kg) in A) all iron-supplemented rowers (n=30) 
 
 
Figure 9.3B. Relationship between supplemental iron intake (mg/kg) to change in total body iron 
(mg/kg) in iron-supplemented rowers with IDNA at baseline (n=15) 
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More infrequent (weekly) supplementation with 60 mg of iron for 7 months 
has been shown to be as effective as daily supplementation in increasing sFer in IDNA 
premenopausal women (9), and several researchers report improved iron status and 
better compliance with this mode of supplementation in pregnant women and children 
(10).  In the current study, compliance did not reach >50% until the midpoint (week 3, 
11±4 capsules per week in the placebo and 10±5 in the iron group) of the trial, before 
which rowers were only consuming ~20-40% of the prescribed iron dose.   This non-
compliance persisted despite several efforts by the research team to demand 
compliance (weekly reminder emails and weekly visits to collect unused capsules and 
training logs).  Potential explanations may be that it took these women longer to make 
taking the capsules part of their daily routines due to the demands and schedules of 
student athletes, or the fact that not many of the subjects were used to routinely taking 
supplements or medications of any kind prior to the study.  At baseline, there were no 
differences between treatment groups in prevalence of past supplementation.  
Furthermore, compliance did not differ according to baseline iron status.   
Compliance with the supplement was poor, although no adverse effects related 
to the capsule consumption were reported at any time during the study.  On average, 
rowers in the placebo group were more compliant (79±19 capsules, range 44-115 
capsules), and consumed a greater number of capsules than rowers in the iron group 
(64±34 capsules, range 0-118 capsules).  At week 6, rowers in the placebo group were 
consuming significantly more capsules per week (12±2) compared to the iron group 
(8±5, p=0.04).  If we had given a larger dose of iron, or supplemented for a longer 
period of time to compensate for the less frequent consumption, we may have seen a 
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greater improvement in iron stores.  Alternatively, at the same consumption rate we 
may have seen greater improvement in iron stores after 9 weeks of supplementation 
compared to 6 weeks.   
Another test of plausibility is an examination of subjects’ potential to benefit 
from the treatment.  In the intervention study, rowers with the poorest iron stores 
(sFer, TBI) had the greatest improvement in iron stores with supplementation 
(Chapter 6).  This is a finding we expected given the regulation of iron absorption 
according to iron status.  However, there was no correlation between supplemental 
iron consumed and change in body iron stores (log sFer, TBI) in either the entire 
sample of rowers, or the subgroup with IDNA at baseline.  This was likely due to the 
combination of poor compliance (did not consume enough iron) and small sample size 
of IDNA rowers who were most likely to respond to treatment.  
We observed significant treatment effects on change in gross efficiency and in 
endpoint lactate response during the 4K TT.    Although we observed no correlation 
between change in efficiency and total supplemental iron consumed, we did find a 
significant correlation between supplemental iron consumed and lactate (as a percent 
of maximal) at 1000 m at the end of the study (r=-0.39, p=0.03), confirming 
plausibility that the improvement in lactate response in the iron group was due to the 
supplementation. 
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Discussion and interpretation of major findings 
Iron status 
The iron-supplemented group was able to replenish their iron stores (sFer, after 
controlling for baseline sFer), and those with the lowest sFer at baseline benefitted 
most from supplementation.  However, there were some subjects in the placebo group 
who had improved iron status.  Some of these “responders” in the placebo group could 
be a statistical artifact of regression to the mean.  It is possible, however, that those 
placebo “responders” truly improved their iron status by other means, such as 
increased dietary intake during the training season.  At baseline, there were no 
differences in energy intake (2000 kcal/d) or iron intake (18 mg /d) between the two 
treatment groups.  We did not collect weekly dietary logs throughout the 6- week 
study, and very few rowers returned a completed 7-d food record at the end of the 
study.  With an increase in training load over the course of the season, it is reasonable 
to believe that kcal intake would have increased, along with dietary iron intake, so it is 
possible that “responders” in the placebo group may have had higher dietary iron 
intakes that resulted in improved iron status.   
Our RCT included randomization of rowers with normal iron status into the 
treatment/placebo groups.  Another RCT of female soldiers (11) reported improved 
iron stores (or a prevention of decline in iron stores) with the same supplementation 
level used in the present study (100 mg/d FeSO4) in subjects with sFer as high as 37 
µg/L.  In the current study, although rowers with IDNA and normal iron status were 
balanced between the two treatment groups, a consequence of including potential 
“non-responders” reduces the ability to see a treatment effect (change in iron stores) in 
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the iron group. Duplicate measurements of iron status were conducted at baseline 
under standard laboratory procedures, along with an indicator of inflammation (AGP), 
so chance of misclassification of IDNA subjects was reduced, however, initial 
misclassification of IDNA rowers may still have existed due to use of cut-off values 
for iron status measurements that are continuous, measured with error and show day to 
day variation, and don’t consider individual sources of normal variation.  Furthermore, 
all rowers in this study had Hgb above the clinical cut-off, and 6 rowers (n=3 placebo, 
3 iron) had baseline sTfR>8.0 mg/dL.  This suggests normal erythropoesis in all 
subjects and impaired tissue iron status in only a small fraction of our sample at 
baseline.   
Calculation of TBI via the sTfR:sFer index (12)  may be preferable to sFer 
alone to assess iron status and the need for supplementation in athletes. An advantage 
of using the index is that, unlike sFer alone, it is sensitive to a wider range of body 
iron status, as it includes a measure of iron-deficient erythropoesis as well as or tissue 
iron status. In IDNA athletes, only those with elevated sTfR values showed 
performance that was responsive to iron supplementation (5, 13, 14).  In the current 
study, 5 rowers began the study with TBI<0 mg/kg (3 of whom had high sTfR, as 
mentioned previously).  At the end of the study, only one of those rowers had a TBI 
<0 mg/kg, however, 13 rowers (n=8 placebo, 5 iron) had decreased TBI (range: -0.2 to 
-3.12 mg/kg), suggesting that the iron status of some subjects deteriorated after six 
weeks of training.    
 There is a negative correlation between iron supply and tissue iron deficiency.  
When there is increased iron supply with the same demand at the tissue level (sTfR), 
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tissues will produces fewer receptors for transferrin and sTfR will decrease.  None of 
the iron status indicators used in this study were correlated with physical performance 
variables in the RCT (see Chapter 7).  Hgb, the largest reserve of functional iron, has 
been associated with VO2peak and blood lactate concentration, however, in our study, 
Hgb was not associated with lactate concentration.   
Despite the absence of anemia in our study, a significant increase in Hgb was 
observed between the midpoint and end of the trial in all subjects (+0.28±0.63 g/dL, 
p=0.02).  This could be due to rowers’ hematological adaptation to training that has 
been previously reported (15, 16), or to hemoconcentration due to change in hydration 
levels during training.  Although women in this study were not clinically anemic, 
criteria used to identify anemia (Hgb <12.0 g/dL) may be insufficient for female 
athletes.  The potential for functional (non-clinical) anemia is much greater in this 
population due to intense training, which may further increase demand for O2-carrying 
capacity (Hgb) and functional tissue iron (sTfR).   
On the other hand, researchers have shown increases in sTfR with muscle 
growth (17), and in the current study, after 6 weeks of training all rowers increased 
their FFM by 1.2 kg.  Although we observed no correlation between change in FFM 
and change in sTfR, it is possible that this factor may have played a role in 
diminishing the effects of iron supplementation on this measure of iron status, and 
may be an explanation for why some rowers in the iron treatment group did not 
display a greater iron status response to treatment. In mixed effect multiple regression 
analyses, change in FFM was not a significant predictor (β=0.10, p=0.72) of change in 
sTfR, nor was treatment group (β=-0.76, p=0.23).  The inclusion of an interaction term 
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(treatment group-by-change in FFM, Figure 9.4) was marginally significant (β=0.73, 
p=0.19), and inclusion of this interaction term greatly improved the effect of treatment 
group (β=-1.6, p=0.08) on change in sTfR in the regression model.   Although 
insignificant, this is possibly an important interaction, and is consistent with previous 
findings from our lab showing that non-athletic IDNA women with the most FFM at 
baseline experienced the largest improvements in sTfR after 6 weeks of training and 
treatment (14).   
 
Figure 9.4.  Relationship between change in fat-free mass (kg) and change in soluble 
transferrin receptor (mg/L) after 6 weeks of treatment (n=31) 
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Physical performance 
Energetic efficiency: Given the findings that supplemental iron replenished 
rowers’ iron stores, it is a logical next step to determine the effects of improved iron 
stores (via supplementation) on physical performance (energetic efficiency, lactate, 
VO2 peak, and endurance capacity).  In our cross-sectional analyses, we found that 
rowers with IDNA reported slower 2K personal records and had a lower VO2peak and 
reduced energetic efficiency compared to rowers with normal iron status (Chapter 4).  
In the RCT analyses, although time to complete the 4K TT was unaffected by iron 
treatment, iron-supplemented rowers were able to significantly increase their energetic 
efficiency after controlling for baseline efficiency and supplement dose consumed.  
Furthermore, analysis of data from the subsample of rowers with baseline serum 
ferritin <20.0 µg/L showed that iron-supplementation clearly increased energetic 
efficiency by 1.3% after 6 weeks of training compared to the placebo group.  
This means that after being supplemented with iron for 6 weeks, non-anemic 
rowers were able to perform the same workload at a lower energy cost (lower level of 
physical exertion = more energetically efficient).  This finding is consistent with other 
iron supplementation studies of non-anemic women.  Researchers have found that O2 
consumption (as % VO2max) during an endurance test was significantly less after iron 
supplementation (-3%) and significantly greater in placebo (+3%) (18).  Zhu & Haas 
showed that after 8 weeks iron supplementation, non-athletic women increased their 
efficiency by decreasing their energy expenditure by 5.1% (p=0.016) compared with 
women in the placebo group, and that this treatment effect on %VO2peak was 
mediated by a change in Hgb (8).  Hinton et al found that after a 4-week training 
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program imbedded in a 6-week iron supplementation trial, although both groups 
increased their efficiency (through training), there were no significant differences in 
total test efficiency between the treatment groups.  However, the iron group decreased 
their O2 consumption by 5% (as a %VO2peak) during the last 5K of 15 K TT. (5).  
Another study of untrained IDNA Mexican women reported 5.2% greater efficiency 
during a cycle ergometer test after 6 weeks of supplementation with18 mg of 
elemental iron (19).  Subsequently, Hinton et al found that after 6 weeks of iron 
supplementation, recreational athletes’ post-trial efficiency was significantly increased 
(+1.1%) compared to placebo (+0.7%), though the post-trial efficiency measure was 
not significantly different between the treatment groups (20).  Additionally, the 
difference in energetic efficiency should not have been due to differences in 
psychological factors between the two treatment groups, as motivation scores 
measured throughout the trial were not significantly different between the two 
treatment groups at baseline and endpoint.  Furthermore, in these studies we measured 
gross efficiency, which does not account for energy expended during and unloaded (0 
watts) condition, termed net energetic efficiency.  Measuring energy expenditure 
during an unloaded bout would have enabled us to calculate net efficiency, which 
many have been more sensitive to changes in iron status, and strengthened the 
relationships between iron status and performance.    
Lactate response: In both the cross-sectional study and RCT, iron 
status/supplementation affected lactate response during the 4K TT.  In the cross-
sectional study, lactate concentrations at 2000m and 10-minutes post-test were 
significantly negatively correlated with log sFer (r=-0.31, p=0.04).  Blood lactate 
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concentrations at pre-test, as well as 1000, 2000, 4000m  (maximal), and 10-minutes 
post-test were significantly higher in rowers with IDNA compared to rowers with 
normal iron status (Figure 5.2), but after controlling for pre-test values, there were no 
significant differences between the two iron status groups.   The higher pre-test lactate 
concentration in the IDNA group could be due to inadequate recovery from warming-
up, or insufficiently warming-up prior to the start of the test compared to rowers with 
normal iron status.  All rowers were encouraged to warm-up for at least 10-min prior 
to testing, but this was not monitored or recorded in this study.   
At the end of the 6-week RCT, rowers in the iron treatment group had 
improved lactate response during the early stages of the 4K TT, regardless of baseline 
iron status (both IDNA and normal iron status).  Rowers supplemented with iron 
showed a slower increase in lactate (10.3% lower, expressed as percent of maximal 
lactate, Figure 7.6) during the first half of the 4K TT (1000-2000m) compared to 
rowers in the placebo group.  Supplementation may have improved lactate clearance, 
reduced lactate production, or both, and thus reduced utilization of lactate as fuel, 
during the first two legs of the TT.  After the first 2000m, however, there was no 
difference between treatment groups until 5-minutes post-test, where rowers in the 
iron group recovered more quickly compared to those in the placebo group.   
Decreased oxidative capacity (a consequence of IDNA) may affect glycolysis 
via the utilization of lactate as a fuel during exercise.  When the rate of lactate 
produced is greater than the rate of clearance, lactate accumulates in the body (21).  
This accumulation of lactate causes fatigue and inhibits muscle contraction, leading to 
impaired performance during continuous endurance exercise.  Due to their greater 
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lactate accumulation or decreased clearance early in the TT, IDNA rowers were 
utilizing their anaerobic energy pathways earlier than were the rowers with normal 
iron status, which is inherently less energetically efficient than using aerobic 
pathways.  
Although many researchers have found no effect of iron supplementation on 
lactate concentration during exercise in IDNA women (5, 22-25), results from the 
current study are similar to those of Zhu and Haas who found that IDNA women 
supplemented with iron showed a slower rise in lactate concentration during first leg 
of 15K TT (5 K mark), as well as an inverse association between lactate concentration 
at the 5 K (first third of 15 K TT) and Hgb, even in marginal iron deficiency  (8).  
Even in the absence of frank anemia (Hgb <12.0 g/dL), impaired O2 transport capacity 
due to IDNA affects lactate metabolism, resulting in impaired oxidative metabolism, 
and ultimately increased reliance on anaerobic metabolism to produce energy (greater 
lactate production at an earlier stage of exercise). In a state of IDNA, lactate 
metabolism may be directly affected, resulting in the prevention or slowing of lactate 
clearance (26, 27).  
The lack of treatment effect on lactate measured after the first half of the 4K 
TT could be due to our study being under-powered (small sample size, poor 
compliance), but is likely due to the fact that towards the end of the TT, lactate 
concentration was reaching a steady state, as well as its maximum tolerable limit, as 
the TT was performed at a fixed WR.  Margin for improvement by iron 
supplementation was likely very small after the first 2000m, and was likely insensitive 
to supplementation.   
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VO2peak :  In the cross-sectional study, after controlling for fat-free mass, 
there was a difference in VO2peak between rowers with IDNA and those with normal 
iron status only in the “low” training group.  There was no difference in VO2peak 
between IDNA and normal iron status in the group of rowers that reported training 
harder at the beginning of the season.  We did not observe an effect of change in iron 
status on VO2peak in the RCT.  Rowers randomized into the trial who were IDNA at 
baseline were no different from rowers with normal iron status with regards to 
baseline performance, or endpoint performance.  However, on average rowers with 
IDNA at baseline tended to have lower VO2peaks at endpoint, regardless of treatment 
assignment (p=0.08).  Among the rowers with IDNA at baseline, there were no 
differences in endpoint or change in VO2peak between the two treatment groups.   
In addition to our RCT being under-powered to demonstrate an effect on 
VO2peak (small sample size and poor compliance), one explanation for the 
discrepancy in VO2peak findings between the two studies may be training (as 
discussed above, Internal Validity).  VO2peak is highly dependent on training, and is 
predictive of endurance performance.  Training increases mitochondrial density and 
number, as well as free fatty acid oxidation, lending to increased O2 utilization 
capacity during exercise (28).  Less highly-trained rowers, then, would have fewer 
mitochondria (meaning less metabolic potential to use O2).   We expected to see 
greater improvements in performance in rowers with IDNA at baseline compared to 
those with normal iron status at baseline.  The iron status of IDNA rowers had a 
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greater potential to benefit from iron supplementation (as discussed above, 
Plausibility).   
Although Hgb concentration is an important determinant of O2 consumption, 
we found no significant correlations between Hgb and VO2peak, probably because no 
rowers included in both the cross-sectional and RCT were anemic.  In the subgroup of 
rowers with IDNA at baseline, however, change in VO2peak was significantly 
associated with change in Hgb between weeks 3 and 6 of the RCT (r=0.51, p=0.05).  
This implicates Hgb as one of the determinants of VO2peak in female athletes with 
IDNA despite absence of anemia.  This could be due to the prevalence of functional 
(sub-clinical) anemia and the inadequacy of the generic Hgb cut-off to classify anemia 
in this population.  We did not find a positive association between change in sFer 
(body iron stores) and change in VO2peak in our RCT, but sFer may be indirectly 
involved in the utilization of O2 via iron-containing enzymes of the tri-carboxylic acid 
cycle (TCA) cycle and electron transport chain (ETC).    
Additionally, we may not have found an effect of iron treatment on VO2peak 
in the RCT because there may be a non-linear relationship between Hgb, sFer, and 
VO2peak.  There may be threshold levels of sFer or Hgb, especially in athletes, and 
when either (or both) indicator is above or below these threshold levels, a linear 
positive relationship with VO2peak emerges.  There were, however, no differences in 
the ranges of sFer and Hgb in the two studies, which weakens this argument. 
Rowers in our study represented a wide range of training and fitness levels 
(NCAA Divisions I and III, teams as well as an intramural club rowing team).  Though 
training sessions across the five schools were comparable in terms of activities, 
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session duration and intensity differed widely across schools, as well as within-schools 
(between-rowers). As mentioned previously, we attempted to control for training and 
fitness differences between schools and seasons by using a mixed effects linear 
multiple regression model, but this method may not have accounted for all 
unmeasured confounders between schools or training seasons.   In the RCT, our 
randomization was successful in that both treatment groups were no different in any 
measured baseline characteristic, iron status, or performance outcome. The 
discrepancy in findings between the two studies may also be due to smaller sample 
size of IDNA rowers in the intervention study (n=24 IDNA compared to 16 in the 
RCT).  
Endurance capacity: Although rowers supplemented with iron did not improve 
their time to complete a 4K TT, studies have shown improved TT performance in 
IDNA non-athletic women after iron supplementation (5).   Other researchers using 
time to exhaustion protocols did not observe an effect of iron status (18, 22, 25).  This 
inconsistency between studies is likely due to methodological limitations of endurance 
testing. The exercise protocol (eg. TT vs time to exhaustion) needs to be sensitive 
enough to detect a difference in performance due to iron status, as well as adequately 
explore differences in energy metabolism.  The time to exhaustion protocol is not the 
best measure of athletic performance in endurance athletes for several reasons. The 
test becomes too long, especially for highly-trained athletes, and consequently 
motivation becomes a major factor affecting the outcome of the test (29).  
Furthermore, this protocol does not mimic training or competitive event performance.  
The 4K fixed length time trial (TT) was used in this study as a measure of endurance 
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performance because it best represents rowers’ training and on-water race 
performance (races last <30 min, short-duration, high-intensity).  The 4K TT protocol 
also allows us to study proxies of oxidative metabolism (VO2, energetic efficiency, 
lactate) throughout the test, during which iron plays an important role, as mentioned 
previously. We most likely did not see a supplement or iron status effect on TT 
performance due to the over-riding influence of heavy training in many of these 
athletes, which decreased their margin for improvement with iron supplementation or 
change in iron status. 
 
Training quality 
In our cross-sectional study, rowers with IDNA at the beginning of a season 
reported training 10 minutes less per day compared to rowers with normal iron status.  
In the RCT, we observed that rowers supplemented with iron reported higher ratings 
of training session intensity, concentration, speed and stress throughout the trial.  To 
adequately show the effect of iron supplementation or change in iron status on 
training, the measure of training needs to be sensitive enough to show difference 
between groups of iron status or treatments.  In the cross-sectional study and the RCT, 
the session-RPE method was used to quantify training.  Although this method has 
been used with various groups of athletes, and has been validated in our lab during 
rowing training (Appendix 1), it is possible that it inadequately captures the 
intermittent and varied nature of collegiate rowers’ training activities.  Much of 
rowing training revolves around repeated short bouts of high-intensity effort with 
intermittent rest (either on a rowing ergometer or in a boat on the water).  It may have 
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been more difficult for rowers to adequately gauge and recall the intensity of an entire 
2-hour workout if bouts were short with adequate rest between bouts.   
In the supplementation trial, exploratory analyses led us to create a training 
quality score (sum of training intensity, motivation, concentration, discomfort, speed, 
and stress) which was then used in mixed effects multiple regression analyses.  After 
controlling for training quality at baseline, iron supplementation resulted in a 
significantly greater improvement in training quality score at the end of 6 weeks 
compared to the placebo group.  Differences in training quality were seen as early as 
two weeks into the study (see Chapter 8, Figure 8.3), and persisted throughout the 
study.  The significant difference in training quality at two weeks was too early for the 
iron to have an effect, especially given the low dose that was being consumed as a 
result of poor compliance (refer back to Table 9.1).  This difference at the two-week 
time point could be attributed to any unmeasured differences between the two groups.  
Differences in training quality were again significant at 6 weeks, which would be a 
reasonable amount of time for the iron treatment to affect training.   
Although the effect of iron supplementation on training quality has not been 
previously studied, training itself has been implicated  in changes in sFer (16, 16, 18, 
30-37).  A common explanation for changes in sFer include the mobilization of iron 
from stores to tissues to support Hgb  and RBC synthesis needed in response to high 
training volume and/or intensity during the early stages of training.  As adaptation to 
training occurs, hemodilution and erythropoesis normalize, given adequate iron intake.   
Another explanation is related to the inflammation of training, resulting in 
inflation of sFer as an acute phase protein, and/or the effect of training on the iron 
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regulatory protein, hepcidin.  A few studies in active individuals have shown an 
increase in hepcidin, and consequent decrease in iron status, with intense training (38), 
but  others have reported no effect of training on hepcidin activity (39).  Liu et al 
attempted to identify the mechanism underlying the effects of training intensity on 
iron status and iron absorption using an animal model (40).  Rats were randomly 
assigned to different training groups for 10 weeks:  no training, moderate training, or 
strenuous training, and hepcidin mRNA expression, FPN 1, and DMT 1 were 
examined.  Body iron status in the moderate-training group was maintained, as 
evidenced by higher DMT-1 and FPN1 and lower hepcidin mRNA expression 
compared to the sedentary and strenuous training groups.  This study suggests that 
moderate exercise actually improved iron status.  These results are contrary to the 
same group’s most recent report of lower DMT1 and FPN1 and up-regulation of 
hepcidin mRNA expression in an exercised group of rats compared to a sedentary 
group (41).  Rats’ performance was not measured in either of these studies.  Possible 
reasons for the discrepancy between the two studies include the length of training (10 
weeks vs 5 weeks), as well as the intensity of training (moderate in the former vs 
various progressive intensity in the latter).  The latter finding is more plausible, given 
the inflammation of training effect.  Hepcidin was not measured in the current study of 
female rowers, but remains an important area of future research. 
 
Recommendations to athletes, coaches, and collegiate athletic programs 
Based on the literature review, data, and discussion presented in this thesis, 
active/training females are more vulnerable to IDNA, and increased iron intake via 
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supplementation and/or dietary means is recommended for these individuals.  Due to 
the inflammation of training and its effects on sFer values, as well as on acute 
hepcidin secretion and iron absorption, athletes who are intensely training may benefit 
from iron supplementation, despite maintaining normal iron status.  However, 
concerns regarding unregulated iron dosage and iron overload (pro-oxidant) should be 
considered, thus iron supplementation should not be initiated without proper 
determination of iron status, including markers of inflammation.  There are currently 
no standards for the evaluation of iron status of female college athletes, but the 
American Dietetic Association and the American College of Sports Medicine suggest 
that female athletes’ iron status should be periodically screened (42).  A survey of 
NCAA Division I schools  found that  not only is iron status screening not a routine 
practice, but there is much variability in diagnostic and treatment criteria used between 
schools (43).   
Given the roles that iron plays in exercise, accurately determining iron status in 
female endurance athletes is critical. At the beginning of the training season, female 
endurance athletes should be screened for iron deficiency and depletion with and 
without anemia using Hgb and sFer cut-off of 20.0 µg/L to identify iron depletion 
before it leads to anemia or frank iron deficiency, thus reducing the adverse affects 
that iron depletion may have on their training and performance.  After identification, 
anemic and IDNA athletes should be provided with treatment (e.g. low dose of 
supplemental iron, 18 mg) and/or nutrition counseling as necessary.  Iron status and 
supplement compliance of anemic and IDNA athletes should be serially monitored 
throughout the training season to assure sufficient dietary iron intakes, and prevent 
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further decrements in iron status with training. Additionally, coaches should take an 
active role in monitoring training quality over the season, and recommend health 
status screening as needed.   
Various supplements are employed by athletes to improve athletic performance 
(44).  Surveys of female college athletes show that more than 50% use some type of 
supplement, iron or iron-containing multivitamins among the most popular (45).  Also, 
college coaches routinely provide or recommend supplementation (46).  With the 
general rise in supplement use, nutrition education targeted at both coaches and 
athletes on the use of traditional and non-traditional supplements is warranted.  
Nutrition education interventions targeted to college athletes have been successful in 
both increasing nutrition knowledge, as well as improving dietary intake (47, 48). 
 
Future research 
Strategies to easily screen and improve iron status may be useful for female 
endurance athletes at the beginning of a training season because data suggest that iron 
status of very active women may decrease with increased levels of physical training 
over time (16, 49-51).  Studies focused on the implementation of screening policies for 
female athletes at both the high school and collegiate levels would help prevent ID, 
IDA and IDNA in this population and may confer benefits to other parts of their lives 
beyond athletics.  Future research should examine the prevalence, risk factors, and 
mechanisms of IDNA in female athletes, including plasma markers of hemolysis, 
accurate measures of athletes’ menstrual blood loss, dietary iron intake/absorption, as 
well as other markers of iron metabolism and inflammation, such as hepcidin, IL-6, 
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and IRP. Indicators of oxidative capacity (e.g. iron-dependent oxidative enzymes in 
muscle) are also needed to better control for potential confounders and investigate the 
mechanism by which IDNA alters energy metabolism and affects endurance 
performance.   
Future studies should employ objective methods of training assessment, such 
as measured heart rate and accelerometry to quantify energy expenditure, training 
intensity, frequency, and duration during the training season.  These methods may be 
more sensitive to changes in iron status and to the effects of iron supplementation. 
Also, further examining the relationship between iron and aspects of training such as 
motivation and concentration would be helpful to elucidate the mechanisms behind the 
relationships between iron, training, and performance in athletes.  
It would also be important to focus on ways to improve supplement 
compliance in training athletes in order to confer maximum benefit to athletes’ iron 
status.  This could include using iron-fortified food products or beverages (versus 
capsules), which may be more acceptable to athletes and could improve compliance 
(39, 52, 53).  Also, dose frequency is another way to examine compliance (e.g. a high 
dose of iron less-frequent weekly dose vs. lower dose daily).  Some studies have 
shown improved iron stores, as well as better compliance with a more infrequent dose 
of iron compared to daily supplementation (9, 9, 54, 55) while others have not (56).   
Defining optimal ferritin levels in female athletes would be helpful in order to 
target those who would benefit most from supplementation.  Furthermore, it is 
important to know how that ferritin level specific to female athletes can be enhanced 
and  maintained most effectively (supplementation vs dietary intervention).  Though it 
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has been shown that physical exercise can lead to a decline in body iron status, we do 
not know the level of dietary (or supplemental) iron that would be sufficient to meet 
the increased demand of chronic endurance training.  Defining iron requirements in 
female athletes is another area that needs more research.  Supplementing female 
endurance athletes with various dosages of elemental iron (e.g. 15, 30, 50, or 100 
mg/d) during a training season is needed to answer this question. 
Finally, future research should investigate different methods to successfully 
deliver sports nutrition education to both athletes and coaches.  To facilitate and 
maintain positive behavior change, design and implementation of education and 
screening interventions should be multi-level and multi-disciplinary, involving 
athletes, coaching staff, athletic trainers and the athletic department, campus health 
services (including dietitians), and food and dining services.  College athletes would 
especially benefit from interventions promoting self-efficacy (57, 58), specifically in 
the areas of supplement compliance, menu planning, cooking demonstrations, and 
making healthy eating choices while traveling to and from competitions.     
 
Conclusions 
 The studies described in this dissertation have shown that there are important 
relationships between iron status, training and performance in female rowers.  
Analyses of plausibility and probability have been discussed, along with the strengths 
and limitations of the cross-sectional study and RCT.  Non-significant findings for 
major outcome measures of change in iron status, training, and performance have been 
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explained, and are due in-part to small sample size and poor compliance with the iron 
treatment intervention.   
Our RCT has shown that IDNA in female collegiate rowers affects physical 
performance as measured by gross energetic efficiency (RCT). This indicates that 
IDNA increases rowers’ exertion and energy cost to do the same load of work, and 
that iron supplementation enhanced some, but not all indicators of rowers’ adaptation 
to training.  In addition, rowers supplemented with iron showed a potentially 
beneficial delayed lactate response during the first half of and early recovery from a 
4K TT, indicating that lactate metabolism is affected by iron depletion in the absence 
of frank anemia.  These results are important for female endurance athletes whose 
dietary patterns and physical training levels increase their risk of IDNA, and suggest 
that iron supplementation may maximize the benefits of endurance training.  
 Despite our findings, many questions remain to be answered to complete the 
picture of how iron status affects training and performance in female athletes.  More 
research is needed to understand the functional consequences of IDNA in training 
female endurance athletes before either supplemental and/or dietary iron intake 
recommendations can be made for this population.  Future research should be focused 
on the hematological changes during endurance training and their effects on iron 
status, as well as strategies to easily screen and treat female athletes with poor iron 
status, before training and performance are adversely affected.  Optimal cut-offs of 
iron status indicators for female athletes, as well as optimal iron doses to prevent 
and/or treat sub-clinical iron deficiency (IDNA) in female athletes should be explored. 
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Results from this study add to the evidence that iron status is an important 
issue facing female endurance athletes at the beginning of a training season.  We have 
shown that IDNA is prevalent among female collegiate rowers.  We have also shown 
that rowers who consumed ~15 mg elemental iron/d improved their iron stores (sFer) 
during training (after controlling for baseline sFer), and that those rowers with the 
lowest iron stores at baseline benefitted the most from iron supplementation, which 
adds to the growing body of evidence that iron supplementation improves the iron 
status of active women, which may ultimately impact training and physical 
performance. 
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Appendix 1:  Validation of training measure 
VALIDATION OF TRAINING MEASURE: QUANITIFICATION OF ROWERS’ 
TRAINING LOAD USING THE SESSION RPE METHOD 
Introduction 
Several methods have been used to monitor athletes’ training load, including 
heart rate (HR), measurement of total physical activity energy expenditure (EE), 
subjective rating of perceived exertion (RPE), and training impulses (TRIMPs).  
TRIMPs are arbitrary units of stress calculated from training session intensity and time 
used to quantify total training load (1).  While determining training load in individual 
events (e.g. long-distance running) is reasonably straightforward (2), techniques for 
monitoring the training load of individuals during intermittent team activities are 
lacking.  Rowing is a team sport with these intermittent patterns of varying intensity, 
and training is often monitored and analyzed via individual ergometer “scores” and 
video analysis.   Session rating of perceived exertion (sessionRPE) has been used to 
quantify a variety of training activities (3-6),  but has not been tested in rowers.  The 
objective of this descriptive study was to compare measured heart rate (HR) with 
subjective ratings of intensity (RPE) to quantify training load in healthy, well-trained 
female collegiate rowers both in the lab and on the water.  This analysis enabled us to 
validate the training load metric (sessionRPE) used in our cross-sectional study and 
iron supplementation trial investigating the effect of iron on performance and training.   
Methods 
Recruitment of subjects: This study was approved by the Institutional Review 
Boards of Cornell University and Syracuse University. Subjects were recruited during 
the conditioning phases of their competitive rowing seasons (fall 2009, spring 2010), 
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as well as prior to a pre-season training trip. All varsity and second-semester novice 
female rowers were eligible to participate in the screening if greater than 18 years of 
age, non-smoking, and were regularly training on the rowing team. Training activities 
during this time included on-water and ergometer rowing of varying intensity, as well 
as general aerobic conditioning (cycling, running).  
Cornell University’s women’s rowing coach was notified of the study, and 
aided in recruitment by passing along the information verbally at the beginning of a 
practice session.  Additionally, undergraduate research assistants aided in the 
recruitment of rowers via email flyers and word-of-mouth.  Rowers from Syracuse 
University were recruited while already participating in the iron supplementation trial.  
All rowers provided written informed voluntary consent prior to participating in the 
study.  Health and demographic data from each rower was collected to ensure 
subjects’ ability to safely participate in athletic training and physical exercise testing 
protocols, and a medical screening (NCAA-required) prior to our study excluded all 
athletes not healthy enough to participate in their rowing team training (current, acute 
or chronic illness, severe asthma, musculoskeletal problems, etc).  Subjects were given 
information from fitness and body composition tests as the benefit of participation.   
Physical performance testing methods: Body weight and height were measured 
with standard procedures and equipment (7).  Body fat and composition was assessed 
via air-displacement plethysmography (BodPod, Life Measurement, Inc, Concord. 
CA).  Physical fitness and endurance performance was assessed using a rowing 
ergometer (Concept2, Morrisville, VT) equipped with a digital readout monitor 
(PM2), displaying work (watts, W), stroke rate (spm), distance (m), and elapsed time 
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(min:sec).  A computerized metabolic cart (TrueMax 2400, ParvoMedics, Salt Lake 
City, Utah) was used to measure VO2 and other physiological measures during all 
testing. Concentrations of O2 and CO2 in expired air were analyzed with gas analyzers 
(which are routinely calibrated with gases of known O2 and CO2 concentration).  
Respiratory volume (VE) was measured with a respiratory pneumotachograph (Fitness 
Instrument Technologies, Farmingdale, NY) through a two-way breathing valve (Hans 
Rudolph, Kansas City, MO).   
Energy expenditure (EE) was assessed via indirect calorimetry during exercise 
testing using a standard protocol that measured expired gases for VE, VO2, VCO2, and 
respiratory exchange ratio (RER), all monitored continuously throughout testing (8).  
Heart rate (HR, Polar FS2, Polar Electro, Inc, Lake Success, NY) was also 
continuously monitored throughout testing.  Cadence (spm) and work rate (WR, watts 
(W) resistance) were monitored and recorded every 30 seconds.   
Blood samples were obtained by finger or ear punctures immediately before 
and after testing.  Blood lactate concentrations were determined by the Lactate Pro 
analyzer (FaCT Canada, Quesnel, British Columbia, Canada) (9), which we have 
concluded to be valid and accurate against an enzymatic assay (r=0.64, p<0.001, 
Sigma Diagnostics, St. Louis, MO), as is consistent with the peer-reviewed literature 
(10-13).   
Subjects were instructed to not consume food or beverages other than water, or 
to perform any strenuous physical activities 2 h prior to testing.  To control for the 
effects of dietary intake and hydration status, subjects were instructed to record all 
food and fluid intake 3d prior to testing, as well as the day of exercise testing 
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(Appendix 7).  Subjects had the opportunity to warm-up for at least 10 min prior to all 
testing.   
VO2peak:  Rowers performed three tests in the lab.  The first was a pre-test 
done in order to acclimate subjects to testing protocol and laboratory procedures, as 
well as to establish a VO2peak.  VO2peak was determined by a modified version of the 
maximum aerobic power (MAP) test, which is a ramped protocol used by rowing 
coaches to assess training progress (14).  
Rowers’ MAP in split-time was converted into watts (W = 2.8/pace per 500 
m
3
), and the test began 100 W below the predicted maximum.  Each stage of the test 
lasted 90s, with a 10s “gear-up” period between each stage (Appendix 12).  Every 90 
s, the rower was asked to increase her WR by 20 W, until she was no longer able to 
maintain the WR.  This test was designed to last between 8-10 min.  VO2peak was 
identified as the highest VO2 value achieved, and was confirmed by at least one of the 
following: 1) VO2 increased by <150 ml/min with an increase in WR; 2) RER >1.10; 
or 3) HRmax was within 10 beats of age-predicted maximum (220-age) (15).  A 15-
min cool-down period followed testing at a self-selected WR, and HR was monitored 
for 10 min post-test.  Blood sampling for lactate was collected pre- and post test, as 
well as at 5- and 10-min post-test.  Complete test time was about 45 min (10-15 min to 
acclimate to equipment; 10 min for actual testing; 15 min cool-down).  Participants 
were able to stop the test at any time, and the investigator was able to stop the test at 
any time (equipment malfunction; subject symptoms of severe fatigue).   
From the VO2peak test, HR (x)-VO2(y) calibration curves were plotted for 
each subject.  These curves were used to predict VO2 and EE from on-water training 
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HR data (outside of the lab).  HR (bpm) was converted to predicted VO2 (based on 
each individual’s VO2 peak HR-VO2 calibration curve), and then to EE (5 kcal per L 
O2).  This EE was summed and divided by 4 (4-15-sec epochs/min) to calculate total 
min-by-min EE during each training session.   
Rowing workout simulations on the ergometer: Two ergometer workouts 
modeled after on-water training were performed in the lab.  VO2/CO2, HR, etc was 
monitored during the tests as described above.  After a self-selected warm-up, subjects 
were asked to perform both a routine “Hard” training session, and a routine “Easy” 
training session, each session was separated by at least 3d.  Rowers chose the order in 
which the tests will be administered (“Easy” vs “Hard”), as dictated by their training 
schedule.   
The “Easy” workout simulation began with 2 min pulling at 50% pressure (18-
20 spm), followed by one minute pulling at 75% pressure (22-24 spm), followed by 
one minute pulling at full (100%) pressure (open stroke rating, range 26-32 spm).  
This was followed by one minute of drills (e.g. “pause at the finish,” etc), as would be 
performed in a boat on the water.  This 5-minute sequence was repeated 4 times (4 x 5 
min), after which rowers were asked to “paddle back to the dock,” as they would 
during an on-water practice in the boat.  The entire “Easy” protocol lasted about 25 
min.  For the “Hard” training session protocol, rowers were asked to perform a “stroke 
rate pyramid:” row for 1-minute on followed by 2-minutes paddle at stroke rates of 
26-28-28-30-30-32 (open) spm, followed by a “paddle back to the dock.”  This “Hard” 
protocol lasted about 25 min.  HR data from both the “Easy” and “Hard” training 
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session simulations were then plotted across time along with WR to examine the 
intermittent patterns of rowing training. 
Monitoring of training: Subjects were asked to maintain and record their 
normal on-water rowing training load daily, as well as to wear a HR monitor on their 
chest (Polar E-series, Polar Electro USA, Lake Success, NY) during all training 
sessions.  HR (bpm) was recorded in 15-sec intervals and data from each on-water 
training session was plotted across time to examine the intermittent pattern of rowing 
training, and these patterns were compared with those simulated in the lab. 
Intensity ratings after laboratory testing and rowing training regimen outside of 
the lab was quantified via detailed training and activity records (Appendix 11).  
Questions in the daily log addressed sleep and nap duration and quality, soreness and 
fatigue, and training or activity frequency, intensity, time, and type.  Questions were 
presented in the format of a Visual Analog Scale (VAS) (16).  Subjects were asked to 
rate each question by placing a solid vertical line on a 100mm scale anchored by 
opposing descriptors (see Figure A.1).  All VAS questions were “scored” by 
measuring the rating with a ruler (mm).  The session-RPE method (3)  was then used 
to quantify daily training load.  VAS Intensity score for each training session was 
multiplied by training session duration (time).   
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Daily Log Instructions 
This training log should be completed on a daily basis for the next 7 days.  Initial use 
of this log may take up to 5 minutes/day. For some questions, please rate each factor, 
as you feel today by placing a solid vertical line on the scale. 
 
Example:  Happy:  How happy do you feel right now? 
 
Not at all happy                                                                                                  Extremely happy 
 
Figure A.1 .  Visual Analog Scale (VAS) instructions and format of training log 
 
Analysis of training data: Training sessions (both in and outside of the lab) 
were categorized according to four major types (steady-state and drills, strength and 
power, endurance, and mixed).  HR data was used to determine training intensity 
based on HR <75%, 75-85%, and >85% of subjects’ HRmax (as determined in the 
VO2peak test).  The average HR and the peak HR for each training session was noted, 
and the training intensity distribution was quantified from the minutes spent in each 
%HRmax zone for each individual training session (17).  The average time in each zone 
for all sessions was then determined.  Ratings of intensity for each session were 
divided into the three zones, and training zone identification based on HR was 
compared with that sessionRPE method.   
Data Analysis: All data are presented as the mean ± sd.  Training intensity 
ratings and physical performance data collected during the laboratory training 
simulations were compared using a t-test, and Pearson’s correlations and linear 
regression analysis were used to examine relationships between TRIMP and the 
sessionRPE methods of calculating training load.  A p-value <0.05 was considered 
statistically significant.   
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Results 
 
Physical performance during the VO2peak test is shown in Table A.1.  Rowers 
(n=11) were 20±0.8 years old, weighed 72.4±10.2 kg (23.5±3.0% BF), and were 
178.2±6.8 cm tall.  HR-VO2 calibration curves were calculated for seven of these 
rowers (R
2
=0.72±0.2), and an example of a typical curve is presented in Figure A.2.  
Table A.1.  Physical performance during the VO2peak test (n=11) 
 
 Mean±SD 
VO2peak, ml/kg/min 
 
47.7±4.8 
VO2 peak, L/min 
 
3.4±0.5 
RERmax 
 
1.1±0.07 
HRmax, bpm 
 
188.6±10.6 
WRmax, W 
 
249.3±27.3 
Maximal lactate, mmol/L 
 
10.8±1.9 
Slope of HR-VO2 curve, L O2/min 0.51 ± 0.37 
(0.03-1.2) 
Intercept of HR-VO2 curve 
 
75.2 ± 56.2 
(2.1-162.6) 
 
 
 
Figure A.2.  Graphic example of typical subject HR-VO2 calibration curve 
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Seven rowers completed the simulated workouts in the laboratory.  Data from 
the “Easy” and “Hard” workout simulations is presented in Table A.2.  The heart rate 
and work rate patterns for all of the subjects during the easy day training session were 
similar within each test type (see Figure A.3 A and B).  The “easy” simulation elicited 
a significantly different physiological response from the “Hard” simulation, and 
rowers rated the intensity of the “Easy” session significantly lower than the “Hard” 
session (p=0.04).   
 
Table A.2.  Laboratory workout simulations, mean ± SD (range) 
 
 Easy Hard p-value 
Mean VO2 (ml/kg/min) 32.1 ± 2.7 
(28.05-36.2) 
33.5 ± 4.6 
(28.3-39.5) 
0.26 
Peak VO2 (ml/kg/min) 44.3 ± 3.8 
(39.1-50.4) 
47.8 ± 5.9 
(40.4-56.3) 
0.01 
Mean HR (bpm) 151.7 ± 15.1 
(134.5-174.5) 
160.4 ± 14.6 
(144.8-175.9) 
0.06 
Peak  HR (bpm) 180.6 ± 11.4 
(168.3-196.9) 
189.7 ± 8.4 
(178.7-198.5) 
0.04 
Mean work rate (w) 138.0 ± 19.7 
(111.1-162) 
152.1 ± 22.0 
(127.2-180.7) 
<0.001 
Peak work rate (w) 242.8 ± 39.6 
(192-293) 
298.2 ± 25.5 
(264-319) 
0.01 
Post-test blood lactate concentration 
(mmol/L) 
2.96 ± 1.5 
(1-5.2) 
6.9 ± 2.3 
(4.4-9.8) 
0.01 
Total EE (kcal) 286.9 ± 42.0 
(225.9-349) 
272.5 ± 48.2 
(216-347.3) 
0.29 
Rate EE (kcal/min) 11.2 ± 2.4 
(7.8-13.7) 
12.0 ±2.2 
(9.8-15.8) 
0.41 
VAS intensity rating (mm) 40.2 ± 18.0 
(25-63) 
79.4 ±8.6 
(64-90.4) 
0.04 
 
 
 
 
 
 
 
 
 272 
 
 
 
 
Figure A.3 A.  Graphic example “Easy” workout simulation  
 
 
 
 
 
 
Figure A.3 B.  Graphic example “Hard” workout simulation  
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Summary of training sessions outside of the lab are presented in Table A.3.  
Eighty-one training sessions were recorded and analyzed (7±3 sessions per rower; 
range: 2-12 sessions).   
 
Table A.3.  Training sessions outside of lab 
 
 Mean±SD 
Mean training duration (min/session) 
 
102.1±33.9 
Training HR (bpm) 
 
118.9±12.3 
Peak HR during training (bpm) 
 
176.15.3 
Percent time in HR zone (%) 
Zone 1: <55% 
Zone 2: 55-64% 
Zone 3: 65-74% 
Zone 4: 75-84% 
Zone 5: 85-94% 
Zone 6: >95% 
 
30.9±16.1 
22.8±8.0 
19.4±6.4 
14.0±7.7 
10.0±7.8 
2.5±4.0 
Mean training load (summated HR zone method)  
 
263.0±109.4 
Mean training load (sessionRPE method) 
 
6029.8±3830.0 
 
 
Training load varied by session type, and this data is presented in Table A.4.  
There were no significant differences in training time or absolute TRIMP among the 
four session types.  However, relative TRIMP during steady-state/drills training was 
significantly lower than during the strength/power (p=0.02) and endurance training 
(p<0.001, Figure A.4 A).  VAS intensity ratings during steady-state/drills training 
were also significantly lower than during the strength/power (p=0.009) and endurance 
training (p<0.001, Figure A.4 B).   
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Table A.4.  Training loads according to session type 
Training session type Number of 
sessions (n) 
Session duration 
(min) 
VAS intensity rating 
(mm) 
TRIMP  
(summed HR) 
Steady-state, drills 35 93.1±29.8 40.7±22.6 215.5±86.6 
Strength and power 20 97.5±30.7 64.9±16.1 265.9±94.7 
Endurance 21 115.5±35.2 72.7±19.7 321.4±115.3 
Mixed 5 126.8±47.2 57.3±9.8 338.5±147.4 
 
 
Figure A.4. A and B. Training load distribution quantified by VAS intensity rating (A) 
and TRIMP (B),  according to session type.  *Significantly different from speed/power 
and endurance sessions. 
 
                
  
There was a significant correlation between training loads calculated using the 
TRIMP (HR summation) and sessionRPE methods (r=0.88, p<0.001).  After 
accounting for time in both methods, there was still a significant correlation between 
VAS intensity rating and relative TRIMP (r=0.61, p<0.001).  Linear regression 
analysis revealed that both sessionRPE and VAS intensity rating were significant 
predictors of TRIMP (Figure A.5 A) and relative TRIMP (Figure A.5 B), respectively 
(p<0.001).   
 
 
 
A B 
* 
* 
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Figure A.5 A and B.  Relationship between training load calculated using the absolute 
(A) and relative (B) sessionRPE and TRIMP methods 
 
 
 
 
 
 
 
 
Training session type was not a significant predictor of relative TRIMP, nor 
was there a significant time-by-session type interaction.  However, training session 
TRIMP= 112.3 +0.03(sessionRPE), R2=0.80 
TRIMP= 180.3 +1.3(VAS intensity rating), R2=0.40 
B 
A 
 276 
 
duration (β=0.19, p=0.01) and training session type (β=9.8, p<0.001, R2=0.30) were 
both significant predictors of VAS intensity ratings (Figure A.6). 
 
Figure A.6.  Relationship between training session duration and VAS intensity rating 
according to training session type 
 
 
Discussion 
The present study examined the validity and application of the sessionRPE 
method for quantifying training loads of female rowers during several types of rowing 
training activities.  Our results are consistent with previous investigations.  We found 
good agreement between the session RPE method using our VAS-intensity rating and 
the summated heart rate zone method (17) during both in-laboratory simulations of 
training, and rowing training outside of the lab.  Given the importance of high-
intensity training to performance, the intermittent nature of rowing, and difficulties 
associated with collecting HR data during rowing training, the sessionRPE method 
provides a valid alternative to monitoring training load in this group of athletes.   
Differentiation of training session types and relation to sessionRPE has not 
been previously reported.  Rowers in this study trained, on average, six times per 
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week, and there were often two separate training sessions per day of varying intensity.  
The four session types differentiated in this study were the combined result of subject 
report, analysis of HR data, and familiarization with goals of rowing training (RJD, 
SKK, KAA, EKC).  Training sessions consisting of steady state exercise and drills 
were related to a technical focus, not intensity.   During these sessions, there was very 
little pulling at full pressure (maximal workload) and HR remained <75% of HRmax 
(see “Easy” workout simulation).   Strength/power and endurance sessions consisted 
of several bouts or intervals of short (2K or less), full-pressure (maximal workload) 
pieces.  Intensity during these sessions was high, despite the rest time between 
intervals (see “Hard” workout simulation).   
  Data from this study also show that rowers in our study spent much of their 
training time working below 75% of their maximal HR, which is consistent with 
previous findings (4). This is due largely to the fact that the time spent within each HR 
zone or as a percent of maximal HR, included sedentary/non-active time during 
training (e.g. waiting for instruction, paddling back to the start, etc).  The intermittent 
nature of rowing training likely skewed the amount of time spent below a certain 
threshold, and we controlled for this time factor in the analysis of relative TRIMP and 
VAS intensity rating. 
 The limitations of this study include the absence of measured resting HR for 
each subject, which limits our ability to examine each individual’s HR response to 
training and predict EE outside of the lab.  Also, our small sample size was small and 
we collected a limited number of training sessions.  It would be useful to quantify 
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training load using the two methods in several rowers on the same team, during the 
same workout sessions to examine the reliability within- and between-subjects.   
Conclusions: Within the limitations of this study, we found the sessionRPE 
method to be a valid metric of training load.  Additionally, the method’s convenience, 
cost-effectiveness, and non-invasiveness makes it a feasible option for researchers and 
coaches to quantify and monitor training load.  From a practical standpoint, 
application of the sessionRPE method would allow coaches to evaluate and compare 
adaptation to training within- and between individuals.   
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Appendix 2.  Voluntary informed consent 
 
Cross-sectional study consent form 
Investigator: Diane M. DellaValle, MS, RD & Dr. Jere D. Haas, PhD  
 
Purpose of the Study:  The purpose of this research is to investigate the association 
between iron status, fitness, and physical activity level in women. 
 
Procedures:  Participation in this research will first entail completing a health history 
questionnaire and having a blood sample collected by a trained phlebotomist.  The 
blood sample will be used to determine your iron status only and will not be used for 
any other purpose.  Based on the results of the blood test you may then be asked to 
perform a maximal and sub-maximal treadmill and sport-specific ergometer (row, 
swim) tests, having a body composition test done by two non-invasive techniques, 
wear 3 activity monitors and maintain a physical activity record for 6 days.  In 
addition, we may ask you to return for a second body composition test once you have 
finished wearing the activity monitors for 6 assigned days.   
 
The body composition tests will consist of two parts.  The first test consists of having 
skinfold measurements performed which require a fatfold to measured at five separate 
sites (tricep, thigh, hip, bicep, and beneath you shoulder blade) using skinfold calipers.  
The second part will use a device called the Bod Pod.  This will entail wearing a one-
piece swimming suit and sitting inside a closed chamber.  For part of the test you will 
be wearing a nose clip and be breathing through a tube so we can measure your lung 
volume.   
 
Maximal aerobic capacity (VO2max) will be assessed.  The VO2max tests on the 
rowing ergometer will begin with a five minute self-selected warm-up; the work load 
will then be set back 5- 20W levels from your fastest 2K erg split time for 1.5 minutes.  
Every 1.5 minutes will be increased by 20 W until you can no longer continue.  It is 
important for you to realize that you may stop when you wish because of feelings of 
fatigue or any other discomfort.  We may stop the test at any time because of signs of 
fatigue, symptoms you may experience, or equipment malfunction.  During the test 
you will also be asked to wear a nose-clip and mouthpiece, which will be supported by 
a head device.  For the test you will be breathing only through your mouth into a hose 
that is connected to a metabolic cart for the measurement of oxygen uptake.  You will 
also be asked to wear a heart rate monitor that will be strapped to your chest.  
 
The endurance test and will also be on the rowing ergometer and will consist of a 4K 
time trial.  After a 5-min self-selected warm-up, you will be rowing at a workload 
equivalent to 85% of your maximal level reached during the maximal exercise test.  
The test will be conducted in 1000 m intervals, after every 1000 m, there will a 60-sec 
break during which we will collect a small blood sample from your finger and/or ear 
lobe. At the last 400 m of the test, you will be asked to sprint to the finish, as you 
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would in a boat race.   During this test you will be fitted with a mouthpiece, nose clip 
and heart rate monitor as described above.  The endurance test will be performed on a 
separate day as the maximal exercise test, but the test must be completed within 7 days 
of each other. 
 
During both the VO2max and endurance tests, we will collect small blood samples 
from your finger or earlobe to determine your blood lactate levels.   
 
Outside of the lab, you will be asked to wear 1 activity monitor and maintain a 
physical activity record/training log for 7 assigned days.  The monitor is worn on the 
waist band during waking hours (except for bathing and swimming), and you will be 
instructed on how to remove it before you go to bed and where to place it when you 
wake up in the morning.   
 
This study requires a great deal of preparation and includes a considerable expense to 
us.  Thus, if you cannot keep your phlebotomy appointment or other testing 
appointments, we ask that you give us at least 24 hours notice so that we can 
reschedule a time for you.  Since each subject can have a great impact on the study, it 
is important that you carefully read through each questionnaire and complete all of the 
questions.  If you feel that this is not possible, please do not join the study.   
 
Discomforts and Risks:  This study requires a small sample of blood (10 mL) to be 
collected from each subject.  The risk this entails includes fainting, nausea, and 
dizziness in some persons.  Our phlebotomist is trained to deal with these situations, 
should they occur.  Some minor annoyances may include slight soreness and bruising 
on your arm due to the blood collection, and on your fingers due to the finger pricks to 
collect samples for lactate analysis.  There are no major risks involved in filling out 
the questionnaires and daily logs.  To protect subject identity, all information obtained 
is filed according to an assigned subject number in a locked filing cabinet.  Your name 
and assigned subject number will be kept in a separate locked filing cabinet that only 
the principle investigator will have access to. 
 
Any discomforts due to exercise testing are not uncommon to those participating in 
training and competition in endurance sporting activities.  Healthy individuals rarely 
experience the following risks while performing moderate or maximal exercise: 
abnormal blood pressure responses, musculo-skeletal injuries, dizziness, difficulty in 
breathing, and in rare instances heart attack or death.   
 
Benefits:   You will receive your blood work results after your sample has been 
analyzed.  Also, if you are recognized as anemic, you will be notified so you can be 
treated appropriately.  In addition, you will receive information about you body 
composition, fitness level, and physical activity level.  This information will be useful 
to your training program. 
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Duration/Time: The health history questionnaire will take approximately 45 minutes 
to complete.  The blood sample will take approximately 5 minutes to collect.  The 
maximal exercise test will take 45 minutes to complete, the sub-maximal test will take 
1 hour, the body composition tests will take 30 minutes, and wearing the activity 
monitor and maintaining the physical activity record will be performed for 7 assigned 
days.   
 
Compensation:  You will not be monetarily compensated for your participation in this 
study. 
 
Contact Information:  If you have questions at any time about the study or the 
procedures, (or you experience adverse effects as a result of participating in this 
study,) you may contact the Investigator, Diane M DellaValle at (607) 229-3683, 213 
Savage Hall, Ithaca, NY 14853.  If you have questions about your rights as a 
participant, contact the Cornell University Office of Research Integrity and Assurance, 
Institutional Review Board (IRB) for Human Participants at (607) 255-5138, or access 
their website at http://www.irb.cornell.edu/.  You may also report your concerns or 
complaints anonymously through Ethicspoint or by calling toll free at 1-866-293-
3077. Ethicspoint is an independent organization that serves as a liaison between the 
University and the person bringing the complaint so that anonymity can be ensured.  
You may also contact the Syracuse University IRB with any questions about your 
rights as a participant, or with any questions, concerns, or complaints you wish to 
address to someone other than the investigator, or in the event that you cannot reach 
the investigator, or for any research-related injuries (ph: 315-443-3013, email: 
orip@syr.edu, web: http://orip.syr.edu).   
 
Right to Ask Questions and to Withdraw 
You are free to decide whether or not to participate in this study and are free to 
withdraw from the study at any time.  If you choose to withdraw from the study at any 
time your present and future relationship with Cornell University and Syracuse 
University will not be adversely affected.  Before you sign this form, please ask 
questions about any aspects of the study, which are unclear to you.  In addition you 
will be given a copy of this form to keep for your records. 
Consent: By signing this paper, I am indicating that I understand and agree to take part in this 
research study, and I am indicating that I am 18 years of age or older.  
 
___________________   ___________________ 
Your signature      Date 
 
______________________   ___________________ 
Researcher’s signature     Date    
 
 
This consent form will be kept by the researcher for at least three years beyond the end of the study 
and was approved by the IRB on (06/10/2008) 
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 (RCT Consent Form) 
Investigators: Diane M. DellaValle, MS, RD & Dr. Jere D. Haas, PhD  
 
Purpose of the Study:  The purpose of this research is to investigate the association 
between iron status, fitness, and physical activity level in women. 
 
Procedures:  A blood sample will be collected by a trained phlebotomist to determine 
your iron status only and will not be used for any other purpose.  Blood samples will 
be collected at weeks 4 and 8 during the 8-week study.  You will be randomized to a 
Placebo (no nutritional value) or supplement (iron) group for 8 weeks.  Neither 
subjects nor investigators involved in monitoring and measuring subjects will know 
who received which treatment until after all hypotheses have been tested.   You will be 
given and instructed to consume 2 capsules every day for 8 weeks.  Minor 
gastrointestinal discomfort is a potential side-effect of iron supplementation.  You are 
to consume the capsules with citrus juice to enhance iron absorption, and with meals 
to reduce gastrointestinal side effects.  You are to avoid consumption of any other 
multivitamin/mineral supplements during the 8 week study period.  You are required 
to record capsule consumption, dietary intake, and keep records of medication and 
other permitted supplement intake, illness, menstrual status, GI symptoms, physical 
activity and training, and any musculoskeletal problems in a daily log.  
 
Body composition will be measured at weeks 4 and 8.  The body composition tests 
will consist of two parts.  The first test consists of having skinfold measurements 
performed which require a fat-fold to measured at five separate sites (tricep, thigh, hip, 
bicep, and beneath you shoulder blade) using skinfold calipers.  The second part will 
use a device called the Bod Pod.  This will entail wearing a one-piece swimming suit 
and sitting inside a closed chamber.  For part of the test you will be wearing a nose 
clip and be breathing through a tube so we can measure your lung volume. 
 
Maximal aerobic capacity (VO2max) will be assessed at 8 weeks.  The VO2max tests 
on the rowing ergometer will begin with a five minute self-selected warm-up; the 
work load will then be set back 5- 20W levels from your fastest 2K erg split time for 
1.5 minutes.  Every 1.5 minutes will be increased by 20 W until you can no longer 
continue.  It is important for you to realize that you may stop when you wish because 
of feelings of fatigue or any other discomfort.  We may stop the test at any time 
because of signs of fatigue, symptoms you may experience, or equipment malfunction.  
During the test you will also be asked to wear a nose-clip and mouthpiece, which will 
be supported by a head device.  For the test you will be breathing only through your 
mouth into a hose that is connected to a metabolic cart for the measurement of oxygen 
uptake.  You will also be asked to wear a heart rate monitor that will be strapped to 
your chest.  
 
The endurance test will be conducted at week 8, and will also be on the rowing 
ergometer and will consist of a 4K time trial.  After a 5-min self-selected warm-up, 
you will be rowing at a workload equivalent to 85% of your maximal level reached 
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during the maximal exercise test.  The test will be conducted in 1000 m intervals, after 
every 1000 m, there will a 60-sec break during which we will collect a small blood 
sample from your finger and/or ear lobe. At the last 400 m of the test, you will be 
asked to sprint to the finish, as you would in a boat race.   During this test you will be 
fitted with a mouthpiece, nose clip and heart rate monitor as described above.  The 
endurance test will be performed on a separate day as the maximal exercise test, but 
the test must be completed within 7 days of each other.  During both the VO2max and 
endurance tests, we will collect small blood samples from the finger or earlobe to 
determine your blood lactate levels.   
 
Outside of the lab, you will be asked to wear 1 activity monitor worn on the waist 
band and maintain a physical activity record/training log for 1 week at a time, every 
other week throughout the 8 weeks.  The waist-mounted monitor is worn during 
waking hours (except for bathing and swimming), and you will be instructed on how 
to remove it before you go to bed and where to place it when you wake up in the 
morning.  This study requires a great deal of preparation and includes a considerable 
expense to us.  Thus, if you cannot keep your phlebotomy and other testing 
appointments, we ask that you give us at least 24 hours notice so that we can 
reschedule a time for you.  Since each subject can have a great impact on the study, it 
is important that you carefully read through each questionnaire and complete all of the 
questions.  If you feel that this is not possible, please do not join the study.   
 
Discomforts and Risks:  This study requires a small sample of blood (10 mL) to be 
collected from each subject.  The risk this entails includes fainting, nausea, and 
dizziness in some persons.  Our phlebotomist is trained to deal with these situations, 
should they occur.  Some minor annoyances may include slight soreness and bruising 
on your arm due to the blood collection, and on your fingers or ear lobes due to the 
pricks to collect samples for lactate analysis.  There are no major risks involved in 
filling out the questionnaires and daily logs.  To protect subject identity, all 
information obtained is filed according to an assigned subject number in a locked 
filing cabinet.  Your name and assigned subject number will be kept in a separate 
locked filing cabinet that only the principle investigator will have access to.  Minor 
gastrointestinal discomfort is a potential side-effect of iron supplementation.   
 
Any discomforts due to exercise testing are not uncommon to those participating in 
training and competition in endurance sporting activities.  Healthy individuals rarely 
experience the following risks while performing moderate or maximal exercise: 
abnormal blood pressure responses, musculo-skeletal injuries, dizziness, difficulty in 
breathing, and in rare instances heart attack or death.   
 
Benefits:  You will receive your blood work results after your sample has been 
analyzed.  Also, if you are recognized as anemic, you will be notified so you can be 
treated appropriately.  In addition, you will receive information about you body 
composition, fitness level, and physical activity level.  All information give to you will 
benefit your training program. 
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Duration/Time:  The health history questionnaire will take approximately 45 minutes 
to complete.  The blood sample will take approximately 5 minutes to collect.  The 
maximal exercise test will take 30 minutes to complete, the submaximal/endurance 
test will take 60 min, and the body composition tests will take 15 minutes.  The 
activity monitor will be worn for 1 week at a time every other week, and maintaining 
the physical activity record will be performed daily throughout the 8 weeks.   
 
Compensation:  You will not be monetarily compensated for your participation in this 
study. 
 
Contact Information:  If you have questions at any time about the study or the 
procedures, (or you experience adverse effects as a result of participating in this 
study,) you may contact the Investigator, Diane M DellaValle at (607) 229-3683, 213 
Savage Hall, Ithaca, NY 14853.  If you have questions about your rights as a 
participant, contact the Cornell University Office of Research Integrity and Assurance, 
Institutional Review Board (IRB) for Human Participants at (607) 255-5138, or access 
their website at http://www.irb.cornell.edu/.  You may also report your concerns or 
complaints anonymously through Ethicspoint or by calling toll free at 1-866-293-
3077. Ethicspoint is an independent organization that serves as a liaison between the 
University and the person bringing the complaint so that anonymity can be ensured.  
You may also contact the Syracuse University IRB with any questions about your 
rights as a participant, or with any questions, concerns, or complaints you wish to 
address to someone other than the investigator, or in the event that you cannot reach 
the investigator, or for any research-related injuries (ph: 315-443-3013, email: 
orip@syr.edu, web: http://orip.syr.edu).   
 
Right to Ask Questions and to Withdraw 
You are free to decide whether or not to participate in this study and are free to 
withdraw from the study at any time.  If you choose to withdraw from the study at any 
time your present and future relationship with Cornell University or Syracuse 
University will not be adversely affected.  Before you sign this form, please ask 
questions about any aspects of the study, which are unclear to you.  In addition you 
will be given a copy of this form to keep for your records. 
Consent: By signing this paper, I am indicating that I understand and agree to take part in this 
research study, and I am indicating that I am 18 years of age or older.  
___________________   ___________________ 
Your signature      Date 
 
______________________   ___________________ 
Researcher’s signature     Date    
 
 
This consent form will be kept by the researcher for at least three years beyond the end of the study 
and was approved by the IRB on (06/10/2008) 
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Appendix 3  Health and demographic questionnaire 
1.  Health & Demographics Questionnaire, pg1 
 
Age:      Date of Birth:     Sex: Female  
 
Height:    Weight:  
 
Are you currently under a physician’s care?   Yes    No 
 
Do you smoke:     Yes   No If yes, how many cigarettes per day?  
 
Do you drink alcohol:   Yes    No      If Yes, frequency and amount of 
alcohol:__________ 
 
Ethnicity (please check only one): 
 HISPANIC OR LATINO                   
 NOT HISPANIC OR LATINO 
 
Race (please check only one):  
 AMERICAN INDIAN/ALASKAN NATIVE    WHITE 
 ASIAN        HAWAIIAN/PACIFIC 
ISLANDER  
 BLACK OR AFRICAN AMERCIAN   
Eating Behavior 
What time do you usually eat the following meals? 
 
 Breakfast:     Dinner:  
 Lunch:      Snack(s):  
 
Are there foods you don’t eat because they are not good for you or disagree with you?  
 
    Yes   No 
 
 If yes, what foods?  
 
Are there any foods you don’t eat because of medication you are on?  Yes    No 
 
 If yes, what foods?  
 
Are there any foods you make it a point to eat because you feel they are good for your health?  
 
    Yes   No 
 
 If yes, what foods?  
 
Are there any foods you don’t eat because they are difficult to chew?   Yes    No 
 
 If yes, what foods?  
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Are you a vegetarian?   Yes    No  Are you a vegan?   Yes    No 
Do you eat: 
Fish   Yes    No   Chicken/poultry  Yes    No  
Eggs   Yes    No   Beef    Yes    No  
Milk   Yes    No    
 
 Health & Demographics Questionnaire, pg2 
Medications: 
Are you presently taking medication (over the counter and/or prescription)?  Yes    No 
If yes, please specify drug(s), when last taken, and dose: 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_______ 
 
Have you taken any analgesics (aspirin, Tylenol, ibuprofen, etc) in the past month?  Yes  
  No   
If Yes, give the name:________________, When last taken:__________ and 
dose:____________ 
 
Have you taken any pain relievers in the past 3 months?  Yes    No 
If Yes, give the name:________________, When last taken:__________ and dose:_______ 
 
Do you take any medications for depression or sleeping difficulty?   
 Currently, Yes  Type and Brand:__________________ 
  Currently, No  When Stopped:_________Type and Brand used 
before:______________ 
  Never 
 
Do you take antihistamines?  Yes    No  If Yes, please specify:_________________ 
 
Are you taking oral contraceptives?   Yes    No  If Yes, please 
specify:_______________ 
 
Are you taking any vitamin, mineral, or herbal supplements?   Yes    No 
 If Yes, please specify item, when last taken, and dose:   
___________________________________________________________________________
___________________________________________________________________________
______ 
 
Have you ever received radiation therapy?  Yes    No 
 
Have you ever received chemotherapy?  Yes    No 
 
Weight History:  
 
 Current weight:  
 
 Highest past adult weight (excluding pregnancy):  
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  When did this occur?  
 
 Lowest past adult weight:    When did this occur?  
 
 Have you experienced any weight change in the last 6 months?  Yes    No 
  
 If yes, did you gain or lose?    How much?  
 
 When did this weight change occur?  
 
 
 
 Health & Demographics Questionnaire, pg3 
Medical and Surgical History Overview 
1) Acute problems (please list, explain if necessary):  
________________________________________________________________________
________________________________________________________________________
______   
 
2) Recurrent problems (please list, explain if necessary):  
________________________________________________________________________
________________________________________________________________________
______ 
 
3) Chronic problems (please list, explain if necessary):  
________________________________________________________________________
________________________________________________________________________
______ 
 
4) Did you have a fever, inflammatory or any infectious diseases in the past 3 months?   
 Yes    No   If Yes, please explain what it was and how long ago:  
________________________________________________________________________
___ 
 
5) History of fainting when blood samples are taken?   Yes    No 
 
6) Exercise-induced asthma?   Yes    No 
 
7) Any allergies   Yes    No         
If Yes, please explain: 
_______________________________________________ 
 
8) History of digestive problems?   Yes    No     
If Yes, please explain: 
_______________________________________________ 
 
9) Glucose intolerance?   Yes    No   
   
10) Abnormal blood lipid profile?   Yes    No   
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11) Recurrent dislocations?   Yes    No   
   
12) Recent (past 3 months) musculoskeletal injuries?   Yes    No     
If Yes, please 
explain:_______________________________________________ 
 
13) Past orthopedic surgery?   Yes    No     
If Yes, please 
explain:_______________________________________________ 
 
14) Other major surgery?   Yes    No     
If Yes, please 
explain:_______________________________________________ 
 
 
Health & Demographics Questionnaire, pg4 
Do you have, or have you had any of the following?  
    High blood pressure         Diabetes  
    Heart trouble          Ulcers (of the digestive system) 
    Thyroid or other glandular disorders   Other stomach or intestinal 
disorders 
    Liver disease         Kidney disease 
    Anemia           Depression 
    Cancer          Respiratory illness (asthma, 
etc.) 
    Angina pectoris         Myocardial infarction 
    ECG disorder      
    Heart murmur 
    Cardiac rhythm abnormalities 
    Other, please specify ______________________________________________________ 
 
 
Have you ever been diagnosed as anemic or iron deficient?   Yes    No 
If Yes, which type?  Please check the following and indicate the date of the most recent 
diagnosis.   
    Sickle cell anemia or thalassemia      
    Pernicious anemia        
    Aplastic anemia   
    Hemolytic anemia 
    Iron-deficiency only        
    Hypoplastic anemia         
    Iron-deficiency anemia       
    Other, please specify ______________________________________________________ 
 
Have you ever been diagnosed, or have a family history of iron overload disease 
(hemochromotosis)?   Yes    No 
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Do you have any of the following eating related problems? Please check all those that apply:  
 
    Sore mouth         Nausea   
    Swallowing problems       Vomiting  
    Chewing problems        Diarrhea  
    Choking problems        Constipation  
    Food allergies:_____________________ 
    Salivation problems       
    Other, please specify      
 
Have you ever been diagnosed/treated for an eating disorder(s)/ disordered eating 
behaviors?   Yes    No     
If Yes, please explain type and 
date(s):_______________________________________________ 
 
Are you currently on any kind of special diet?  Yes    No 
 
 If yes, what kind (low-salt, low-fat, 
etc.):_______________________________________ 
 
 
 
Health & Demographics Questionnaire, pg5 
Menstrual Status 
1) At what age did you first menstruate?___________________________________ 
2) What was the date of your last menstrual period?__________________________ 
3) In the previous 12 months, has your menstrual cycle been (please check only one):  
 
 Regular (normal cycles of approximately equal length) 
 
 Irregular (amenorrhea; absence of periods; irregular periods; missed cycles, 
cycles of varying length, marked changes in flow; when did the abnormality start? )  
Please explain:  
 
 I did not menstruate in the last 12 months 
 
4) How many days does your menstrual cycle last (from the beginning of the menstrual 
period to the beginning of the next period?  
 
5) Your menstrual blood flow is (circle one): Low  Normal  High 
 
6) How many pads/tampons do you use per day on the peak-flow day:  _______ 
pads/tampons 
 
7) How many days of heavy flow do you experience:___________ days of heavy flow 
 
8) Do you use an intrauterine device (IUD)?   Yes    No 
If Yes, how long have you been using it?________________ 
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9) Have you taken any hormones (birth control pills, Depo-Provera , hormone 
replacement therapy, etc.) in the past year?  
 
10) Have you given birth in the past 12 months?  Yes    No 
 
11) Are you planning to become pregnant within the next 12 months?  Yes    No 
 
 
Blood Loss 
1)  Do you donate blood regularly?   Yes    No 
2) When was the last time you donated blood:____________ 
 
3) How much blood did you donate:____________ 
 
4) Did you lose blood for reasons other than menstruation in the past 3 months?  Yes    
No 
If Yes, how much:  __________________ and When: ____________________ 
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Appendix 4 Female athlete screening tool (FAST):Instructions: Please circle the answer 
that applies best to each of the numbered statements.  Exercise = Physical activity lasting >20 min; 
Practice = Scheduled time allotted by coach to work as a team or individually in order to improve 
performance; Training = Intense physical activity.  The goal is to improve fitness level in order to 
perform optimally. 
1.  I participate in additional physical activity >20 min in 
length on days that I have practice or competition. 
Frequently Sometimes Rarely Never 
2.  If I cannot exercise, I find myself worrying that I will 
gain weight. 
Frequently Sometimes Rarely Never 
3.  I believe that most female athletes have some form of 
disordered eating habits. 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
4.  During training, I control my fat and calorie intake 
carefully.   
Frequently Sometimes Rarely Never 
5.  I do not eat foods that have more than 3 g of fat. Strongly 
agree 
Agree Disagree Strongly 
disagree 
6.  My performance would improve if I lost weight. Strongly 
agree 
Agree Disagree Strongly 
disagree 
7. If I got on the scale tomorrow and gained 2 pounds, I 
would practice or exercise harder or longer than usual. 
Frequently Sometimes Rarely Never 
8.  I weigh myself: Daily >2 times per 
week 
Weekly Monthly 
9.  If I choose to exercise on the day of a competition,  I 
exercise for: 
>2 hours 45 min –   1 
hour 
30-45 min <30 min 
10.  If I know that I will be consuming alcoholic 
beverages, I will skip meals on that day or on the 
following day. 
Frequently Sometimes Rarely Never 
11. I feel guilty if I choose fried foods for a meal. Frequently Sometimes Rarely Never 
12.  If I were to be injured, I would still exercise even if I 
was instructed not to do so by my athletic trainer, 
physician, or coach. 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
13.  I take dietary and/or herbal supplements in order to 
increase my metabolism and/or to assist in burning fat. 
Frequently Sometimes Rarely Never 
14.  I am concerned about my percent body fat. Frequently Sometimes Rarely Never 
15.  Being an athlete, I am very conscious about 
consuming adequate calories and nutrients on a daily 
basis. 
Frequently Sometimes Rarely Never 
16. I am worried that if I were to gain weight my 
performance would decline. 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
17.  I think that being thin is associated with winning. Strongly 
agree 
Agree Disagree Strongly 
disagree 
18. I train intensely for my sport so that I will not gain 
weight. 
Frequently Sometimes Rarely Never 
19.  During the season, I choose to exercise on my one 
day off from practice or competition. 
Frequently Sometimes Rarely Never 
20.  My friends tell me that I am thin, but I feel fat. Frequently Sometimes Rarely Never 
21.  I feel uncomfortable eating around others. Frequently Sometimes Rarely Never 
22.  I limit the amount of carbohydrates that I eat. Frequently Sometimes Rarely Never 
23.   I try to lose weight to please others. Frequently Sometimes Rarely Never 
24.  If I were unable to compete in my sport I would not 
feel good about myself. 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
25.If I were injured and unable to exercise, I would 
restrict my calorie intake. 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
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26. In the past 2 years, I have been unable to compete 
due to an injury. 
>7 times 4-6 times 1-3 times No 
significant 
injuries 
27.  During practice I have trouble concentrating due to 
feelings of guilt about what I have eaten that day. 
Frequently Sometimes Rarely Never 
28.  I feel that I have a lot of good qualities. Strongly 
agree 
Agree Disagree Strongly 
disagree 
29.  At times I feel that I am no good at all. Strongly 
agree 
Agree Disagree Strongly 
disagree 
30.  I strive for perfection in all aspects of my life. Strongly 
agree 
Agree Disagree Strongly 
disagree 
31. I avoid eating meat in order to stay thin. Strongly 
agree 
Agree Disagree Strongly 
disagree 
32. I am happy with my present weight. Yes No   
33.  I have done things to keep my weight down that I 
believe are unhealthy. 
Frequently Sometimes Rarely Never 
 
 
Please indicate to what extent the following factors have contributed to your PRESENT eating patterns by writing 
in the appropriate number next to each question.  Also for each question, please circle “was,” meaning the past 
and/or “is,” meaning the present, as it applies appropriately to you. 
 
 
 
0 1 2 3 4 5 6 7 8 9 
No Contribution    Moderate      Strong 
    Contribution     Contribution 
 
 
 
_______  Weight loss was (past) /is (at present) required for performance excellence in my sport. 
 
 
_______  Weight loss was / is required to meet a lower weight category. 
 
 
_______  Weight loss was / is required to reach aesthetic ideals of beauty. 
 
 
_______  A member of the athletic personnel (e.g. coach, trainer, psychologist) made a remark concerning 
my need for weight loss. 
 
_______  A member of my team made a remark concerning my need for weight loss. 
 
 
_______  I had / have to be weighed in front of others (e.g. team members). 
 
 
_______  Each team member’s weight was / is made public knowledge. 
 
 
_______  I was / am required to reduce my level of body fat in accordance with coach’s (or other athletic  
personnel) desired ideal level of body fat. 
 
_______  I was / am fearful of losing a position on the team or of being kicked off of the team if I did not /  
do not lose weight. 
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Appendix 5 Eating inventory (EI):  Read each of the following 36 statements carefully.  If you agree 
with the statement, or feel that it is true as applied to you, answer true by circling the “T”.  If you disagree with the 
statement, or feel that it is false as applied to you, answer false by circling the “F”.   
        
  1. When I smell a freshly baked pizza, I find it very 
difficult to keep from eating, even if I have just 
finished a meal. 
T F   
19. Being with someone who is eating  
often makes me hungry enough to eat 
also. 
T F 
  2. I usually eat too much at social occasions, like 
parties and picnics. 
T F   20. When I feel sad or blue, I often overeat. T F 
  3. I am usually so hungry that I eat more than 
three times a day. 
T F   
21. I enjoy eating too much to spoil it by 
counting calories, counting grams of fat, 
or watching my weight. 
T F 
  4. When I have eaten my quota of calories or fat, I 
am usually good about not eating any more. 
T F   
22. When I see a real delicacy, I often get so 
hungry that I have to eat it right away. 
T F 
  5. Dieting is so hard for me because I just get too 
hungry. 
T F   
23. I often stop eating when I am not really 
full as a conscious means of limiting the 
amount that I eat. 
T F 
  6. I deliberately take small helpings as a means of 
controlling my weight. 
T F   
24. I get so hungry that my stomach often 
seems like a bottomless pit. 
T F 
  7. Sometimes things just taste so good that I keep 
on eating even when I am no longer hungry. 
T F   
25. My weight has hardly changed at all in 
the last ten years. 
T F 
  8. Since I am often hungry, I sometimes wish that 
an expert would tell me that I have had enough 
to eat or that I can have some more. 
T F   
26. I am always hungry, so it is hard for me 
to stop eating before I finish the food on 
my plate. 
T F 
  9. When I feel anxious, I find myself eating. T F   
27. When I feel lonely, I console myself by 
eating. 
T F 
10. Life is too short to worry about dieting. T F   
28. I consciously hold back at meals in order 
not to gain weight. 
T F 
11. Since my weight goes up and down, I have gone 
on reducing diets more than once. 
T F   
29. I sometimes get very hungry late in the 
evening or at night. 
T F 
12. I often feel so hungry that I just have to eat 
something. 
T F   30. I eat anything I want, any time I want. T F 
13. When I am with someone who is overeating, I 
usually overeat too. 
T F   
31. Without even thinking about it, I take a 
long time to eat. 
T F 
14. I have a pretty good idea of the number of 
calories or grams of fat in common foods. 
T F   
32. I count calories or grams of fat as a 
conscious means of controlling my 
weight. 
T F 
15. Sometimes when I start eating, I just can’t seem 
to stop. 
T F   
33. I do not eat some foods because they 
make me fat. 
T F 
16. It is not difficult for me to leave something on 
my plate. 
T F   
34. I am always hungry enough to eat at any 
time. 
T F 
17. At certain times of the day, I get hungry 
because I have gotten used to eating then. 
T F   
35. I pay a great deal of attention to changes 
in my figure. 
T F 
18. While on a diet, if I eat food that is not allowed, 
I consciously eat less for a period of time to 
make up for it. 
T F   
36. While on a diet, if I eat a food that is not 
allowed, I often then splurge and eat 
other high-calorie foods. 
T F 
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Eating inventory, page 2 
37. How often are you dieting in a conscious effort to 
control your weight? 
  
46. How likely are you to consciously eat slowly in order to cut 
down on how much you eat? 
1 
rarely 
2 
sometimes 
3 
usually 
4 
always 
  
1 
unlikely 
 
2 
slightly 
likely 
3 
moderately 
likely 
4 
very  
likely 
38. Would a weight fluctuation of five pounds affect the 
way you live your life? 
  47. How frequently do you skip dessert because you are  
no longer hungry? 
1 
not at all 
2 
slightly 
3 
moderately 
4 
very much 
  
1 
almost  
never 
2 
seldom 
 
3 
at least  
once a week 
4 
almost  
every day 
39. How often do you feel hungry?   48. How likely are you to consciously eat less than you want? 
1 
only at meal 
times 
 
2 
sometimes 
between meals 
3 
often between 
meals 
4 
almost always 
 
  
1 
unlikely 
 
2 
slightly  
likely 
3 
moderately 
likely 
4 
very  
likely 
40. Do your feelings of guilt about overeating help you to 
control your food intake? 
  
49. Do you go on eating binges even though you are not hungry? 
1 
never 
2 
rarely 
3 
often 
4 
always 
  
1 
never 
 
2 
rarely 
 
3 
sometimes 
 
4 
at least  
once a week 
41. How difficult would it be for you to stop eating 
halfway through dinner and not eat for the next four 
hours? 
  
 
 
50. To what extent does this statement describe your eating 
behavior? 
“ I start dieting in the morning, but because of any number of things 
that happen during the day, by evening I have given up and eat what 
I want, promising myself to start dieting again tomorrow. ” 
1 
easy 
 
2 
slightly 
difficult 
3 
moderately 
difficult 
4 
very difficult 
  
42. How conscious are you of what you are eating?   1 
not  
like me 
 
2 
a little  
like me 
 
3 
pretty good 
description  
of me 
4 
describes 
me perfectly 
 
1 
not at all 
2 
slightly 
3 
moderately 
4 
extremely 
  
43. How frequently do you avoid buying a large amount 
of tempting foods? 
  
51. On a scale of 1 to 6, where 1 means no restraint in eating (eat 
whatever you want, whenever you want it) and 6 means total 
restraint (constantly limiting food intake and never “giving in”), 
what number would you give yourself? 
1 
almost never 
2 
seldom 
 
3 
usually 
 
4 
almost always 
  
44. How likely are you to shop for low-calorie or  
low-fat foods? 
  1 Eat whatever you want, whenever you want it 
 
2 Usually eat whatever you want, whenever you want it 
 
3 Often eat whatever you want, whenever you want it 
1 
unlikely 
 
2 
slightly likely 
3 
moderately 
likely 
4 
very likely 
 
  
45. Do you eat sensibly in front of others and splurge 
alone? 
  
4 Often limit food intake, but often “give in” 
 
5 Usually limit food intake, rarely “give in” 
 
6 Constantly limit food intake, never “give in” 
1 
never 
2 
rarely 
3 
often 
4 
always 
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Appendix 6 Food frequency questionnaire for dietary iron 
Think about your most recent eating habits and how often you eat each of the following foods.  Please 
mark one box for each food.  Please write in other iron-fortified foods where there is space available if 
those foods you consume are not listed.  Also, please write in vitamins/minerals, supplements and 
medications in the space available if what you consume is not listed (and check the frequency of these, 
as well).   
  Last 4 weeks Each Week Each Day 
 Preparation? 
Portion size?  
0x 1-3x 1x 2-
4x 
5-6x 1x 2-
3x 
4-
5x 
6+x 
Meats           
Beef liver           
Chicken liver           
Pork liver           
Beef           
Pork           
Chicken           
Turkey           
Tuna           
Eggs           
           
Vegetables           
Spinach           
Green peas           
Broccoli           
Legumes 
(chickpeas,lentils, 
black beans) 
          
Nuts/Seeds           
Other dark greens:           
           
Fruits/Juices           
Prune juice           
Apricots           
Raisins           
Orange juice, regular           
Orange juice, extra C           
Orange juice, other 
fortified (Calcium, D, 
other) 
          
Fortified Breakfast 
Cereals* 
Brand name?   
Portion size? 
   
           
Cream of wheat           
Raisin bran           
Special-K           
Total           
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FFQ pg2.   
Fortified Breads* 
Brand name?   
Portion size? 
Last  
4 weeks 
Each Week Each Day 
  0x 1-3x 1x 2-
4x 
5-6x 1x 2-
3x 
4-
5x 
6+x 
White           
Wheat           
Whole Wheat           
Rye           
Multigrain           
Other           
Vitamin/Mineral 
Supplements 
 
Dose?   
Brand name? 
   
Multi-vitamin           
Mega-Multi-vitamin           
Iron supplement           
Vitamin C           
Calcium           
Other:           
           
Other Supplements     
Fiber           
Other:           
           
           
Medications (please 
list) 
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Appendix 7 Food record 
Food and Activity Diary 
Instructions for Participants 
 
The following information will help you in keeping your food diaries, and is intended 
to add to the information provided to you by the members of the study staff. 
 
1. On the first line, record your name and the date of the food/activity diary. 
For example:   
 
Name: Diane M. DellaValle  Date Completed: 06/02/2004 
 
2. Record the following on your Diary sheet: 
a. Time of the food item or meal eaten 
b. Record H or C (Homemade or Commercial) 
c. Record the Place where you ate the item or meal: home, restaurant 
(specify name), friend’s house 
d. Record the Amount of each item: see Common Serving Sizes guides to 
help estimate. 
e. Description of the food:  record each item on a separate line.  If a food 
contains several items, such as a sandwich, list each ingredient on a 
separate line.  Also, indicate how the food was prepared (Baked, fried, 
broiled, grilled, with or without skin) 
For example:  
Time  H or C Place  Amount Description of Food 
8 AM  C  Home  1 c  Raisin bran cereal 
      ¾ c   2% milk 
½ c Orange juice, Tropicana, 
not from concentrate, 
some pulp 
10.00 AM C  Home  1  Fruit cocktail cup, Dole 
12.30 PM H  Home  1  Tuna fish sandwich 
    2 slices Whole wheat bread 
    ¼ c  Tuna, canned in water 
    1 t  Hellman’s mayonnaise, 
full-fat 
    2 leaves Iceberg lettuce  
4.30 PM C Friend’s house 1  Fudgesicle 
      1-12 oz can Coca-cola 
7.00 PM C  Home  1/8 of 16” Pizza, plain, DiGiorgno 
  H    3 oz  Chicken, baked, with skin 
8.30 PM C  Home  ½ c  Vanilla ice cream, 
Breyer’s full-fat   
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Food Diary 
 
Name:_______________________  Date Completed:________________
  Day:________________________ 
 
Time H or 
C* 
Place Amount Description of Food For Office 
Use Only 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
*Homemade or Commercial 
 
 
 
 
 302 
 
Appendix 8 Leisure-time physical activity (LTPA) and Rowing PR 
 
These questions are about your physical activities (exercise, sports, physically active 
hobbies...) that you may do in your LEISURE time. 
 
How often do you do VIGOROUS leisure-time physical activities for AT LEAST 10 
MINUTES that cause HEAVY sweating or LARGE increases in breathing or heart 
rate? (e.g. running, cross-country skiing, cycling, basketball) 
 
000 Never  
001-995    per day / week / month / year  
996 Unable to do this type activity  
999 Don't know  
 
About how long do you do these vigorous leisure-time physical activities each time?  
 
001-995    minutes / hours  
999 Don't know  
 
How often do you do LIGHT OR MODERATE LEISURE-TIME physical 
activities for AT LEAST 10 MINUTES that cause ONLY LIGHT sweating or a 
SLIGHT to MODERATE increase in breathing or heart rate? (e.g., walking, easy 
cycling, tennis) 
 
000 Never  
001-995    per day / week / month / year  
996 Unable to do this type activity  
999 Don't know  
 
About how long do you do these light or moderate leisure-time physical activities each 
time?  
 
001-995    minutes / hours  
999 Don't know  
 
 
Do you have a job(s) other than student (circle one)?  Yes No   
 
If Yes, what is your job(s)?          
 
How many hours per week do you work at each job?:     
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Fe & Training – Events – Crew 
 
Please indicate your personal records (PRs) from last season (Fall08-Spring09) for the 
following: 
 
How many years of rowing experience have you had?_______________ 
 
When was the last time you were on an erg?__________________________ 
 
Best (PR) 2K Erg Time:________________   
 
Best (PR) 6 K Erg Time:________________   
 
Fastest (PR) 500m split time (for a 2K):_____________  
 
Your PRESENT (what you can do NOW) 2 K Erg Time:_____________ 
 
Your PRESENT (what you can do NOW) 500m split time (for a 2K):____________ 
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Appendix 9 Iron status report 
 
Date:__________ 
 
Dear Study Participant _____, 
 
Here is a report of your iron status.  There are 4 values we examined:  
 
1) RBC (red blood cell count) – Red blood cells function in hemoglobin transport, which results 
in delivery of oxygen to the body tissues.  Low values may indicate anemia, but the cause of 
the anemia may require further testing.  
 
2) Hgb (hemoglobin) – Hemoglobin is the oxygen-carrying pigment of the RBCs.  It is composed 
of amino acids that form a single protein called globin and a compound called heme.  Heme 
contains iron atoms and the red pigment porphyrin. Low values indicate anemia, but the cause 
of the anemia may require further testing. 
 
3) Hct (hematocrit) – Hematocrit is the percentage of RBC in a volume of whole blood. Low 
values may indicate anemia, the cause of which must be confirmed by further tests 
 
4) Fer (ferritin) – Ferritin is a measure of iron stored in the liver.  Low values accompanied by 
low Hgb indicate iron deficiency anemia. 
 
Next to your values, I have included the range of normal values for your reference.  Circled below 
is a description of your iron status. 
 
Your Value    Normal Value Range 
RBC  _____   3.90 – 5.70 x10^6/uL 
Hgb  _____   12.0 – 16.0 g/dL 
Hct  _____   35.0 – 47.0 % 
Fer  _____    12 – 150 ng/mL 
 
Normal iron status:  All of your iron status measures are within the normal ranges. 
 
Anemia:  Your Fer values are within the normal range.  Your Hgb values are outside of the normal 
range.  An iron supplement or multi-vitamin containing iron may be of benefit to you at this time.  If 
you are regularly taking an iron supplement, you should consult with a physician to ensure that the 
dosage of iron you are taking is adequate, as well as to monitor your iron status. 
 
Iron-deficiency with Anemia:  Both your Fer  and Hgb values are outside of the normal ranges.  You 
should continue to monitor your Fer and Hgb values.  An iron supplement or multi-vitamin containing 
iron may be of benefit to you at this time.  If you are regularly taking an iron supplement, you should 
consult with a physician to ensure that the dosage of iron you are taking is adequate.   
 
Iron-deficiency without Anemia:  Your Fer values are outside of the normal range.  Your Hgb is 
within the normal range.  You should continue to monitor your Fer and Hgb values.  An iron 
supplement or multi-vitamin containing iron may be of benefit to you at this time.  If you are regularly 
taking an iron supplement, you should consult with a physician to ensure that the dosage of iron you are 
taking is adequate.   
 
If you have any questions about this report, please contact me (Diane M. DellaValle,  
dd235@cornell.edu) for further information. Thanks so much again for your participation in our study! 
 
Sincerely, 
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Appendix 10 Body composition and fitness test report 
 
Cornell University 
Iron and Training Study Fall 2009 
Body Composition & Fitness Testing Results 
 
 
 
 
First and foremost, we would like to thank you for participating in our study!  We really 
appreciate your time and enthusiasm!  We have compiled your Iron Status, Body Composition 
and Fitness Testing results in this summary profile.  
 
If you have any questions regarding this information, please contact Diane M DellaValle, 
dd235@cornell.edu.  Thanks again for all of your time!  We have really enjoyed working with 
you! 
 
Sincerely, 
 
 
 
Diane M DellaValle, MS, RD, Graduate Student 
Cornell University 
Division of Nutritional Sciences 
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Iron and Training Study, Fall ’09 
Body Composition 
   Baseline    End-point  
        %Change 
Body Weight = _____ kg (_____ lb)   _____ kg (_____ lb)  
        _____ % 
Your weight in kilograms as measured in your bathing suit prior to the body composition 
measurements. Your “ideal weight” is best determined from your body composition rather than 
from “average weights”. 
 
Body Height = _____ cm (_____ in)   _____ cm (_____ in)  
        _____ % 
Your height in centimeters as measured in your bathing suit prior to the body composition 
measurements.  
 
Body Mass Index (BMI) = _____ kg/m^2    _____ kg/m^2  
        _____ % 
BMI (Body Mass Index) = wt/ht2.  This index is used to indirectly assess energy balance.  BMI is based 
on assumption that weight corrected for height is correlated with body fatness & obesity.   
 
A BMI of <18.5 is indicative of underweight status, which may be associated with malnutrition or 
disease.  A BMI of 18.5-24.9 indicates normal weight status, associated with little health risk.  A BMI 
25.0-29.9 indicates overweight status, which may be associated with health problems when coupled 
with other weight- or cardiovascular-related conditions.  A BMI >30 indicates obesity, which poses 
significant health risks.  BMI does not distinguish between fat mass & fat-free mass (body 
composition), and tends to overestimate fatness in muscular individuals 
 
Percent Body Fat = _____%     _____%   
        _____%  
This value represents the percentage of your body that is composed of fat. Normal values for your age 
and gender are given in the chart below. 
 
Lean Body Mass = _____ kg     _____ kg  
        _____% 
This represents the weight of your lean tissues such as muscle and bone. This value should be preserved 
or increased in most people. It is undesirable to lose lean body mass in any weight loss program except 
in people who are morbidly obese. 
 
Fat Weight = _____ kg      _____ kg  
        _____% 
This is the weight of your body fat. This is the value we would like to lower in those people who need 
to lose weight. 
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Iron and Training Study, Fall ’09  
Fitness Assessment 
 
Maximal Heart rate (HRmax) during exercise testing (beats per minute, bpm) 
   Baseline   Endpoint   
       %Change 
    
 _______ (bpm)   _______ (bpm)   _
     ____% 
 
 
 
 
To calculate the percent of your HRmax to determine HR levels for training, first find your predicted 
HRmax, which is equal to 220 - your age in years.  Multiply that number (predicted HRmax) by the 
training level you desire.  To find the lower limit of your HR training range =  HRmax*0.50.  To find 
the upper limit of your HR training range = HRmax*0.90. 
 
 
Oxygen consumption (VO2) is also known as oxygen intake, oxygen utilization, oxygen uptake.  This 
is the amount of O2 taken into the body and used in the cells of your body to produce energy.  The 
ability to take up oxygen is dependent on how well your heart, lungs, blood, blood vessels, and muscle 
cells function.  VO2 is a useful measure of aerobic fitness, and is represented in liters of oxygen per 
minute (l/min) or milliliters per kilogram per minute (ml/kg/min). 
Baseline   Endpoint   
     %Change 
Your VO2max:   ________ml/kg/min  ________ml/kg/min   
       _____%    
________l/min   ________l/min    
 
VO2max is the maximal amount of oxygen the body can use during a given period of time, and is 
measured during a graded exercise test to fatigue during which the work load is progressively increased, 
which increases O2 consumption.  VO2max represents the functional capacity of the cardio-respiratory 
system.  In short, VO2 increases as exercise intensity increases. The harder a person exercises, the 
higher their volume of oxygen utilized (VO2).   People with higher values generally have greater energy 
reserves, increased work capacity, and are less-easily fatigued.   
 
Fitness Level (aerobic capacity) VO2 (ml/kg/min) 
20-29 years, Females 
Low (poor) <24 
Low-moderate (below average) 24-31 
Moderate (average) 31-38 
High-moderate (above average) 38-49 
Very High (excellent) >49 
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Blood Lactate: Lactic acid is produced in many of the cells of the body, particularly in muscle cells 
during exercise. From these cells lactic acid diffuses out into the blood where it can be measured (this is 
why we pricked your fingers and/or ears!). Accumulation of lactic acid occurs when the supply of 
oxygen to the cells is limited because the muscle cells are working so hard that the oxygen supply 
cannot keep up with the oxygen demand. During everyday activities and at low levels of exertion, the 
oxygen supply to the muscle cells is sufficient, and cells are able to utilize energy from various sources; 
this is known as the aerobic (oxygen) phase of exercise. When there is a sudden need for excessive 
muscular effort, the lactic acid mechanism is available to enable activity to continue even though the 
oxygen supply is insufficient. This is known as the anaerobic (without oxygen) phase of exercise. 
 
During very high-intensity exercise, lactic acid will be produced faster than it can be removed, and it 
starts to accumulate in the working muscles, greatly reducing their efficiency.   This causes an athlete 
discomfort (e.g. muscle burn), and ultimately results in reduced intensity or ending of the activity. As 
training progresses, the rate of lactate formation during exercise decreases, and the rate of lactate 
clearance (removal) increases during exercise.   When exercise stops the lactate level falls much more 
slowly than during the build-up. This is the process of recovery from exercise, sometimes referred to as 
the warm-down or cool-down. Various factors influence the rate of recovery, such as an active cool-
down period, which accelerates the rate of lactate fall. 
 
From Endurance test:   
 
% VO2 max and lactate levels maintained during the 4 stages of the 4K Time Trial: 
Baseline   Endpoint    
     %Change 
           
 VO2        Lactate 
 
1000m _______% _______mmol/l _______%  _______mmol/l   
     _____%_____ % 
  
2000m _______% _______mmol/l _______%  _______mmol/l   
     _____%_____ % 
     
3000m _______% _______mmol/l _______%  _______mmol/l   
     _____%_____ % 
   
4000m _______% _______mmol/l _______%  _______mmol/l   
     _____%_____ % 
   
400 m time: _______   _______      
     _____% 
 
Treatment Group Assignment 
 
For the eight-week study, you were assigned to receive the following:  
 
Placebo (lactose filler)   
 
Iron (1 capsule = 50 mg FeSO4; 2 capsules/d = 100 mg FeSO4) 
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Appendix 11 Daily training log 
 
 
Daily Log Instructions 
This training log should be completed on a daily basis for the next 7 days.  Initial use 
of this log may take up to 5 minutes/day. For some questions, please rate each factor, 
as you feel today by placing a solid vertical line on the scale. 
 
Example:  Happy:  How happy do you feel right now? 
 
Not at all happy                                                                                                  Extremely happy 
 
Physical Activities: record today’s physical activities, sport-specific and general 
conditioning workouts, as well as VIGOROUS leisure-time physical activities lasting 
at least 10 minutes (examples:  running to class, club sports, riding bike, swimming, 
playing active games with friends, etc).  
 
Please record total time for each activity (Minutes).  If applicable, record total distance 
(m, yards, mi, km); pace (mph, spm). 
 
AM and PM workouts should be recorded separately.   
 
Please include any comments/thoughts you have on your performance today (how 
well you felt, what you did or did not do well, etc).   
 
Please rate activities’ intensities in your log as follows: 
1= I can talk easy, only light sweating, and/or a slight increase in breathing or heart 
rate (low-Intensity) 
2= I can talk with some difficulty, light to moderate sweating, and/or a moderate 
increase in breathing or heart rate (moderate Intensity) 
3= I can’t talk comfortably, heavy sweating, and/or large increases in breathing or 
heart rate (vigorous intensity)   
 
Please include the following information from each ergometer workout session: 
 Meters (distance) rowed on ergometer 
 Minutes (time) rowed on ergometer 
 Stroke rating(s) during piece(s) performed 
 Average split time (/500m) during piece(s) performed 
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(This section to be completed in the morning) 
How many capsules did you consume today?__________ capsules.   
If you did not consume any capsules today, please explain: 
 
How long did you sleep last night?  Length of sleep:__________(hr).   
 
Please rate the quality of last night’s sleep:   
Not at all restful                                                                                                 Extremely restful 
 
 
How motivated are you to train today?   
Not at all motivated                                                                                                 Extremely motivated 
 
 
How do you feel today? 
 Not at all well                                                                                                  Extremely well 
 
 
Please explain (note any GI, respiratory, severe headaches, etc):  
 
 
Are you menstruating today?  (  )  Yes (  ) No 
 
 
(This section to be completed at the end of the day) 
Did you have any sore joints &/or pains in your muscles today?   
No pain/soreness at all                                                                                                  Severe pain/soreness          pain/soreness 
Please explain: 
  
How fatigued did you feel today? 
 Not at all fatigued                                                                                                 Extremely fatigued 
 
Please explain: 
 
How much was your workout today affected by illness? 
Not at all affected                                                                                                 Could not work out  today        today  
Please explain: 
 
 
Did you take a nap today?  (  )  Yes (  ) No  If Yes, how long? ____________ 
minutes 
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(This section to be completed at the end of the day, or as you complete your activities 
throughout the day) 
Today’s Physical Activities 
Time  
(00:00 
AM/PM) 
Activity Total Time 
(min) 
Intensity 
1=Lo  2=Mod 
3=Vig 
Comments 
     
     
     
     
     
     
     
     
     
     
 
 
 
Intensity of today’s training session?   
No exertion                                                                                                  Maximum, all-out, extreme 
exertion 
 
 
What was today’s training session level of discomfort? 
None                                                                                                 Very severe 
 
 
Please rate your level of concentration during your training session today: 
How well were you able to concentrate on the task content during your session? 
0%                                                                                                  100% 
 
 
Please rate your training speed of today’s training session: 
Low-intensity                                                                                                  Maximum speed 
 
 
 
Please rate the stress of your training load today:   
Extremely easy                                                                                                  Extremely hard 
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Appendix 12. Exercise test data collection forms 
VO2peak 
 
Best 2K erg split-time (maintained 30 sec) you can do right now:____min:sec = ____W  
(to be used for level 6) 
 
Start test 5 levels above best split time: 
Level   Split time  Watts 
1 
2 
3 
4 
5 
6 
7 
 
Level Stage-time WR (W - monitor) HR Parvo time (min: sec) 
1 0:30    
 1:00    
 1:30    
 0:10 Rest    
2 0:30    
 1:00    
 1:30    
 0:10 Rest    
3 0:30    
 1:00    
 1:30    
 0:10 Rest    
4 0:30    
 1:00    
 1:30    
 0:10 Rest    
5 0:30    
 1:00    
 1:30    
 0:10 Rest    
6 0:30    
 1:00    
 1:30    
 0:10 Rest    
7 0:30    
 1:00    
 1:30    
 0:10 Rest    
VO2peak:_____L/min at Level:_____ HRmax:_______bpm WRmax:_______W 
WR at 85% VO2peak:_________ L/min,  _______W ________ min 
 
 313 
 
Endurance – 4K Time Trial(TT) 
Interval Parvo-time (min:sec) WR (W)- monitor HR 
WR at 85% VO2peak:_______W.   
 
Start test at WR at 85% VO2peak for 
the first 3600m (4- 1000m intervals).  
At last 400m (last 1000m level), 
increase WR (W) by pulling as hard 
or as fast as you can in order to 
sprint to finish. 
0:30   
1:00   
1:30   
2:00   
2:30   
3:00   
3:30   
4:00    
4:30   
1000m 5:00   
Rest time start (1:00)    
Restart time    
 0:30   
 1:00   
 1:30   
 2:00   
 2:30   
 3:00    
 3:30   
 4:00   
 4:30   
2000m 5:00    
Rest time start (1:00)    
Restart time    
 0:30   
 1:00   
 1:30   
 2:00   
 2:30   
 3:00   
 3:30   
 4:00   
 4:30   
3000m 5:00    
Rest time start (1:00)    
Restart time    
 0:30   
 1:00   
 1:30   
 2:00   
 2:30   
 3:00    
 3:30   
Record Start sprint time (400m left) 4:00   
 4:30   
4000m 5:00   
Record total time to finish 4K    
VO2peak___at ____m, ___bpm HR, __W, ___spm;  85% VO2peak____at ____W 
 
